# Effectiveness of miniscrew-supported maxillary molar distalization according to temporary anchorage device features and appliance design: systematic review and meta-analysis

Chiara Ceratti<sup>a</sup>; Marco Serafin<sup>b</sup>; Massimo Del Fabbro<sup>c</sup>; Alberto Caprioglio<sup>d</sup>

# ABSTRACT

**Objectives:** To evaluate the effectiveness of distalizing maxillary first molars (U6) by temporary anchorage devices (TADs) according to their location (palatal, buccal, and zygomatic), their number, and appliance design.

**Materials and Methods:** An electronic search of maxillary molar distalization with TADs was done through April 2023. After study selection, data extraction, and risk-of-bias assessment, meta-analyses were performed for the extent of distalization, distal tipping, and vertical movement of U6 using the generic inverse variance and random-effects model. The significance level was set at 0.05.

**Results:** Forty studies met the inclusion criteria: 4 randomized controlled trials (RCTs), 13 prospective studies, and 23 retrospective studies (total of 1182 patients). Distalization of the U6 was not significantly greater (P = .64) by palatal (3.74 mm) and zygomatic (3.68 mm) than by buccal (3.23 mm) TADs. Distal tipping was significantly higher (P < .001) in nonrigid (9.84°) than in rigid (1.97°) appliances. Vertical movement was mostly intrusive and higher but not significantly different (P = .28) in zygomatic anchorage (-1.16 mm).

**Conclusions:** Distalization of U6 with TADs can be an effective and stable treatment procedure, especially when performed with rigid palatal appliances. However, further RCTs or prospective cohort studies are strongly recommended to provide more clinical evidence. (*Angle Orthod.* 0000;00:000–000.)

KEY WORDS: Class II malocclusion; Molar distalization; Orthodontic miniscrew; Systematic review

# INTRODUCTION

Maxillary molar distalization is the most frequently performed treatment for correcting Class II malocclusion and achieving Class I molar and canine relationships without extractions.<sup>1</sup> However, finding appropriate anchorage to avoid side effects is fundamental. Anchorage is crucial for the successful treatment of Class II malocclusion,<sup>2</sup> as instability of anchor teeth can result in unfavorable occlusal relationships and an unsatisfactory outcome.<sup>3</sup>

Extraoral appliances (e.g., headgear) and intraoral options (e.g., Nance button) are commonly used to reinforce anchorage. However, extraoral traction poses compliance challenges, while intraoral methods often result in anchorage loss.<sup>4</sup> To address this, intraoral distalization devices have been used and supported by skeletal anchorage. Dental implants have emerged as a stable solution for orthodontic purposes, benefiting from their osteointegration capabilities<sup>5</sup>; implants have demonstrated resilience against forces and remain stable following orthodontic loading over time.<sup>6</sup>

Although implants offer clear advantages in preserving anchorage, their invasive insertion and removal techniques hinder widespread adoption in daily practice. To address this limitation, temporary anchorage devices (TADs), including mini-implants,<sup>7</sup> miniscrews,<sup>8</sup> and onplants,<sup>9</sup> have emerged as promising alternatives. Miniscrews especially utilize less-invasive methods

<sup>&</sup>lt;sup>a</sup> Private Practice, Milan, Italy.

<sup>&</sup>lt;sup>b</sup> PhD Student in Translational Medicine, Department of Biomedical Sciences for Health, University of Milan, Milan, Italy.

<sup>&</sup>lt;sup>c</sup> Professor, Coordinator of PhD in Clinical Research, Department of Biomedical, Surgical, and Dental Sciences, University of Milan, Milan, Italy.

<sup>&</sup>lt;sup>d</sup> Associate Professor, School of Orthodontics, Department of Biomedical, Surgical, and Dental Sciences, University of Milan, Milan, Italy.

Corresponding author: Dr Marco Serafin, Department of Biomedical Sciences for Health, Via Mangiagalli 31, Milan 20133, Italy

<sup>(</sup>e-mail: marco.serafin@unimi.it)

Accepted: August 2023. Submitted: May 2023.

Published online: October 24, 2023

 $<sup>\</sup>ensuremath{\textcircled{\sc 0}}$  2023 by The EH Angle Education and Research Foundation, Inc.

Table 1. Eligibility and Inclusion Criteria	able 1.	nd Inclusion Criteria	ity an	Criteria <sup>a</sup>
---	---------	-----------------------	--------	-----------------------

Inclusion Criteria	Exclusion Criteria					
P (population): patients with Class II malocclusion who received distalization treatment of the maxillary molars	Case reports or case series, editorials, personal opinions, and narrative reviews					
I (intervention): distalization of U6 with TADs	No sample or an insufficient sample (fewer than 5 patients)					
C (comparison): between pre- and posttreatment	Distalization without the use of TAD					
O (outcomes): assessment of distalization (mm), distal tipping (°), and vertical displacement movements (mm)	Nonhuman subjects, non-English written					
S (study design): RCTs and nonrandomized prospective or retrospective clinical studies that included at least pre- and posttreatment measurements	Non-Class II malocclusion					

<sup>a</sup> U6 indicates maxillary first molars; TAD, temporary anchorage device; RCT, randomized controlled trials.

than conventional implants and hold great potential for providing stable skeletal anchorage, particularly for posterior tooth distalization.<sup>10</sup>

TAD-supported appliances can be placed buccally in interdental spaces, palatally<sup>11</sup> in the retromolar region,<sup>12</sup> or even in the zygomatic area.<sup>13</sup> The varied bone characteristics in these regions require smaller implants, particularly in length, while ensuring stability to withstand orthodontic forces. Factors such as ease of insertion, active treatment and removal, reliable wire fixation, and ease of handling are crucial for successful implant application in orthodontics.<sup>14</sup>

Recent reviews have examined the use of TAD-supported appliances for nonextraction treatment of Class II malocclusion and highlighted their advantages.<sup>15–18</sup> All of the reviews agreed regarding the advantages provided by TADs, but to date, no systematic reviews have evaluated and compared the overall efficacy of molar distalization performed with different TAD-supported appliances categorized by the location of placement, rigidity of the appliance, and number of TADs used. It is interesting and important to evaluate which types of anchorage and appliance can be used more effectively and efficiently for different malocclusions. Clinically, this information may affect the choice of appliance, depending on specific side effects in terms of changes in molar tipping, vertical movement, or inclination of the occlusal plane. The studies included in this review were stratified based on the location of placement and rigidity of the device used. Therefore, it was possible to evaluate various dental effects and propose a new, different analysis from previous systematic reviews. Therefore, this systematic review and meta-analysis aimed to evaluate the treatment effects of TAD-supported maxillary molar distalization in Class II malocclusion, considering the amount of distalization, tipping, and vertical movement of the maxillary first molars (U6).

#### MATERIALS AND METHODS

#### **Protocol and Registration**

This review followed the PRISMA standards of quality for reporting systematic reviews and meta-analyses.<sup>19</sup> The protocol was registered in PROSPERO (CRD420 22333115).

#### Inclusion Criteria and Search Strategy

An electronic search of PubMed and MEDLINE, Google Scholar, and the Cochrane Oral Health trial registry was conducted from January 2011 to April 2023. Studies with the following characteristics were selected: studies on human subjects, studies published in English, sample size mentioned (at least five patients); prospective and retrospective studies, and random clinical trials (RCTs) that included descriptions of the distalization appliance. Table 1 describes the inclusion and exclusion criteria.

The search strategy included the following terms: Maxillary\_molar\_distalization\_AND\_Class\_II\_AND\_ skeletal anchorage AND miniscrew OR mini-implants AND\_(y\_10[Filter"]). (((("maxilla"[MeSH\_Terms]\_OR"\_ "maxilla"[All\_Fields]\_OR\_"maxillary"[All\_Fields]\_OR\_ "maxillaries" [All Fields] OR "maxillaris" [All Fields]) AND\_("molar"[MeSH\_Terms]\_OR\_"molar"[All\_Fields]\_ OR\_"molars"[All\_Fields]\_OR\_"molars"[All\_Fields])\_ AND\_("distal"[All\_Fields]\_OR\_"distalization"[All\_ Fields]\_OR\_"distalize"[All\_Fields]\_OR\_"distalized" [All Fields] OR "distalizer"[All Fields] OR "distalizers" [All\_Fields]\_OR\_"distalizes"[All\_Fields]\_OR\_"distalizing" [AllFields]\_OR\_"distally"[All\_Fields]\_OR\_"distals" [All\_Fields])\_AND\_(""class"[All\_Fields]\_OR\_"classe" [All\_Fields]\_OR\_"classed"[All\_Fields]\_OR\_"classes" [All\_Fields])\_AND\_"II"[All\_Fields])\_AND\_(("skeletal"[All\_ Fields]\_OR\_"skeletals"[All\_Fields])\_AND\_("anchorage" [All\_Fields]\_OR\_"anchorages"[All\_Fields]))\_AND\_ ("miniscrew" [All\_Fields]\_OR\_"miniscrews" [All\_Fields]))\_ OR\_"mini-implants"[All Fields])\_AND\_((y\_10[Filter])\_ AND (humans[Filter])).

Manual searches were performed using reference lists in full-text articles deemed appropriate for inclusion in the study and other relevant systematic reviews. Two authors conducted the search for studies to be included independently, and differences were resolved by discussion and consensus with a third, trained researcher. Data were finally extracted according to the PICOS questions and categorized.

#### Assessment of Study Quality

The quality of the included studies was assessed independently by two independent researchers. The Joanna Briggs Institute (JBI) checklist was used for randomized trials (7 questions) and nonrandomized cohort studies (11 questions).<sup>20</sup>

#### **Data Collection and Analysis**

The study design, sample size, age, type of appliance, location of placement, number of miniscrews, and material used for measurements were obtained. The means and standard deviations (SDs) of distalization, distal tipping, and vertical movement of the U6 were calculated. All data were extracted into an Excel spreadsheet by one author and reviewed by another author to confirm accuracy. Studies whose mean was more than double the mean of the subgroups were excluded from the meta-analysis after testing them by analysis of variance.

Meta-analysis was performed using Review Manager software (RevMan version 5.4; The Cochrane Collaboration, 2020) with a generic inverse variance approach. The random-effects method was used because the studies included in the analysis had a high degree of heterogeneity and were quite diverse in terms of the entity of the forces applied. Heterogeneity was first assessed from a clinical perspective based on the position of the TADs, their number, and the rigidity of the distalization system. The significance level was set at 0.05. For meta-analysis, the standard error (SE) value of the SD of the individual results was also calculated.

## RESULTS

#### **Study Selection and Trial Flow**

The database search identified 805 studies, and after the removal of duplicates, titles and abstracts were independently evaluated for inclusion. After the study selection, the percentage of agreement between reviewers reached a Cohen's kappa coefficient value of 0.93. A third author was consulted for resolution of the disagreements to obtain the final list of included studies. Ultimately, 40 studies met the inclusion criteria for qualitative and quantitative analyses (Figure 1).

#### **Characteristics of the Studies**

The studies included in this review were published between January 2011 and April 2023: 4 RCTs, 13 prospective studies, and 23 retrospective studies.

Distalization groups included 1182 patients. Studies were divided into palatal,  $^{21-47}$  buccal,  $^{10,28,32,48-52}$  and zygomatic  $^{53-59}$  according to the position of TADs. For studies with palatal TADs, a distinction was made between rigid  $^{21-23,25,26,28,29,38,47}$  and




Figure 1. PRISMA flow diagram of the study selection process.

nonrigid<sup>21,30,35</sup> appliances and between 2-TADsupported<sup>21–23,25,26,28–30,35,38,47</sup> and 3-TAD-supported<sup>24,27,31–34,36,37,39–46</sup> appliances. The characteristics of the 40 studies included in the qualitative analysis are summarized in Table 2.

#### **Risk of Bias**

The JBI checklist was used. In the analysis of retrospective and prospective cohort studies, 10 studies were classified as "low" risk, 17 studies as "moderate," 7 studies as "serious," and 2 studies as "critical." The risk of bias (ROB) in the included RCTs was "serious" in two studies and "moderate" in the other two. Tables 3 and 4 show the summary of ROB for nonrandomized and RCT studies, respectively.

#### **Quantitative Analysis**

U6 distalization with palatal anchorage ranged from 1.65 mm<sup>32</sup> to 5.4 mm,<sup>44</sup> with tipping values ranging from  $0.1^{\circ 38,47}$  to  $11.24^{\circ}$ .<sup>30</sup> Most studies reported U6 intrusion ( $-0.04 \text{ mm}^{43}$  to  $-2.6 \text{ mm}^{46}$ ), while some reported extrusion ( $0.2 \text{ mm}^{28}$  to  $1.6 \text{ mm}^{39}$ ).

Using buccal TADs, U6 distalization ranged from 1.29 mm<sup>48</sup> to 5.05 mm,<sup>28</sup> with tipping ranging from  $0.6^{\circ 51}$  to  $7.2^{\circ}$ .<sup>32</sup> Vertical movement varied from intrusion of -1.4 mm<sup>48</sup> to extrusion of 1.3 mm.<sup>10</sup>

U6 distalization with zygomatic anchorage ranged from 2.93 mm<sup>54</sup> to 5.31 mm.<sup>55</sup> Distal tipping varied from  $1.21^{\circ 54}$  to  $11.29^{\circ}$ .<sup>59</sup> Vertical movement ranged from  $-3.7 \text{ mm}^{56}$  (intrusion) to 0.6 mm<sup>58</sup> (extrusion).

Devices with 2 TADs had a distalization range of 2.3 mm<sup>26</sup> to 5.3 mm,<sup>38</sup> while the distalization range of devices with 3 TADs ranged from 1.65 mm<sup>36</sup> to 5.4 mm.<sup>44</sup> Distal tipping for devices with 2 TADs was  $0.1^{\circ 38}$  to  $11.24^{\circ 30}$ , and for devices with 3 TADs, it was  $0.28^{\circ 41}$  to  $5.09^{\circ}$ .<sup>46</sup> Vertical movement values for the 2-TAD-supported subgroup ranged from  $-1 \text{ mm}^{22,28}$  (intrusion) to 0.7 mm<sup>23</sup> (extrusion), and the values for

Table 2. Qualitative and Quantitative Analyses of the 40 Included Studies<sup>a</sup>

	Type of Sample Age, Years Measurin		Measuring			
Study	Study	Size	Mean	SD	Material	Appliance Design
Nur et al., <sup>53</sup> 2012 Sar et al., <sup>21</sup> 2013	PS	15	15.87	1.09	Ceph	Zygoma gear
Sar et al., <sup>21</sup> 2013	PS	14	14.8	3.6	Ceph	MISDS
		14	14.5	1.5	oopn	BAPA
Bechtold et al.,48 2013	RCT	12	23.58	6.92	Ceph	Miniscrew between 2P and 1M
Dechtoid et al., 2013	nor	13	22.92	7.1	Oepii	Miniscrews between 1P and 2P and between
		15	22.92	7.1		
Suzuki and Suzuki, <sup>22</sup>	PS	20	23.2	4.7	Ceph	2P and 1M 2 miniscrews in the midpalatal suture (iPanda)
2013 El-Dawlatly et al., <sup>54</sup> 2014	DOT	10	N1/A	N1/A	ODOT	170
El-Dawially et al., 2014	RCT	10	N/A	N/A	CBCT	IZC screw
Cozzani et al., <sup>23</sup> 2014	RCT	18	11.5	1.7	Ceph	Distal screw
Mariani et al., <sup>10</sup> 2014 Kook et al., <sup>24</sup> 2014	RS	30	13.3	2.3	Ceph	MGBM system
Kook et al., 27 2014	RS	20	22.9	N/A	CBCT	MPAP
Caprioglio et al., <sup>25</sup> 2015	RS	19	11.3	1.9	Ceph	Distal screw
Miresmaeili et al., <sup>26</sup> 2015	PS	26	19.8	6.3	3D cast CBCT	Palatal miniscrews between 2P and 1M
Sa'aed et al., <sup>27</sup> 2015	RS	24	12.42	1.69	Ceph	MPAP
Cozzani et al., <sup>28</sup> 2016	RS	29	12.3	1.5	Ceph	MGBM system
		24	11.3	1.2		Distal screw
Duran et al., <sup>29</sup> 2016	PS	21	13.6	N/A	3D cast	Miniscrew-supported hyrax screw
Kilkis et al., <sup>55</sup> 2016	PS	21	15.68	2.18	Ceph	Zygoma gear
Ali et al., <sup>49</sup> 2016	RS	17	26.4	10.8	3D cast	Miniscrew between 2P and 1M
Cambiano et al., <sup>30</sup> 2017	PS	18	14	1.08	Ceph	BAPA
Callibratio et al., $2017$						
Park et al., <sup>31</sup> 2017 Lee et al., <sup>32</sup> 2018	RS	22	24.7	7.77	Ceph	MCPP
Lee et al., <sup>32</sup> 2018	RS	22	21.9	6.6	Ceph	MCCP
50		18	24.2	6.8		Interradicular miniscrew
Wu et al., <sup>56</sup> 2018 Jo et al., <sup>33</sup> 2018 Park et al., <sup>34</sup> 2018	RS	20	23	5	CBCT	IZC screw
Jo et al., <sup>33</sup> 2018	RS	20	22.4	6.3	Ceph	MCPP
Park et al., <sup>34</sup> 2018	RS	17	21.5	3.99	CBCT	MCPP exo group
		16	22.9	3.99		MCPP nonexo group
Kırcalı and Yüksel, <sup>35</sup> 2018	PS	20	14.05	2.4	Ceph	ВАРА
Lee et al., <sup>36</sup> 2019	RS	20	12.5	1.2	Ceph	MCPP
Shoaib et al., <sup>37</sup> 2019	RS	23	20.1	N/A	Ceph	MCPP
Shahani et al., <sup>57</sup> 2019	PS	6	>18	N/A	Ceph	IZC screw + passive self-ligating
	10	6	>18	N/A	oopn	IZC screw + clear aligner
Cassetta et al.,38 2019	DOT					•
Cassella et al., 2019	RCT	10	13.1	N/A	3D cast Ceph	Distal screw
Abdelhady et al.,50	PS	11	12.4	N/A	Ceph	Miniscrew between 2P and 1M
2020					1-	
Bechtold et al., <sup>51</sup> 2020	RS	19	24.9	5.0	Ceph	Miniscrew between 2P and 1M
Alfaifi et al.,39 2020	RS	21	11.7	1.3	Ceph	MCPP
Chou et al.,40 2021	RS	20	12.9	1.0	CBCT	MCPP
Jung et al., <sup>41</sup> 2021	RS	20	12.1	1.1	Ceph	MCPP hyperdivergent
	110	20	12.3	1.5	oopn	MCPP hypodivergent
Park et al., <sup>42</sup> 2021	RS					MCPP
Park et al., <sup>43</sup> 2021		284	N/A	N/A	3D cast	
Park et al., * 2021	RS	15	13.2	1.32	CBCT	MCPP
Shaikh et al., <sup>58</sup> 2021	PS	12 10	12.0 N/A	1.24 N/A	Ceph	MCPP IZC screw between 1M and 2M + interradicu-
					·	lar miniscrew
Song et al., <sup>52</sup> 2022	RS	39	24.5	5.38	Ceph Dental cast	Miniscrews between 2P and 1M or between 1M and 2M
Alfawaz et al.,44 2022	RS	25	22.5	7.2	Ceph	MCPP
Kim et al., <sup>45</sup> 2022	RS	30	25.1	-	CBCT	MCPP
Kim et al., <sup>45</sup> 2022 Lim et al., <sup>46</sup> 2022	RS	24	19.0	7.9	Ceph 3D model	MCPP
Altieri et al.,47 2022	PS	22	13.2	1.7	Ceph	Distal screw
<b>D</b>	D.C.				3D model	170
Rosa et al., <sup>59</sup> 2023	PS	25	13.6	1.5	Ceph	IZC screw
					3D model	

<sup>a</sup> Data extracted for quantitative analysis included the means of T0-T1 changes and standard deviations, description of the TAD site, and type of device: palatal (subsets according to numbers [#] of TADs between rigid and nonrigid devices), buccal, and zygomatic. TAD indicates temporary anchorage device; SD, standard deviation; PS, prospective study; RS, retrospective study; RCT, randomized controlled trial; N/A, not applicable; P, palatal; B, buccal; Z, zygomatic; R, rigid device; NR, nonrigid device; MISDS, miniscrew implant-supported distalization system; BAPA, bone-anchored pendulum appliance; IZC, infrazygomatic crest; MGBM system, Maino-Giannelly-Bednar-Mura system; MPAP, modified palatal anchorage plate; MCPP, modified C-palatal plate; 1M, first molar; 2M, second molar; 1P, first premolar; 2P, second premolar; CBCT, Cone Beam Computed Tomography; and Ceph, cephalometry.

Table 2. Extended

# of Site         Appliance TADs         Ot Distance Type         Ot Distance Mean           Z         -         -         4.36           P         2         R         2.81           2         NR         2.93           B         -         -         1.29           -         -         2.91           P         2         R         4.5           Z         -         -         2.93           P         2         R         4.5           Z         -         -         2.93           P         2         R         4.7           B         -         -         4.6           P         3         -         3.3           P         2         R         4.2           P         3         -         3.06           B         -         -         5.5           P         2         R         4.1           Z         -         -         5.31           B         -         -         2.04           P         3         -         3.1           P         3         -         3.1<	SD           2.15           2.7           1.74           0.66           0.96           1.5           0.7           1.6           0.3           1.8           1.4           1.1           0.54           1.8           0.7           1.5           0.7           1.6           0.3           1.8           1.4           1.1           0.54           1.8           0.7           1.57           2.46           1.41           1.54           2.0           1.25           1.26           1.0           0.67           1.25           1.79           0.8	Mean           3.3           1.65           9.0           3.19           1.55           1.8           1.21           2.8           9.75           3.42           3.2           0.6           1.53           10.3           3.0           11.02           6.39           4.59           11.24           3.85           2.0           7.2           N/A           2.93           3.68           3.07           8.9	SD           2.31           7.29           6.74           4.61           1.32           4.0           0.89           2.2           0.75           5.79           3.0           4.3           0.98           2.9           1.5           5.32           5.39           7.97           3.44           3.11           4.20           5.22           N/A           1.90           4.97           6.67           3.1	Mean -0.5 N/A N/A -0.84 -1.4 -1.0 -1.57 0.7 1.3 -1.75 0.3 -0.53 -1.66 -1.0 0.2 -0.59 -0.76 -0.11 -0.74 -2.53 -1.64 -0.13 -3.7 -1.31 -1.02 -1.41	SD 0.46 N/A N/A 1.09 0.99 0.8 1.18 1.9 0.9 1.35 0.8 0.56 0.55 0.3 0.3 0.5 5 2.85 1.39 0.868 1.40 2.06 1.88 3.0 1.33 1.67 2.07
P       2       R       2.81         2       NR       2.93         B       -       -         -       2.91         P       2       R         4.5       -         Z       -         P       2       R         4.6       -         P       2       R         4.6       -       -         P       2       R         2       R       4.2         P       2       R         2       R       2.3         P       2       R         2       R       2.3         P       2       R         2       R       2.3         P       2       R         2       R       3.2         P       2       R         2       R       3.1         P       2       NR         3       -       3.06         B       -       2.0         Z       -       3.1         P       3       -       3.41         3       -       3.80     <	$\begin{array}{c} 2.7\\ 1.74\\ 0.66\\ 0.96\\ \end{array}$ $\begin{array}{c} 1.5\\ 0.7\\ 1.6\\ 0.3\\ 1.8\\ 1.4\\ 1.1\\ 0.54\\ 1.8\\ 0.7\\ 1.57\\ 2.46\\ 1.41\\ 1.54\\ 2.0\\ 1.25\\ 1.26\\ 1.0\\ 0.67\\ 1.25\\ 1.25\\ 1.79\\ \end{array}$	1.65 9.0 3.19 1.55 1.8 1.21 2.8 9.75 3.42 3.2 0.6 1.53 10.3 3.0 11.02 6.39 4.59 11.24 3.85 2.0 7.2 N/A 2.93 3.68 3.07	7.29 6.74 4.61 1.32 4.0 0.89 2.2 0.75 5.79 3.0 4.3 0.98 2.9 1.5 5.32 5.39 7.97 3.44 3.11 4.20 5.22 N/A 1.90 4.97 6.67	$\begin{array}{c} N/A\\ N/A\\ -0.84\\ -1.4\\ -1.0\\ -1.57\\ 0.7\\ 1.3\\ -1.75\\ 0.3\\ -0.53\\ -1.66\\ -1.0\\ 0.2\\ -0.59\\ -0.76\\ -0.11\\ -0.74\\ -2.53\\ -1.64\\ -0.13\\ -3.7\\ -1.31\\ -1.02\\ -1.41\\ \end{array}$	N/A N/A 1.09 0.99 0.8 1.18 1.9 0.9 1.35 0.8 0.56 0.55 0.3 0.5 2.85 1.39 0.868 1.40 2.06 1.88 3.0 1.33 1.67
B $2$ NR $ 2.93$ $1.29$ $2.91$ P2R $4.5$ Z $  2.93$ P2R $4.7$ B $ -$ P2R $4.7$ B $ -$ QR $4.2$ P2RQR $2.3$ P2RQR $2.3$ P2RQR $3.3$ P2RQR $3.2$ P2RA $-$ D2RQNR $3.45$ P2NRA $-$ P3 $-$ QNR $3.45$ P3 $-$ A $3.97$ P3 $-$ A $3.97$ P3 $-$ A $3.24$ P $3$ $-$ A $3.24$ P $3$ $-$ A $3.20$ P $2$ RB $ -$ A $3.96$ P $3$ $-$ A $4.26$ P $3$ $-$ A $2.69$ P $3$ $-$ A $3.35$ <td><math display="block">\begin{array}{c} 2.7\\ 1.74\\ 0.66\\ 0.96\\ \end{array}</math> <math display="block">\begin{array}{c} 1.5\\ 0.7\\ 1.6\\ 0.3\\ 1.8\\ 1.4\\ 1.1\\ 0.54\\ 1.8\\ 0.7\\ 1.57\\ 2.46\\ 1.41\\ 1.54\\ 2.0\\ 1.25\\ 1.26\\ 1.0\\ 0.67\\ 1.25\\ 1.25\\ 1.79\\ \end{array}</math></td> <td>9.0 3.19 1.55 1.8 1.21 2.8 9.75 3.42 3.2 0.6 1.53 10.3 3.0 11.02 6.39 4.59 11.24 3.85 2.0 7.2 N/A 2.93 3.68 3.07</br></br></br></td> <td>7.29 6.74 4.61 1.32 4.0 0.89 2.2 0.75 5.79 3.0 4.3 0.98 2.9 1.5 5.32 5.39 7.97 3.44 3.11 4.20 5.22 N/A 1.90 4.97 6.67</td> <td><math display="block">\begin{array}{c} N/A\\ -0.84\\ -1.4\\ -1.0\\ -1.57\\ 0.7\\ 1.3\\ -1.75\\ 0.3\\ -0.53\\ -1.66\\ -1.0\\ 0.2\\ -0.59\\ -0.76\\ -0.11\\ -0.74\\ -2.53\\ -1.64\\ -0.13\\ -3.7\\ -1.31\\ -1.02\\ -1.41\\ \end{array}</math></td> <td>N/A 1.09 0.99 0.8 1.18 1.9 0.9 1.35 0.8 0.55 0.3 0.55 0.3 0.5 2.85 1.39 0.868 1.40 2.06 1.88 3.0 1.33 1.67</td>	$\begin{array}{c} 2.7\\ 1.74\\ 0.66\\ 0.96\\ \end{array}$ $\begin{array}{c} 1.5\\ 0.7\\ 1.6\\ 0.3\\ 1.8\\ 1.4\\ 1.1\\ 0.54\\ 1.8\\ 0.7\\ 1.57\\ 2.46\\ 1.41\\ 1.54\\ 2.0\\ 1.25\\ 1.26\\ 1.0\\ 0.67\\ 1.25\\ 1.25\\ 1.79\\ \end{array}$	9.0 3.19 1.55 1.8 1.21 2.8 9.75 3.42 3.2 0.6 	7.29 6.74 4.61 1.32 4.0 0.89 2.2 0.75 5.79 3.0 4.3 0.98 2.9 1.5 5.32 5.39 7.97 3.44 3.11 4.20 5.22 N/A 1.90 4.97 6.67	$\begin{array}{c} N/A\\ -0.84\\ -1.4\\ -1.0\\ -1.57\\ 0.7\\ 1.3\\ -1.75\\ 0.3\\ -0.53\\ -1.66\\ -1.0\\ 0.2\\ -0.59\\ -0.76\\ -0.11\\ -0.74\\ -2.53\\ -1.64\\ -0.13\\ -3.7\\ -1.31\\ -1.02\\ -1.41\\ \end{array}$	N/A 1.09 0.99 0.8 1.18 1.9 0.9 1.35 0.8 0.55 0.3 0.55 0.3 0.5 2.85 1.39 0.868 1.40 2.06 1.88 3.0 1.33 1.67
B2NR2.93B1.29P2R4.5Z2.93P2R4.7BQR4.2P3-3.3P2R4.2P3-3.06B5.5P2R3.2P2R3.2P2R3.2P2R3.2P2R3.2P2R3.2P2R3.2P2R3.2P3-4.2P3-3.1P3-3.1P3-3.1P3-3.24P3-3.80P3-3.80P3-3.80P3-4.09B4.09B4.26P3-3.96P3-3.96P3-2.69P3-3.35	1.74 0.66 0.96 1.5 0.7 1.6 0.3 1.8 1.4 1.1 0.54 1.8 0.7 1.57 2.46 1.41 1.54 2.0 1.25 1.25 1.25 1.25 1.25 1.25 1.79	9.0 3.19 1.55 1.8 1.21 2.8 9.75 3.42 3.2 0.6 1.53 10.3 3.0 11.02 6.39 4.59 11.24 3.85 2.0 7.2 N/A 2.93 3.68 3.07	6.74 4.61 1.32 4.0 0.89 2.2 0.75 5.79 3.0 4.3 0.98 2.9 1.5 5.32 5.39 7.97 3.44 3.11 4.20 5.22 N/A 1.90 4.97 6.67	$\begin{array}{c} N/A\\ -0.84\\ -1.4\\ -1.0\\ -1.57\\ 0.7\\ 1.3\\ -1.75\\ 0.3\\ -0.53\\ -1.66\\ -1.0\\ 0.2\\ -0.59\\ -0.76\\ -0.11\\ -0.74\\ -2.53\\ -1.64\\ -0.13\\ -3.7\\ -1.31\\ -1.02\\ -1.41\\ \end{array}$	N/A 1.09 0.99 0.8 1.18 1.9 0.9 1.35 0.8 0.55 0.3 0.55 0.3 0.5 2.85 1.39 0.868 1.40 2.06 1.88 3.0 1.33 1.67
B $  1.29$ P       2       R $4.5$ Z $  2.93$ P       2       R $4.7$ B $  2.93$ P       2       R $4.7$ B $  3.3$ P       2       R $4.2$ P       2       R $4.2$ P       2       R $2.3$ P       2       R $3.2$ P       2       NR $3.45$ P       3 $ 4.2$ P       3 $ 3.97$ P       3 $ 3.80$ Z $  3.80$ P       3 $ 3.80$ P       3 $ 3.96$	0.66 0.96 1.5 0.7 1.6 0.3 1.8 1.4 1.1 0.54 1.8 0.7 1.57 2.46 1.41 1.54 2.0 1.25 1.26 1.0 0.67 1.25 1.25 1.25 1.25 1.25 1.79	3.19 1.55 1.8 1.21 2.8 9.75 3.42 3.2 0.6 1.53 10.3 3.0 11.02 6.39 4.59 11.24 3.85 2.0 7.2 N/A 2.93 3.68 3.07	4.61 1.32 4.0 0.89 2.2 0.75 5.79 3.0 4.3 0.98 2.9 1.5 5.32 5.39 7.97 3.44 3.11 4.20 5.22 N/A 1.90 4.97 6.67	$\begin{array}{c} -0.84 \\ -1.4 \\ -1.0 \\ \end{array}$	$\begin{array}{c} 1.09\\ 0.99\\ 0.8\\ 1.18\\ 1.9\\ 0.9\\ 1.35\\ 0.8\\ 0.56\\ 0.55\\ 0.3\\ 0.5\\ 2.85\\ 1.39\\ 0.868\\ 1.40\\ 2.06\\ 1.88\\ 3.0\\ 1.33\\ 1.67\\ \end{array}$
-2.91P2R4.5Z2.93P2R4.7B4.6P3-3.3P2R4.2P2R2.3P3-3.06B5.5P2R4.1Z5.31B2.04P2NR3.45P3-4.2P3-3.1P3-3.41P3-3.41P2NR4.2P3-3.80P2R5.3B4.09B4.09B4.66P3-3.96P3-2.69P3-3.35	0.96 1.5 0.7 1.6 0.3 1.8 1.4 1.1 0.54 1.8 0.7 1.57 2.46 1.41 1.54 2.0 1.25 1.26 1.0 0.67 1.25 1.25 1.25 1.25	1.55 1.8 1.21 2.8 9.75 3.42 3.2 0.6 1.53 10.3 3.0 11.02 6.39 4.59 11.24 3.85 2.0 7.2 N/A 2.93 3.68 3.07	1.32 4.0 0.89 2.2 0.75 5.79 3.0 4.3 0.98 2.9 1.5 5.32 5.39 7.97 3.44 3.11 4.20 5.22 N/A 1.90 4.97 6.67	$\begin{array}{c} -1.4 \\ -1.0 \\ -1.57 \\ 0.7 \\ 1.3 \\ -1.75 \\ 0.3 \\ -0.53 \\ -1.66 \\ -1.0 \\ 0.2 \\ -0.59 \\ -0.76 \\ -0.11 \\ -0.74 \\ -2.53 \\ -1.64 \\ -0.13 \\ -3.7 \\ -1.31 \\ -1.02 \\ -1.41 \end{array}$	0.99 0.8 1.18 1.9 0.9 1.35 0.8 0.56 0.55 0.3 0.3 0.5 2.85 1.39 0.868 1.40 2.06 1.88 3.0 1.33 1.67
Z $  2.93$ P $2$ $R$ $4.7$ B $  3.3$ P $3$ $ 3.3$ P $2$ $R$ $4.2$ P $2$ $R$ $2.3$ P $3$ $ 3.06$ B $  5.5$ P $2$ $R$ $4.1$ Z $  5.51$ P $2$ $R$ $4.1$ Z $  2.04$ P $2$ $NR$ $3.45$ P $3$ $ 4.22$ B $ 2.00$ $Z$ Z $  3.11$ P $3$ $ 3.20$ P $3$ $ 3.20$ P $3$ $  Z$ $R$ $5.3$ B $  4.26$ P $3$ <td>0.7 1.6 0.3 1.4 1.1 0.54 1.8 0.7 1.57 2.46 1.41 1.54 2.0 1.25 1.26 1.0 0.67 1.25 1.25 1.79</td> <td>1.21 2.8 9.75 3.42 3.2 0.6 1.53 10.3 3.0 11.02 6.39 4.59 11.24 3.85 2.0 7.2 N/A 2.93 3.68 3.07</td> <td>0.89 2.2 0.75 5.79 3.0 4.3 0.98 2.9 1.5 5.32 5.39 7.97 3.44 3.11 4.20 5.22 N/A 1.90 4.97 6.67</td> <td><math display="block">\begin{array}{c} -1.57\\ 0.7\\ 1.3\\ -1.75\\ 0.3\\ -0.53\\ -1.66\\ -1.0\\ 0.2\\ -0.59\\ -0.76\\ -0.11\\ -0.74\\ -2.53\\ -1.64\\ -0.13\\ -3.7\\ -1.31\\ -1.02\\ -1.41\end{array}</math></td> <td><math display="block">\begin{array}{c} 1.18\\ 1.9\\ 0.9\\ 1.35\\ 0.8\\ 0.56\\ 0.55\\ 0.3\\ 0.3\\ 0.5\\ 2.85\\ 1.39\\ 0.868\\ 1.40\\ 2.06\\ 1.88\\ 3.0\\ 1.33\\ 1.67\\ \end{array}</math></td>	0.7 1.6 0.3 1.4 1.1 0.54 1.8 0.7 1.57 2.46 1.41 1.54 2.0 1.25 1.26 1.0 0.67 1.25 1.25 1.79	1.21 2.8 9.75 3.42 3.2 0.6 1.53 10.3 3.0 11.02 6.39 4.59 11.24 3.85 2.0 7.2 N/A 2.93 3.68 3.07	0.89 2.2 0.75 5.79 3.0 4.3 0.98 2.9 1.5 5.32 5.39 7.97 3.44 3.11 4.20 5.22 N/A 1.90 4.97 6.67	$\begin{array}{c} -1.57\\ 0.7\\ 1.3\\ -1.75\\ 0.3\\ -0.53\\ -1.66\\ -1.0\\ 0.2\\ -0.59\\ -0.76\\ -0.11\\ -0.74\\ -2.53\\ -1.64\\ -0.13\\ -3.7\\ -1.31\\ -1.02\\ -1.41\end{array}$	$\begin{array}{c} 1.18\\ 1.9\\ 0.9\\ 1.35\\ 0.8\\ 0.56\\ 0.55\\ 0.3\\ 0.3\\ 0.5\\ 2.85\\ 1.39\\ 0.868\\ 1.40\\ 2.06\\ 1.88\\ 3.0\\ 1.33\\ 1.67\\ \end{array}$
Z       -       -       2.93         P       2       R       4.7         B       -       -       3.3         P       2       R       4.2         P       2       R       2.3         P       2       R       2.3         P       3       -       3.06         B       -       -       5.5         P       2       R       4.1         Z       -       -       5.31         B       -       -       2.04         P       2       NR       3.45         P       3       -       4.2         B       -       -       2.0         Z       -       -       3.1         P       3       -       3.97         P       3       -       3.41         P       3       -       3.80         P       3       -       3.80         P       3       -       3.80         P       2       R       5.3         B       -       -       4.09         B       -       -	0.7 1.6 0.3 1.4 1.1 0.54 1.8 0.7 1.57 2.46 1.41 1.54 2.0 1.25 1.26 1.0 0.67 1.25 1.25 1.79	1.21 2.8 9.75 3.42 3.2 0.6 1.53 10.3 3.0 11.02 6.39 4.59 11.24 3.85 2.0 7.2 N/A 2.93 3.68 3.07	0.89 2.2 0.75 5.79 3.0 4.3 0.98 2.9 1.5 5.32 5.39 7.97 3.44 3.11 4.20 5.22 N/A 1.90 4.97 6.67	$\begin{array}{c} -1.57\\ 0.7\\ 1.3\\ -1.75\\ 0.3\\ -0.53\\ -1.66\\ -1.0\\ 0.2\\ -0.59\\ -0.76\\ -0.11\\ -0.74\\ -2.53\\ -1.64\\ -0.13\\ -3.7\\ -1.31\\ -1.02\\ -1.41\end{array}$	$\begin{array}{c} 1.18\\ 1.9\\ 0.9\\ 1.35\\ 0.8\\ 0.56\\ 0.55\\ 0.3\\ 0.3\\ 0.5\\ 2.85\\ 1.39\\ 0.868\\ 1.40\\ 2.06\\ 1.88\\ 3.0\\ 1.33\\ 1.67\\ \end{array}$
P       2       R       4.7         B       -       -       4.6         P       3       -       3.3         P       2       R       4.2         P       2       R       4.2         P       2       R       2.3         P       3       -       5.5         P       2       R       3.2         P       2       R       3.2         P       2       R       3.2         P       2       R       3.1         P       2       NR       3.45         P       3       -       4.2         B       -       -       2.04         P       3       -       4.2         B       -       -       3.11         P       3       -       3.97         P       3       -       3.84         P       3       -       3.80         -       3.20       -       3.20         P       2       R       5.3         B       -       -       4.26         P       3       -	$\begin{array}{c} 1.6\\ 0.3\\ 1.8\\ 1.4\\ 1.1\\ 0.54\\ 1.8\\ 0.7\\ 1.57\\ 2.46\\ 1.41\\ 1.54\\ 2.0\\ 1.25\\ 1.26\\ 1.0\\ 0.67\\ 1.25\\ 1.25\\ 1.79\end{array}$	2.8 9.75 3.42 3.2 0.6 1.53 10.3 3.0 11.02 6.39 4.59 11.24 3.85 2.0 7.2 N/A 2.93 3.68 3.07	2.2 0.75 5.79 3.0 4.3 0.98 2.9 1.5 5.32 5.39 7.97 3.44 3.11 4.20 5.22 N/A 1.90 4.97 6.67	$\begin{array}{c} 0.7\\ 1.3\\ -1.75\\ 0.3\\ -0.53\\ -1.66\\ -1.0\\ 0.2\\ -0.59\\ -0.76\\ -0.11\\ -0.74\\ -2.53\\ -1.64\\ -0.13\\ -3.7\\ -1.31\\ -1.02\\ -1.41\\ \end{array}$	$\begin{array}{c} 1.9\\ 0.9\\ 1.35\\ 0.8\\ 0.56\\ 0.55\\ 0.3\\ 0.3\\ 0.5\\ 2.85\\ 1.39\\ 0.868\\ 1.40\\ 2.06\\ 1.88\\ 3.0\\ 1.33\\ 1.67\end{array}$
B       -       -       4.6         P       3       -       3.3         P       2       R       4.2         P       2       R       2.3         P       3       -       3.06         B       -       -       3.06         B       -       -       3.06         B       -       -       5.5         P       2       R       4.1         Z       -       -       5.31         B       -       -       2.04         P       2       NR       3.45         P       3       -       4.22         P       3       -       4.2         B       -       2.0       2         Z       -       -       3.1         P       3       -       3.97         P       3       -       3.44         P       3       -       3.80         -       3.20       -       3.20         P       2       R       5.3         B       -       -       4.09         B       -       -	0.3 1.8 1.4 1.1 0.54 1.8 0.7 1.57 2.46 1.41 1.54 2.0 1.25 1.79	9.75 3.42 3.2 0.6 1.53 10.3 3.0 11.02 6.39 4.59 11.24 3.85 2.0 7.2 N/A 2.93 3.68 3.07	0.75 5.79 3.0 4.3 0.98 2.9 1.5 5.32 5.39 7.97 3.44 3.11 4.20 5.22 N/A 1.90 4.97 6.67	$\begin{array}{c} 1.3 \\ -1.75 \\ 0.3 \\ -0.53 \\ -1.66 \\ -1.0 \\ 0.2 \\ -0.59 \\ -0.76 \\ -0.11 \\ -0.74 \\ -2.53 \\ -1.64 \\ -0.13 \\ -3.7 \\ -1.31 \\ -1.02 \\ -1.41 \end{array}$	0.9 1.35 0.8 0.56 0.55 0.3 0.5 2.85 1.39 0.868 1.40 2.06 1.88 3.0 1.33 1.67
P       3       - $3.3$ P       2       R $4.2$ P       2       R $2.3$ P       3       - $3.06$ B       -       - $5.5$ P       2       R $4.1$ Z       -       - $5.5$ P       2       R $4.1$ Z       -       - $5.31$ B       -       - $2.04$ P       2       NR $3.45$ P       3       - $4.22$ P       3       - $4.2$ B       -       - $2.0$ Z       -       - $3.97$ P       3       - $3.97$ P       3       - $3.97$ P       3       - $3.97$ P       3       - $3.20$ P       3       - $3.80$ -       - $3.20$ $3.20$ P       3       - $3.96$	$\begin{array}{c} 1.8\\ 1.4\\ 1.1\\ 0.54\\ 1.8\\ 0.7\\ 1.57\\ 2.46\\ 1.41\\ 1.54\\ 2.0\\ 1.25\\ 1.26\\ 1.0\\ 0.67\\ 1.25\\ 1.79\end{array}$	3.42 3.2 0.6 1.53 10.3 3.0 11.02 6.39 4.59 11.24 3.85 2.0 7.2 N/A 2.93 3.68 3.07	5.79 3.0 4.3 0.98 2.9 1.5 5.32 5.39 7.97 3.44 3.11 4.20 5.22 N/A 1.90 4.97 6.67	$\begin{array}{c} -1.75\\ 0.3\\ -0.53\\ -1.66\\ -1.0\\ 0.2\\ -0.59\\ -0.76\\ -0.11\\ -0.74\\ -2.53\\ -1.64\\ -0.13\\ -3.7\\ -1.31\\ -1.02\\ -1.41\end{array}$	$\begin{array}{c} 1.35\\ 0.8\\ 0.56\\ 0.55\\ 0.3\\ 0.3\\ 0.5\\ 2.85\\ 1.39\\ 0.868\\ 1.40\\ 2.06\\ 1.88\\ 3.0\\ 1.33\\ 1.67\end{array}$
P       2       R       4.2         P       2       R       2.3         P       3       -       3.06         B       -       -       5.5         P       2       R       4.1         Z       -       -       5.31         B       -       -       -       5.31         B       -       -       2.04         P       2       NR       3.45         P       3       -       4.2         B       -       -       2.04         P       3       -       4.2         B       -       -       2.0         Z       -       -       3.11         P       3       -       3.97         P       3       -       3.80         -       3.20       -       3.80         P       3       -       4.09         B       - </td <td><math display="block">\begin{array}{c} 1.4\\ 1.1\\ 0.54\\ 1.8\\ 0.7\\ 1.57\\ 2.46\\ 1.41\\ 1.54\\ 2.0\\ 1.25\\ 1.26\\ 1.0\\ 0.67\\ 1.25\\ 1.79\end{array}</math></td> <td>3.2 0.6 1.53 10.3 3.0 11.02 6.39 4.59 11.24 3.85 2.0 7.2 N/A 2.93 3.68 3.07</td> <td>3.0 4.3 0.98 2.9 1.5 5.32 5.39 7.97 3.44 3.11 4.20 5.22 N/A 1.90 4.97 6.67</td> <td><math display="block">\begin{array}{c} 0.3 \\ -0.53 \\ -1.66 \\ -1.0 \\ 0.2 \\ -0.59 \\ -0.76 \\ -0.11 \\ -0.74 \\ -2.53 \\ -1.64 \\ -0.13 \\ -3.7 \\ -1.31 \\ -1.02 \\ -1.41 \end{array}</math></td> <td><math display="block">\begin{array}{c} 0.8\\ 0.56\\ 0.55\\ 0.3\\ 0.3\\ 0.5\\ 2.85\\ 1.39\\ 0.868\\ 1.40\\ 2.06\\ 1.88\\ 3.0\\ 1.33\\ 1.67\\ \end{array}</math></td>	$\begin{array}{c} 1.4\\ 1.1\\ 0.54\\ 1.8\\ 0.7\\ 1.57\\ 2.46\\ 1.41\\ 1.54\\ 2.0\\ 1.25\\ 1.26\\ 1.0\\ 0.67\\ 1.25\\ 1.79\end{array}$	3.2 0.6 1.53 10.3 3.0 11.02 6.39 4.59 11.24 3.85 2.0 7.2 N/A 2.93 3.68 3.07	3.0 4.3 0.98 2.9 1.5 5.32 5.39 7.97 3.44 3.11 4.20 5.22 N/A 1.90 4.97 6.67	$\begin{array}{c} 0.3 \\ -0.53 \\ -1.66 \\ -1.0 \\ 0.2 \\ -0.59 \\ -0.76 \\ -0.11 \\ -0.74 \\ -2.53 \\ -1.64 \\ -0.13 \\ -3.7 \\ -1.31 \\ -1.02 \\ -1.41 \end{array}$	$\begin{array}{c} 0.8\\ 0.56\\ 0.55\\ 0.3\\ 0.3\\ 0.5\\ 2.85\\ 1.39\\ 0.868\\ 1.40\\ 2.06\\ 1.88\\ 3.0\\ 1.33\\ 1.67\\ \end{array}$
P       2       R       2.3         P       3       -       3.06         B       -       -       5.5         P       2       R       3.2         P       2       R       3.2         P       2       R       3.2         P       2       R       3.1         Z       -       -       2.04         P       2       NR       3.45         P       3       -       4.22         P       3       -       2.0         Z       -       -       2.0         Z       -       -       3.11         P       3       -       3.97         P       3       -       3.97         P       3       -       3.97         P       3       -       3.97         P       3       -       3.841         Z       -       3.80       -         3       -       3.80       -         B       -       -       4.09         B       -       -       4.09         B       -       -	$\begin{array}{c} 1.1\\ 0.54\\ 1.8\\ 0.7\\ 1.57\\ 2.46\\ 1.41\\ 1.54\\ 2.0\\ 1.25\\ 1.26\\ 1.0\\ 0.67\\ 1.25\\ 1.79\end{array}$	0.6 1.53 10.3 3.0 11.02 6.39 4.59 11.24 3.85 2.0 7.2 N/A 2.93 3.68 3.07	4.3 0.98 2.9 1.5 5.32 5.39 7.97 3.44 3.11 4.20 5.22 N/A 1.90 4.97 6.67	$\begin{array}{c} -0.53 \\ -1.66 \\ -1.0 \\ 0.2 \\ -0.59 \\ -0.76 \\ -0.11 \\ -0.74 \\ -2.53 \\ -1.64 \\ -0.13 \\ -3.7 \\ -1.31 \\ -1.02 \\ -1.41 \end{array}$	0.56 0.55 0.3 0.5 2.85 1.39 0.868 1.40 2.06 1.88 3.0 1.33 1.67
P       3       -       3.06         B       -       -       5.5         P       2       R       3.2         P       2       R       4.1         Z       -       -       5.31         B       -       -       2.04         P       2       NR       3.45         P       3       -       4.22         P       3       -       3.11         P       3       -       3.97         P       3       -       3.41         Z       -       -       3.41         P       3       -       3.80         P       3       -       3.80         P       3       -       3.80         P       3       -       3.80         P       2       R       5.3         B       -       -       4.29         P       3       -       4.09         B       -       -       4.26         P       3       -       4.66         P       3       -       4.66         P       3       - </td <td>0.54 1.8 0.7 1.57 2.46 1.41 1.54 2.0 1.25 1.26 1.0 0.67 1.25 1.25 1.79</td> <td>1.53 10.3 3.0 11.02 6.39 4.59 11.24 3.85 2.0 7.2 N/A 2.93 3.68 3.07</td> <td>0.98 2.9 1.5 5.32 5.39 7.97 3.44 3.11 4.20 5.22 N/A 1.90 4.97 6.67</td> <td><math display="block">\begin{array}{c} -1.66 \\ -1.0 \\ 0.2 \\ -0.59 \\ -0.76 \\ -0.11 \\ -0.74 \\ -2.53 \\ -1.64 \\ -0.13 \\ -3.7 \\ -1.31 \\ -1.02 \\ -1.41 \end{array}</math></td> <td>0.55 0.3 0.5 2.85 1.39 0.868 1.40 2.06 1.88 3.0 1.33 1.67</td>	0.54 1.8 0.7 1.57 2.46 1.41 1.54 2.0 1.25 1.26 1.0 0.67 1.25 1.25 1.79	1.53 10.3 3.0 11.02 6.39 4.59 11.24 3.85 2.0 7.2 N/A 2.93 3.68 3.07	0.98 2.9 1.5 5.32 5.39 7.97 3.44 3.11 4.20 5.22 N/A 1.90 4.97 6.67	$\begin{array}{c} -1.66 \\ -1.0 \\ 0.2 \\ -0.59 \\ -0.76 \\ -0.11 \\ -0.74 \\ -2.53 \\ -1.64 \\ -0.13 \\ -3.7 \\ -1.31 \\ -1.02 \\ -1.41 \end{array}$	0.55 0.3 0.5 2.85 1.39 0.868 1.40 2.06 1.88 3.0 1.33 1.67
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	1.8 0.7 1.57 2.46 1.41 1.54 2.0 1.25 1.26 1.0 0.67 1.25 1.79	10.3 3.0 11.02 6.39 4.59 11.24 3.85 2.0 7.2 N/A 2.93 3.68 3.07	2.9 1.5 5.32 5.39 7.97 3.44 3.11 4.20 5.22 N/A 1.90 4.97 6.67	$\begin{array}{c} -1.0\\ 0.2\\ -0.59\\ -0.76\\ -0.11\\ -0.74\\ -2.53\\ -1.64\\ -0.13\\ -3.7\\ -1.31\\ -1.02\\ -1.41\end{array}$	0.3 0.5 2.85 1.39 0.868 1.40 2.06 1.88 3.0 1.33 1.67
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	0.7 1.57 2.46 1.41 1.54 2.0 1.25 1.26 1.0 0.67 1.25 1.79	3.0 11.02 6.39 4.59 11.24 3.85 2.0 7.2 N/A 2.93 3.68 3.07	1.5 5.32 5.39 7.97 3.44 3.11 4.20 5.22 N/A 1.90 4.97 6.67	$\begin{array}{c} 0.2 \\ -0.59 \\ -0.76 \\ -0.11 \\ -0.74 \\ -2.53 \\ -1.64 \\ -0.13 \\ -3.7 \\ -1.31 \\ -1.02 \\ -1.41 \end{array}$	0.3 0.5 2.85 1.39 0.868 1.40 2.06 1.88 3.0 1.33 1.67
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	1.57 2.46 1.41 1.54 2.0 1.25 1.26 1.0 0.67 1.25 1.79	11.02 6.39 4.59 11.24 3.85 2.0 7.2 N/A 2.93 3.68 3.07	5.32 5.39 7.97 3.44 3.11 4.20 5.22 N/A 1.90 4.97 6.67	$\begin{array}{c} -0.59 \\ -0.76 \\ -0.11 \\ -0.74 \\ -2.53 \\ -1.64 \\ -0.13 \\ -3.7 \\ -1.31 \\ -1.02 \\ -1.41 \end{array}$	0.5 2.85 1.39 0.868 1.40 2.06 1.88 3.0 1.33 1.67
Z       -       -       5.31         B       -       -       2.04         P       2       NR       3.45         P       3       -       4.22         P       3       -       4.2         B       -       2.0       2         Z       -       -       3.1         P       3       -       3.97         P       3       -       3.80         -       3.80       -       3.20         P       2       R       5.3         B       -       -       4.09         B       -       -       4.66         P       3	2.46 1.41 1.54 2.0 1.25 1.26 1.0 0.67 1.25 1.79	6.39 4.59 11.24 3.85 2.0 7.2 N/A 2.93 3.68 3.07	5.39 7.97 3.44 3.11 4.20 5.22 N/A 1.90 4.97 6.67	-0.76 -0.11 -0.74 -2.53 -1.64 -0.13 -3.7 -1.31 -1.02 -1.41	2.85 1.39 0.868 1.40 2.06 1.88 3.0 1.33 1.67
Z       -       -       5.31         B       -       -       2.04         P       2       NR       3.45         P       3       -       4.22         P       3       -       4.2         B       -       2.0       2         Z       -       -       3.1         P       3       -       3.97         P       3       -       3.80         -       3.80       -       3.20         P       2       R       5.3         B       -       -       4.09         B       -       -       4.66         P       3	2.46 1.41 1.54 2.0 1.25 1.26 1.0 0.67 1.25 1.79	6.39 4.59 11.24 3.85 2.0 7.2 N/A 2.93 3.68 3.07	5.39 7.97 3.44 3.11 4.20 5.22 N/A 1.90 4.97 6.67	-0.76 -0.11 -0.74 -2.53 -1.64 -0.13 -3.7 -1.31 -1.02 -1.41	2.85 1.39 0.868 1.40 2.06 1.88 3.0 1.33 1.67
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	1.41 1.54 2.0 1.25 1.26 1.0 0.67 1.25 1.79	4.59 11.24 3.85 2.0 7.2 N/A 2.93 3.68 3.07	7.97 3.44 3.11 4.20 5.22 N/A 1.90 4.97 6.67	-0.11 -0.74 -2.53 -1.64 -0.13 -3.7 -1.31 -1.02 -1.41	1.39 0.868 1.40 2.06 1.88 3.0 1.33 1.67
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	1.54 2.0 1.25 1.26 1.0 0.67 1.25 1.79	11.24 3.85 2.0 7.2 N/A 2.93 3.68 3.07	3.44 3.11 4.20 5.22 N/A 1.90 4.97 6.67	-0.74 -2.53 -1.64 -0.13 -3.7 -1.31 -1.02 -1.41	0.868 1.40 2.06 1.88 3.0 1.33 1.67
P       3       - $4.22$ P       3       - $4.2$ B       -       2.0         Z       -       - $3.1$ P       3       - $3.97$ P       3       - $3.97$ P       3       - $3.41$ P       2       NR $4.2$ P       3       - $3.44$ Z       -       - $3.80$ P       3       - $3.20$ P       2       R $5.3$ B       -       - $4.09$ B       -       - $4.09$ B       -       - $4.26$ P       3       - $4.66$ P       3       - $4.26$ P       3       - $4.26$ P       3       - $3.35$	2.0 1.25 1.26 1.0 0.67 1.25 1.79	3.85 2.0 7.2 N/A 2.93 3.68 3.07	3.11 4.20 5.22 N/A 1.90 4.97 6.67	-2.53 -1.64 -0.13 -3.7 -1.31 -1.02 -1.41	1.40 2.06 1.88 3.0 1.33 1.67
P       3       - $4.2$ B       -       2.0         Z       -       -         P       3       -         3       -       3.97         P       3       -         P       3       -         P       3       -         P       3       -         P       3       -         P       3       -         P       3       -         P       3       -         P       3       -         P       3       -         P       3       -         P       3       -         B       -       -         P       3       -         B       -       -         P       3       -         B       -       -         P       3       -         P       3       -         P       3       -         P       3       -         P       3       -         P       3       -         P       3	1.25 1.26 1.0 0.67 1.25 1.79	2.0 7.2 N/A 2.93 3.68 3.07	4.20 5.22 N/A 1.90 4.97 6.67	-1.64 -0.13 -3.7 -1.31 -1.02 -1.41	2.06 1.88 3.0 1.33 1.67
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	1.26 1.0 0.67 1.25 1.79	7.2 N/A 2.93 3.68 3.07	5.22 N/A 1.90 4.97 6.67	-0.13 -3.7 -1.31 -1.02 -1.41	1.88 3.0 1.33 1.67
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	1.0 0.67 1.25 1.79	N/A 2.93 3.68 3.07	N/A 1.90 4.97 6.67	-3.7 -1.31 -1.02 -1.41	3.0 1.33 1.67
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	0.67 1.25 1.79	2.93 3.68 3.07	1.90 4.97 6.67	-1.31 -1.02 -1.41	1.33 1.67
P       3       - $3.41$ P       2       NR $4.2$ P       3       - $1.65$ P       3       - $3.44$ Z       -       - $3.80$ P       3       - $3.80$ P       2       R $5.3$ B       -       - $4.09$ B       -       - $4.2$ P       3       - $3.96$ P       3       - $4.66$ P       3       - $4.26$ P       3       - $3.35$	1.25 1.79	3.68 3.07	4.97 6.67	-1.02 -1.41	1.67
NR     3.24       P     2     NR     4.2       P     3     -     1.65       P     3     -     3.44       Z     -     -     3.80       -     -     3.20       P     2     R     5.3       B     -     -     4.09       B     -     -     4.09       P     3     -     3.96       P     3     -     2.69       P     3     -     3.35	1.79	3.07	6.67	-1.41	
P     2     NR     4.2       P     3     -     1.65       P     3     -     3.44       Z     -     -     3.80       -     -     3.80       -     -     3.20       P     2     R     5.3       B     -     -     4.09       B     -     -     4.09       P     3     -     3.96       P     3     -     2.69       A     -     3.35					2 07
P       3       -       1.65         P       3       -       3.44         Z       -       -       3.80         -       3.20       -       3.20         P       2       R       5.3         B       -       -       4.09         B       -       -       4.66         P       3       -       4.66         P       3       -       4.26         P       3       -       3.35	0.0		0.1	06	1.0
P       3       -       3.44         Z       -       -       3.80         -       3.20       3.20         P       2       R       5.3         B       -       -       4.09         B       -       -       4.2         P       3       -       3.96         P       3       -       4.66         P       3       -       2.69         -       -       3.35	-	0.3		-0.6	1.0
Z – – – 3.80 – 3.20 P 2 R 5.3 B – – – 4.09 B – – – 4.2 P 3 – 3.96 P 3 – 4.66 P 3 – 2.69 4.26 P 3 – 3.35	3.74	0.93	8.26	-0.35	2.13
-     3.20       P     2     R     5.3       B     -     -     4.09       B     -     -     4.2       P     3     -     3.96       P     3     -     2.69       P     3     -     3.35	1.08	2.35	6.74	1.42	1.12
P     2     R     5.3       B     -     -     4.09       B     -     -     4.2       P     3     -     3.96       P     3     -     2.69       P     3     -     3.35	1.16	7.41	1.5	-2.50	1.64
P     2     R     5.3       B     -     -     4.09       B     -     -     4.2       P     3     -     3.96       P     3     -     2.69       P     3     -     3.35	0.43	3.33	1.75	-0.93	0.16
B     -     -     4.2       P     3     -     3.96       P     3     -     4.66       P     3     -     2.69       -     4.26       P     3     -     3.35	2.1	0.1	12.4	-0.9	0.2
P 3 – 3.96 P 3 – 4.66 P 3 – 2.69 4.26 P 3 – 3.35	0.92	2.48	6.16	0.11	0.63
P 3 – 3.96 P 3 – 4.66 P 3 – 2.69 4.26 P 3 – 3.35	2.0	0.6	2.0	-0.8	0.6
P 3 – 4.66 P 3 – 2.69 4.26 P 3 – 3.35	2.0	0.6	3.8		2.6
P 3 – 2.69 4.26 P 3 – 3.35	1.46	1.86	1.94	1.60	1.45
4.26 P 3 – 3.35	2.23	1.48	6.68	-0.25	3.48
P 3 – 3.35	1.76	0.28	3.24	-0.57	1.90
	1.68	2.18	2.82	-0.15	1.76
P 3 – 436	0.42	N/A	N/A	N/A	N/A
6 1.00	4.26	0.94	6.59	0.04	2.54
3.18	3.33	4.36	8.54	0.95	2.55
Z – – 4.0	4.5	N/A	N/A	0.6	0.3
B – – 2.46	1.97	2.66	3.97	-0.92	1.16
P 3 – 5.4		3.3	1.4	-1.3	1.8
P 3 – 3.48	1.1	5.09	4.23	-2.53	2.39
P 3 – 4.4	1.1 2.20	0.8	1.0	-2.6	3.6
P 2 R 3.9		5.6		0.6	1.1
Z – – 4.0	2.20	0.1	3.0	0.0	

Downloaded from http://meridian.allenpress.com/angle-orthodontist/article-pdf/doi/10.2319/052223-364.1/3279216/10.2319\_052223-364.1.pdf by guest on 23 October 2023

the 3-TAD-supported subgroup ranged from -2.6 mm<sup>46</sup> (intrusion) to 1.6 mm<sup>39</sup> (extrusion).

Nonrigid devices had a slightly smaller distalization range (2.93  $\text{mm}^{21}$  to 4.2  $\text{mm}^{35}$ ) than rigid devices (2.3 mm<sup>26</sup> to 5.3 mm<sup>38</sup>). Distal tipping was greater in nonrigid devices ( $8.9^{\circ 35}$  to  $11.24^{\circ 30}$ ) than in rigid devices (0.1°38 to 11.02°29). Vertical movement values were similar between nonrigid and rigid palatal devices, ranging from -0.74 mm<sup>30</sup> to -0.6 mm<sup>35</sup> and from -1 mm<sup>22</sup> to 0.7 mm<sup>23</sup>, respectively.

#### Meta-analysis

Treatment comparison among buccal, palatal, and zygomatic TAD-supported appliances. Figure 2 compares devices with palatal, buccal, and zygomatic TADs in terms of distalization, tipping, and vertical

Table 3. ROB Table and Summary for the Nonrandomized Controlled Studies Included<sup>a</sup>

Study	D1	D2	D3	D4	D5	D6	D7	D8	D9	D10	D11	Overall
Nur et al., <sup>53</sup> 2012	+	+	+	+	+/-	+	+	+	+	+	+	+/-
Sar et al., <sup>21</sup> 2013	+	+	+	+	+	+	+	+	+	×	+	+
Suzuki and Suzuki, <sup>22</sup> 2013	+	+	+	+/-	+/-	+	+	+	+	×	+	+/-
Mariani et al., <sup>10</sup> 2014	+	+	+	+	+	+	+	+	+	×	+	+
Kook et al., <sup>24</sup> 2014	+	+	+	+/-	+	+	+	+	+	×	×	+/-
Caprioglio et al., <sup>25</sup> 2015	+	+	+	+	+	+	+	+	+	×	+	+
Miresmaeili et al., <sup>26</sup> 2015	+	+	+	+/-	+/-	+	+	+	+	×	+	+/-
Sa'aed et al., <sup>27</sup> 2015	+	+	+	+	+	+	+	+	+	×	+	+
Cozzani et al., <sup>28</sup> 2016	+	+	+	+	+	+	+	+	+	×	+	+
Duran et al., <sup>29</sup> 2016	+	+	+	+/-	+/-	+	+	+	+	×	+	+/-
Kilkis et al., <sup>55</sup> 2016	+	+	+	+	+	+	+	+	+	+	+	+
Ali et al., <sup>49</sup> 2016	+	+	+	+/-	+	+	+	+	+	×	×	+/-
Cambiano et al., <sup>30</sup> 2017	+	+	+	+/-	+/-	+	+	+	+	+/-	+	_
Park et al., <sup>31</sup> 2017	+	+	+	+	+/-	+	+	+	+	×	×	+/-
Lee et al., <sup>32</sup> 2018	+	+	+	+	+/-	+	+	+	+	×	+	+/-
Wu et al., <sup>56</sup> 2018	+	+	+	+/-	+	+	+	+	+	×	+	+/-
Jo et al., <sup>33</sup> 2018	+	+	+	+	+	+	+	+	+	×	+	+
Park et al., <sup>34</sup> 2018	+	+	+	+/-	+	+	+	+	+	×	+	+/-
Kırcalı and Yüksel, <sup>35</sup> 2018	+	+	+	+/-	+/-	+	+	+	+	×	+	+/-
Lee et al., <sup>36</sup> 2019	+	+	+	+	+	+	+	+	+	+	+	+
Shoaib et al., <sup>37</sup> 2019	+/-	+/-	+	+/-	+	+	+	+	+	×	+	_
Shahani et al., <sup>57</sup> 2019	+/-	+/-	+	?	+/-	+	+	+	+	×	×	?
Abdelhady et al., <sup>50</sup> 2020	+	+	+	+/-	+/-	+	+	+	+	+/-	+	_
Bechtold et al., <sup>51</sup> 2020	+	+	+	+/-	+	+	+	+	+	×	+	+/-
Alfaifi et al., <sup>39</sup> 2020	+	+	+	+	+/-	+	+	+	+	×	+	+/-
Chou et al., <sup>40</sup> 2021	+/-	+/-	+	+/-	+	+	+	+	+	×	+	_
Jung et al., <sup>41</sup> 2021	+	+	+	+/-	+	+	+	+	+	×	×	+/-
Park et al., <sup>42</sup> 2021	+/-	+/-	+	+/-	+	+	+	+	+	×	+	_
Park et al., <sup>43</sup> 2021	+	+	+	?	+	+	+	+	+	+	+/-	?
Shaikh et al., <sup>58</sup> 2021	+/-	+/-	+	+/-	+	+	+	+	+	×	×	_
Song et al., <sup>52</sup> 2022	+/-	+/-	+	+/-	+/-	+	+	+	+	×	+	_
Alfawaz et al.,44 2022	+	+	+	+	+/-	+	+	+	+	×	+	+/-
Kim et al., <sup>45</sup> 2022	+/-	+	+	+/-	+	+	+	+	+	×	+	+/-
Lim et al., <sup>46</sup> 2022	+	+	+	+	+	+	+	+	+	×	+	+
Altieri et al.,47 2022	+	+	+	+/-	+/-	+	+	+	+	×	+	+/-
Rosa et al., <sup>59</sup> 2023	+	+	+	+	+	+	+	+	+	×	+	+

<sup>a</sup> D1, were the two groups similar and recruited from the same population?; D2, were the exposures measured similarly to assign people to both exposed and unexposed groups?; D3, was the exposure measured in a valid and reliable way?; D4, were cofounding factors identified?; D5, were strategies to deal with confounding factors started?; D6, were the groups/participants free of the outcome at the start of the study?; D7, were the outcomes measured in a valid and reliable way?; D8, was the follow-up time reported and sufficient to be long enough for outcomes to occur?; D9, was the follow-up complete, and if not, were the reasons for loss to follow-up described and explored?; D10, were the strategies to address incomplete follow-up utilized?; D11, was the appropriate statistical analysis used?. ROB indicates risk of bias; +, low ROB; +/-, moderate ROB; -, serious ROB;?, critical ROB; and ×, no information.

movements. High heterogeneity ( $I^2 = 95\%$ ) and no significant differences in the amount of distalization (P = .64) were found among palatal (3.74 mm; 95% confidence interval [CI], [3.51, 3.98]; P < .0001;

 $I^2 = 87\%$ ), zygomatic (3.68 mm; 95% CI, [3.21, 4.14]; P < .0001;  $I^2 = 95\%$ ), and buccal (3.23 mm; 95% CI, [2.16, 4.30]; P < .0001;  $I^2 = 98\%$ ) anchorage locations.

Table 4.	ROB Graph and Summar	y for the Randomized Controlled Studies Included <sup>a</sup>
----------	----------------------	---

Table II HOB diapitana of	anninary for and							
Study	D1	D2	D3	D4	D5	D6	D7	Overall
Bechtold et al.,48 2013	+	+	+/-	+/-	+	+/-	+/-	+/-
Cozzani et al., <sup>23</sup> 2014	+	_	+/-	+/-	+	+	+/-	_
El-Dawlatly et al., <sup>54</sup> 2014	+	+	+/-	+/-	+	+	+/-	+/-
Cassetta et al., <sup>38</sup> 2019	+	+	+/-	_	+	+	+/-	_

<sup>a</sup> D1, was true randomization used for assignment of participants to a treatment group? (selection bias); D2, was allocation to treatment groups concealed? (selection bias); D3, were participants blind to treatment assignment? (performance bias); D4, were outcomes measured in a reliable way? (detection bias); D5, was the follow-up complete, and if not, were differences between groups in terms of their follow-up adequately described and analyzed? (attrition bias); D6, was appropriate statistical analysis used? (reporting bias); D7, was the trial design appropriate, and were any deviations from the standard RCT design accounted for in the conduct and analysis of the trial? (statistical conclusion validity). ROB indicates risk of bias; –, low ROB; +/–, moderate ROB; and –, serious ROB.

Chudu an Cubanaun			то	T1		Mean Difference	Mean Difference	
Study or Subgroup	Mean Difference	SE	Total	Total	Weight	IV, Random, 95% CI Ye	ear IV, Random, 95% Cl	
Palatal								
Sar et al. 2013b	2.93	0.47	14	14	1.9%	2.93 [2.01, 3.85] 20	13	
Sar et al. 2013a	2.81	0.7	14	14	1.5%	2.81 [1.44, 4.18] 20	13	
Suzuki et al. 2013	4.5	0.33	20	20	2.2%	4.50 [3.85, 5.15] 20	13	-
Cozzani et al. 2014	4.7	0.38	18	18	2.1%	4.70 [3.96, 5.44] 20	14	_
Kook et al 2014	3.3	0.4	20	20	2.1%	3.30 [2.52, 4.08] 20	14	
Caprioglio et al. 2015	4.2	0.32	19	19	2.2%	4.20 [3.57, 4.83] 20	15	
Miresmaelli et al. 2015	2.3	0.22	26	26	2.4%	2.30 [1.87, 2.73] 20	15 -	
Sa'aed et al 2015	3.06	0.11	24	24	2.6%	3.06 [2.84, 3.28] 20	15 -	
Cozzani et al. 2016b	3.2	0.14	24	24	2.5%	3.20 [2.93, 3.47] 20	16 -	
Duran et al. 2016	4.1	0.34	21	21	2.2%	4.10 [3.43, 4.77] 20	16	
Cambiano et al. 2017	3.45	0.36	18	18	2.2%	3.45 [2.74, 4.16] 20	17	
Park et al 2017	4.22	0.43	22	22	2.0%	4.22 [3.38, 5.06] 20	17	
Park et al 2018a	3.41	0.3	17	17	2.3%	3.41 [2.82, 4.00] 20	18	
Park et al 2018b	3.24	0.45	16	16	2.0%	3.24 [2.36, 4.12] 20	18	
Kircali et al. 2018	4.2	0.18	20	20	2.5%	4.20 [3.85, 4.55] 20		
Jo et al 2018	3.97	0.15	20	20	2.5%	3.97 [3.68, 4.26] 20		
Lee et al 2018a		0.27	22	22	2.3%	4.20 [3.67, 4.73] 20	and the second se	
Shoaib et al 2019		0.22	23	23	2.4%	3.44 [3.01, 3.87] 20		
Cassetta et al. 2019		0.66	10	10	1.5%	5.30 [4.01, 6.59] 20		<u> </u>
Lee et al 2019		0.84	20	20	1.2%	1.65 [0.00, 3.30] 20		
Alfaifi et al 2020		0.32	21	21	2.2%	3.96 [3.33, 4.59] 20		
Jung et al 2021a		0.39	20	20	2.1%	2.69 [1.93, 3.45] 20		
Jung et al 2021b		0.37	20	20	2.1%	4.26 [3.53, 4.99] 20		
Park et al 2021a		0.03	284	284	2.6%	3.35 [3.29, 3.41] 20		
Park et al 2021b	4.36	1.1	15	15	0.9%	4.36 [2.20, 6.52] 20		
Park et al 2021c		0.96	12	12	1.1%	3.18 [1.30, 5.06] 20		
Chou et al 2021	4.66	0.90	20	20	1.1%	a come decision on the rest of		
Alfawaz et al 2022		0.22	25	25		4.66 [3.68, 5.64] 20		-
	3.9	0.22	23	22	2.4% 2.3%	5.40 [4.97, 5.83] 20		
Altieri et al. 2022		0.20	30	30		3.90 [3.39, 4.41] 20		
Kim et al. 2022	3.48				2.1%	3.48 [2.70, 4.26] 20		
Lim et al. 2022 Subtotal (95% CI)	4.4	0.89	24 881	24 881	1.2% 63.5%	4.40 [2.66, 6.14] 20 3.74 [3.51, 3.98]	A	
Test for overall effect: Z	= 31.40 (P < 0.0000	1)						
Buccal								
Buccal	1.20	0 10	10	10	2 5%	1 20 10 02 1 661 20		
Bechtold et al 2013a		0.19	12	12	2.5%	1.29 [0.92, 1.66] 20		
Bechtold et al 2013a Bechtold et al 2013b	2.91	0.26	13	13	2.3%	2.91 [2.40, 3.42] 20	13 -	
Bechtold et al 2013a Bechtold et al 2013b Mariani et al. 2014	2.91 4.6	0.26 0.05	13 30	13 30	2.3% 2.6%	2.91 [2.40, 3.42] 20 4.60 [4.50, 4.70] 20	13 <del>-</del> 14 ·	
Bechtold et al 2013a Bechtold et al 2013b Mariani et al. 2014 Ali et al 2016	2.91 4.6 2.04	0.26 0.05 0.34	13 30 17	13 30 17	2.3% 2.6% 2.2%	2.91 [2.40, 3.42] 20 4.60 [4.50, 4.70] 20 2.04 [1.37, 2.71] 20	113	
Bechtold et al 2013a Bechtold et al 2013b Mariani et al. 2014 Ali et al 2016 Cozzani et al 2016a	2.91 4.6 2.04 5.5	0.26 0.05 0.34 0.33	13 30 17 29	13 30 17 29	2.3% 2.6% 2.2% 2.2%	2.91 [2.40, 3.42] 20 4.60 [4.50, 4.70] 20 2.04 [1.37, 2.71] 20 5.50 [4.85, 6.15] 20	113	<u> </u>
Bechtold et al 2013a Bechtold et al 2013b Mariani et al. 2014 Ali et al 2016 Cozzani et al 2016a Lee et al 2018b	2.91 4.6 2.04 5.5 2	0.26 0.05 0.34 0.33 0.29	13 30 17 29 18	13 30 17 29 18	2.3% 2.6% 2.2% 2.2% 2.3%	2.91 [2.40, 3.42] 20 4.60 [4.50, 4.70] 20 2.04 [1.37, 2.71] 20 5.50 [4.85, 6.15] 20 2.00 [1.43, 2.57] 20	113	
Bechtold et al 2013a Bechtold et al 2013b Mariani et al. 2014 Ali et al 2016 Cozzani et al 2016a Lee et al 2018b Abdelhady et al 2020	2.91 4.6 2.04 5.5 2 4.09	0.26 0.05 0.34 0.33 0.29 0.28	13 30 17 29 18 11	13 30 17 29 18 11	2.3% 2.6% 2.2% 2.2% 2.3% 2.3%	2.91         [2.40, 3.42]         20           4.60         [4.50, 4.70]         20           2.04         [1.37, 2.71]         20           5.50         [4.85, 6.15]         20           2.00         [1.43, 2.57]         20           4.09         [3.54, 4.64]         20	113	
Bechtold et al 2013a Bechtold et al 2013b Mariani et al. 2014 Ali et al 2016 Cozzani et al 2016a Lee et al 2018b Abdelhady et al 2020 Bechtold et al 2020	2.91 4.6 2.04 5.5 2 4.09 4.2	0.26 0.05 0.34 0.33 0.29 0.28 0.46	13 30 17 29 18 11 19	13 30 17 29 18 11 19	2.3% 2.6% 2.2% 2.3% 2.3% 1.9%	2.91 [2.40, 3.42] 20 4.60 [4.50, 4.70] 20 2.04 [1.37, 2.71] 20 5.50 [4.85, 6.15] 20 2.00 [1.43, 2.57] 20 4.09 [3.54, 4.64] 20 4.20 [3.30, 5.10] 20	113	
Bechtold et al 2013a Bechtold et al 2013b Mariani et al. 2014 Ali et al 2016 Cozzani et al 2016a Lee et al 2018b Abdelhady et al 2020 Bechtold et al 2020 Song et al 2022	2.91 4.6 2.04 5.5 2 4.09	0.26 0.05 0.34 0.33 0.29 0.28 0.46	13 30 17 29 18 11 19 39	13 30 17 29 18 11 19 39	2.3% 2.6% 2.2% 2.3% 2.3% 1.9% 2.3%	2.91 [2.40, 3.42] 20 4.60 [4.50, 4.70] 20 2.04 [1.37, 2.71] 20 5.50 [4.85, 6.15] 20 2.00 [1.43, 2.57] 20 4.09 [3.54, 4.64] 20 4.20 [3.30, 5.10] 20 2.46 [1.85, 3.07] 20	113	
Bechtold et al 2013a Bechtold et al 2013b Mariani et al. 2014 Ali et al 2016 Cozzani et al 2016a Lee et al 2018b Abdelhady et al 2020 Bechtold et al 2020 Song et al 2022 Subtotal (95% CI)	2.91 4.6 2.04 5.5 2 4.09 4.2 2.46	0.26 0.05 0.34 0.33 0.29 0.28 0.46 0.31	13 30 17 29 18 11 19 39 <b>188</b>	13 30 17 29 18 11 19 39 <b>188</b>	2.3% 2.6% 2.2% 2.3% 2.3% 1.9% 2.3% 20.6%	2.91 [2.40, 3.42] 20 4.60 [4.50, 4.70] 20 2.04 [1.37, 2.71] 20 5.50 [4.85, 6.15] 20 2.00 [1.43, 2.57] 20 4.09 [3.54, 4.64] 20 4.20 [3.30, 5.10] 20	113	
Bechtold et al 2013a Bechtold et al 2013b Mariani et al. 2014 Ali et al 2016 Cozzani et al 2016a Lee et al 2018b Abdelhady et al 2020 Bechtold et al 2020 Song et al 2022 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 2	2.91 4.6 2.04 5.5 2 4.09 4.2 2.46 .60; Chi <sup>2</sup> = 468.15, d	0.26 0.05 0.34 0.29 0.28 0.46 0.31 f = 8 (F	13 30 17 29 18 11 19 39 <b>188</b>	13 30 17 29 18 11 19 39 <b>188</b>	2.3% 2.6% 2.2% 2.3% 2.3% 1.9% 2.3% 20.6%	2.91 [2.40, 3.42] 20 4.60 [4.50, 4.70] 20 2.04 [1.37, 2.71] 20 5.50 [4.85, 6.15] 20 2.00 [1.43, 2.57] 20 4.09 [3.54, 4.64] 20 4.20 [3.30, 5.10] 20 2.46 [1.85, 3.07] 20	113	
Bechtold et al 2013a	2.91 4.6 2.04 5.5 2 4.09 4.2 2.46 .60; Chi <sup>2</sup> = 468.15, d	0.26 0.05 0.34 0.29 0.28 0.46 0.31 f = 8 (F	13 30 17 29 18 11 19 39 <b>188</b>	13 30 17 29 18 11 19 39 <b>188</b>	2.3% 2.6% 2.2% 2.3% 2.3% 1.9% 2.3% 20.6%	2.91 [2.40, 3.42] 20 4.60 [4.50, 4.70] 20 2.04 [1.37, 2.71] 20 5.50 [4.85, 6.15] 20 2.00 [1.43, 2.57] 20 4.09 [3.54, 4.64] 20 4.20 [3.30, 5.10] 20 2.46 [1.85, 3.07] 20	113	
Bechtold et al 2013a Bechtold et al 2013b Mariani et al. 2014 Ali et al 2016 Cozzani et al 2016a Lee et al 2018b Abdelhady et al 2020 Bechtold et al 2020 Song et al 2022 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 2 Test for overall effect: Z Zygomatic	2.91 4.6 2.04 5.5 2 4.09 4.2 2.46 .60; Chi <sup>2</sup> = 468.15, d = 5.91 (P < 0.00001	0.26 0.05 0.34 0.33 0.29 0.28 0.46 0.31 f = 8 (F	13 30 17 29 18 11 19 39 <b>188</b> <b>2 &lt; 0.00</b>	13 30 17 29 18 11 19 39 <b>188</b> 0001); I	2.3% 2.6% 2.2% 2.3% 2.3% 2.3% 2.3% 2.3% 2.3% 2.6% 2.3%	2.91 [2.40, 3.42] 20 4.60 [4.50, 4.70] 20 2.04 [1.37, 2.71] 20 5.50 [4.85, 6.15] 20 4.09 [3.54, 4.64] 20 4.20 [3.30, 5.10] 20 2.46 [1.85, 3.07] 20 3.23 [2.16, 4.30]	113	
Bechtold et al 2013a Bechtold et al 2013b Mariani et al. 2014 Ali et al 2016 Cozzani et al 2016a Lee et al 2018b Abdelhady et al 2020 Bechtold et al 2020 Song et al 2022 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 2 Test for overall effect: Z Zygomatic Nur et al 2012	2.91 4.6 2.04 5.5 2 4.09 4.2 2.46 .60; Chi <sup>2</sup> = 468.15, d = 5.91 (P < 0.00001 4.36	0.26 0.05 0.34 0.33 0.29 0.28 0.46 0.31 f = 8 (F )	13 30 17 29 18 11 19 39 <b>188</b> <b>&gt; &lt;</b> 0.00	13 30 17 29 18 11 19 39 <b>188</b> 0001); I	2.3% 2.6% 2.2% 2.3% 2.3% 2.3% 2.3% 2.3% 2.3% 2.3	2.91 [2.40, 3.42] 20 4.60 [4.50, 4.70] 20 2.04 [1.37, 2.71] 20 5.50 [4.85, 6.15] 20 2.00 [1.43, 2.57] 20 4.09 [3.54, 4.64] 20 4.20 [3.30, 5.10] 20 2.46 [1.85, 3.07] 20 3.23 [2.16, 4.30] 4.36 [3.28, 5.44] 20	113	
Bechtold et al 2013a Bechtold et al 2013b Mariani et al. 2014 Ali et al 2016 Cozzani et al 2016a Lee et al 2018b Abdelhady et al 2020 Bechtold et al 2020 Song et al 2022 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 2 Test for overall effect: Z Zygomatic Nur et al 2012 El-Dawlaty et al 2014	2.91 4.6 2.04 5.5 2 4.09 4.2 2.46 .60; Chi <sup>2</sup> = 468.15, d = 5.91 (P < 0.00001 4.36 2.93	0.26 0.05 0.34 0.29 0.28 0.46 0.31 f = 8 (F ) 0.55 0.22	13 30 17 29 18 11 19 39 <b>188</b> <b>&gt; &lt; 0.00</b> 15 10	13 30 17 29 18 11 19 39 <b>188</b> 0001); I 15 10	2.3% 2.6% 2.2% 2.3% 2.3% 2.3% 2.3% 2.3% 20.6% 2° = 98%	2.91 [2.40, 3.42]       20         4.60 [4.50, 4.70]       20         2.04 [1.37, 2.71]       20         5.50 [4.85, 6.15]       20         2.00 [1.43, 2.57]       20         4.09 [3.54, 4.64]       20         4.20 [3.30, 5.10]       20         2.46 [1.85, 3.07]       20         3.23 [2.16, 4.30]       4.36 [3.28, 5.44]       20         2.93 [2.50, 3.36]       20	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	 -
Bechtold et al 2013a Bechtold et al 2013b Mariani et al. 2014 Ali et al 2016 Cozzani et al 2016a Lee et al 2018b Abdelhady et al 2020 Bechtold et al 2020 Song et al 2022 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 2 Test for overall effect: Z Zygomatic Nur et al 2012 El-Dawlaty et al 2014 Kilkis et al 2016	2.91 4.6 2.04 5.5 2 4.09 4.2 2.46 .60; Chi <sup>2</sup> = 468.15, d = 5.91 (P < 0.00001 4.36 2.93 5.31	0.26 0.05 0.34 0.29 0.28 0.46 0.31 f = 8 (F ) 0.55 0.22 0.53	13 30 17 29 18 11 19 39 <b>188</b> <b>&gt; &lt; 0.00</b> 15 10 21	13 30 17 29 18 11 19 39 <b>188</b> 0001); I 15 10 21	2.3% 2.6% 2.2% 2.3% 2.3% 2.3% 2.3% 2.6% 2.3% 20.6% 2 = 98%	2.91 [2.40, 3.42]       20         4.60 [4.50, 4.70]       20         2.04 [1.37, 2.71]       20         5.50 [4.85, 6.15]       20         2.00 [1.43, 2.57]       20         4.09 [3.54, 4.64]       20         2.46 [1.85, 3.07]       20         3.23 [2.16, 4.30]       20         4.36 [3.28, 5.44]       20         2.93 [2.50, 3.36]       20         5.31 [4.27, 6.35]       20	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	
Bechtold et al 2013a Bechtold et al 2013b Mariani et al. 2014 Ali et al 2016 Cozzani et al 2016a Lee et al 2018b Abdelhady et al 2020 Bechtold et al 2020 Song et al 2022 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 2 Test for overall effect: Z Zygomatic Nur et al 2012 EI-Dawlaty et al 2014 Kilkis et al 2016 Mu et al 2018	2.91 4.6 2.04 5.5 2 4.09 4.2 2.46 .60; Chi <sup>2</sup> = 468.15, d = 5.91 (P < 0.00001 4.36 2.93 5.31 3.1	0.26 0.05 0.34 0.29 0.28 0.46 0.31 f = 8 (F ) 0.55 0.22 0.53 0.22	13 30 17 29 18 11 19 39 <b>188</b> > < 0.00 15 10 21 20	13 30 17 29 18 11 19 39 <b>188</b> 0001); I 15 10 21 20	2.3% 2.6% 2.2% 2.3% 2.3% 2.3% 20.6% 2.3% 20.6% 2.3% 20.6% 2.4%	2.91 [2.40, 3.42]       20         4.60 [4.50, 4.70]       20         2.04 [1.37, 2.71]       20         5.50 [4.85, 6.15]       20         2.00 [1.43, 2.57]       20         4.09 [3.54, 4.64]       20         2.20 [3.30, 5.10]       20         2.32 [2.16, 4.30]       20         4.36 [3.28, 5.44]       20         2.93 [2.50, 3.36]       20         5.31 [4.27, 6.35]       20         3.10 [2.67, 3.53]       20	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	
Bechtold et al 2013a Bechtold et al 2013b Mariani et al. 2014 Ali et al 2016 Cozzani et al 2016a Lee et al 2018b Abdelhady et al 2020 Bechtold et al 2020 Song et al 2022 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 2 Test for overall effect: Z Zygomatic Nur et al 2012 El-Dawlaty et al 2014 Kilkis et al 2016 Wu et al 2018 Shahani et al 2019a	2.91 4.6 2.04 5.5 2 4.09 4.2 2.46 .60; Chi <sup>2</sup> = 468.15, d = 5.91 (P < 0.00001 4.36 2.93 5.31 3.1 3.8	0.26 0.05 0.34 0.29 0.28 0.46 0.31 f = 8 (F) 0.55 0.22 0.53 0.22 0.53 0.22 0.47	13 30 17 29 18 11 19 39 <b>188</b> > < 0.00 15 10 21 20 6	13 30 17 29 18 11 19 39 <b>188</b> 0001); I 15 10 21 20 6	2.3% 2.6% 2.2% 2.3% 2.3% 2.3% 2.3% 20.6% <sup>2</sup> = 98% 1.8% 2.4% 1.8% 2.4% 1.9%	2.91 [2.40, 3.42] 20 4.60 [4.50, 4.70] 20 2.04 [1.37, 2.71] 20 5.50 [4.85, 6.15] 20 2.00 [1.43, 2.57] 20 4.09 [3.54, 4.64] 20 4.20 [3.30, 5.10] 20 2.46 [1.85, 3.07] 20 3.23 [2.16, 4.30] 4.36 [3.28, 5.44] 20 2.93 [2.50, 3.36] 20 5.31 [4.27, 6.35] 20 3.80 [2.88, 4.72] 20	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	
Bechtold et al 2013a Bechtold et al 2013b Mariani et al. 2014 Ali et al 2016 Cozzani et al 2016a Lee et al 2018b Abdelhady et al 2020 Bechtold et al 2020 Song et al 2022 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 2 Test for overall effect: Z Zygomatic Nur et al 2012 EI-Dawlaty et al 2014 Kilkis et al 2016 Wu et al 2018 Shahani et al 2019a	2.91 4.6 2.04 5.5 2 4.09 4.2 2.46 .60; Chi <sup>2</sup> = 468.15, d = 5.91 (P < 0.00001 4.36 2.93 5.31 3.1 3.8 3.2	0.26 0.05 0.34 0.29 0.28 0.46 0.31 f = 8 (F ) 0.55 0.22 0.53 0.22 0.53 0.22 0.47 0.17	13 30 17 29 18 11 19 39 188 > < 0.00 15 10 21 20 6 6	13 30 17 29 18 11 19 39 188 0001); I 15 10 21 20 6 6	2.3% 2.6% 2.2% 2.3% 1.9% 2.3% 20.6% 2° = 98% 1.8% 2.4% 1.8% 2.4% 1.8% 2.5%	2.91 [2.40, 3.42] 20 4.60 [4.50, 4.70] 20 2.04 [1.37, 2.71] 20 5.50 [4.85, 6.15] 20 4.09 [3.54, 4.64] 20 4.20 [3.30, 5.10] 20 2.46 [1.85, 3.07] 20 3.23 [2.16, 4.30] 4.36 [3.28, 5.44] 20 2.93 [2.50, 3.36] 20 5.31 [4.27, 6.35] 20 3.10 [2.67, 3.53] 20 3.20 [2.87, 3.53] 20	113 114 116 118 120 122 122 122 14 114 116 118 119 119 119 119 111 113 114 114 115 116 117 118 118	
Bechtold et al 2013a Bechtold et al 2013b Mariani et al. 2014 Ali et al 2016 Cozzani et al 2016a Lee et al 2018b Abdelhady et al 2020 Bechtold et al 2020 Song et al 2022 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 2 Test for overall effect: Z Zygomatic Nur et al 2012 EI-Dawlaty et al 2014 Kilkis et al 2016 Wu et al 2018 Shahani et al 2019a Shahani et al 2019b	2.91 4.6 2.04 5.5 2 4.09 4.2 2.46 .60; Chi <sup>2</sup> = 468.15, d = 5.91 (P < 0.00001 4.36 2.93 5.31 3.1 3.8 3.2 4	0.26 0.05 0.34 0.33 0.29 0.28 0.46 0.31 f = 8 (F 0.55 0.22 0.53 0.22 0.53 0.22 0.47 0.17 1.42	13 30 17 29 18 11 39 39 188 > < 0.00 15 10 21 20 6 6 10	13 30 17 29 18 11 19 39 <b>188</b> 0001); 1 15 10 21 20 6 6 10	2.3% 2.6% 2.2% 2.3% 1.9% 2.3% 20.6% 2° = 98% 1.8% 2.4% 1.8% 2.4% 1.8% 2.5% 0.6%	2.91 [2.40, 3.42] 20 4.60 [4.50, 4.70] 20 2.04 [1.37, 2.71] 20 5.50 [4.85, 6.15] 20 2.00 [1.43, 2.57] 20 4.09 [3.54, 4.64] 20 4.20 [3.30, 5.10] 20 2.46 [1.85, 3.07] 20 3.23 [2.16, 4.30] 4.36 [3.28, 5.44] 20 2.93 [2.50, 3.36] 20 5.31 [4.27, 6.35] 20 3.10 [2.67, 3.53] 20 3.80 [2.88, 4.72] 20 3.80 [2.88, 4.72] 20 3.20 [2.87, 3.53] 20 4.00 [1.22, 6.78] 20	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	- -
Bechtold et al 2013a Bechtold et al 2013b Mariani et al. 2014 Ali et al 2016 Cozzani et al 2016a Lee et al 2018b Abdelhady et al 2020 Bechtold et al 2020 Song et al 2022 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 2 Test for overall effect: Z Zygomatic Nur et al 2012 El-Dawlaty et al 2014 Kilkis et al 2016 Wu et al 2018 Shahani et al 2019a Shahani et al 2019a Shahani et al 2021 Rosa et al. 2023	2.91 4.6 2.04 5.5 2 4.09 4.2 2.46 .60; Chi <sup>2</sup> = 468.15, d = 5.91 (P < 0.00001 4.36 2.93 5.31 3.1 3.8 3.2 4	0.26 0.05 0.34 0.29 0.28 0.46 0.31 f = 8 (F ) 0.55 0.22 0.53 0.22 0.53 0.22 0.47 0.17	13 30 17 29 18 11 19 39 <b>188</b> 5 < 0.00 15 10 21 20 6 6 10 25	13 30 17 29 18 11 19 39 188 0001); I 15 10 21 20 6 6 10 25	2.3% 2.6% 2.2% 2.3% 2.3% 2.3% 20.6% 2* = 98% 1.8% 2.4% 1.8% 2.4% 1.9% 2.5% 0.6% 2.4%	2.91 [2.40, 3.42] 20 4.60 [4.50, 4.70] 20 2.04 [1.37, 2.71] 20 5.50 [4.85, 6.15] 20 2.00 [1.43, 2.57] 20 4.09 [3.54, 4.64] 20 4.20 [3.30, 5.10] 20 2.46 [1.85, 3.07] 20 3.23 [2.16, 4.30] 4.36 [3.28, 5.44] 20 2.93 [2.50, 3.36] 20 5.31 [4.27, 6.35] 20 3.10 [2.67, 3.53] 20 3.80 [2.88, 4.72] 20 3.80 [2.87, 3.53] 20 3.80 [2.87, 3.53] 20 4.00 [1.22, 6.78] 20 4.00 [3.59, 4.41] 20	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	- -
Bechtold et al 2013a Bechtold et al 2013b Mariani et al. 2014 Ali et al 2016 Cozzani et al 2016a Lee et al 2018b Abdelhady et al 2020 Bechtold et al 2020 Song et al 2022 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 2 Test for overall effect: Z Zygomatic Nur et al 2012 El-Dawlaty et al 2014 Kilkis et al 2016 Wu et al 2018 Shahani et al 2019a Shahani et al 2019a Shahani et al 2021 Rosa et al. 2023 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0	2.91 4.6 2.04 5.5 2 4.09 4.2 2.46 .60; Chi <sup>2</sup> = 468.15, d = 5.91 (P < 0.00001 4.36 2.93 5.31 3.1 3.1 3.8 3.2 4 4 .30; Chi <sup>2</sup> = 32.83, df	0.26 0.05 0.34 0.33 0.29 0.28 0.46 0.31 f = 8 (f 0.55 0.22 0.53 0.22 0.53 0.22 0.47 0.17 1.42 0.21 = 7 (P	13 30 17 29 18 11 19 39 188 5 < 0.00 6 6 6 0 10 21 20 6 10 21 20 6 10 21 21 20 12 13	13 30 17 29 18 11 19 39 <b>188</b> 0001); I 15 10 21 20 6 6 10 21 20 6 10 21	2.3% 2.6% 2.2% 2.3% 2.3% 2.3% 20.6% 2* = 98% 1.8% 2.4% 1.8% 2.4% 1.9% 2.5% 0.6% 2.4% 15.9%	2.91 [2.40, 3.42] 20 4.60 [4.50, 4.70] 20 2.04 [1.37, 2.71] 20 5.50 [4.85, 6.15] 20 2.00 [1.43, 2.57] 20 4.09 [3.54, 4.64] 20 4.20 [3.30, 5.10] 20 2.46 [1.85, 3.07] 20 3.23 [2.16, 4.30] 4.36 [3.28, 5.44] 20 2.93 [2.50, 3.36] 20 5.31 [4.27, 6.35] 20 3.10 [2.67, 3.53] 20 3.80 [2.88, 4.72] 20 3.80 [2.88, 4.72] 20 3.20 [2.87, 3.53] 20 4.00 [1.22, 6.78] 20	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	
Bechtold et al 2013a Bechtold et al 2013b Mariani et al. 2014 Ali et al 2016 Cozzani et al 2016a Lee et al 2018b Abdelhady et al 2020 Bechtold et al 2020 Song et al 2022 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 2 <b>Zygomatic</b> Nur et al 2012 EI-Dawlaty et al 2014 Kilkis et al 2016 Wu et al 2018 Shahani et al 2019a Shahani et al 2019a Shahani et al 2019a Shahani et al 2021 Rosa et al. 2023 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0 Test for overall effect: Z	2.91 4.6 2.04 5.5 2 4.09 4.2 2.46 .60; Chi <sup>2</sup> = 468.15, d = 5.91 (P < 0.00001 4.36 2.93 5.31 3.1 3.1 3.8 3.2 4 4 .30; Chi <sup>2</sup> = 32.83, df	0.26 0.05 0.34 0.33 0.29 0.28 0.46 0.31 f = 8 (f 0.55 0.22 0.53 0.22 0.53 0.22 0.47 0.17 1.42 0.21 = 7 (P	13 30 17 29 18 11 19 39 188 11 19 39 188 11 10 21 20 6 6 6 10 25 113 < < 0.000	13 30 17 29 18 11 19 39 <b>188</b> 11 19 39 <b>188</b> 0001); I 15 10 21 20 21 20 6 6 6 10 25 113 01); I <sup>2</sup> =	2.3% 2.6% 2.2% 2.3% 1.9% 2.3% 20.6% 2.3% 2.4% 1.8% 2.4% 1.8% 2.4% 1.9% 2.5% 0.6% 2.4% 15.9%	2.91 [2.40, 3.42] 20 4.60 [4.50, 4.70] 20 2.04 [1.37, 2.71] 20 5.50 [4.85, 6.15] 20 2.00 [1.43, 2.57] 20 4.09 [3.54, 4.64] 20 4.20 [3.30, 5.10] 20 2.46 [1.85, 3.07] 20 3.23 [2.16, 4.30] 4.36 [3.28, 5.44] 20 2.93 [2.50, 3.36] 20 5.31 [4.27, 6.35] 20 3.10 [2.67, 3.53] 20 3.20 [2.87, 3.53] 20 4.00 [1.22, 6.78] 20 4.00 [3.59, 4.41] 20 3.68 [3.21, 4.14]	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	- -
Bechtold et al 2013a Bechtold et al 2013b Mariani et al. 2014 Ali et al 2016 Cozzani et al 2016a Lee et al 2018b Abdelhady et al 2020 Bechtold et al 2020 Song et al 2022 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 2 Test for overall effect: Z Zygomatic Nur et al 2012 EI-Dawlaty et al 2014 Kilkis et al 2016 Wu et al 2018 Shahani et al 2019a Shahani et al 2021 Rosa et al. 2023 Subtotal (95% CI)	2.91 4.6 2.04 5.5 2 4.09 4.2 2.46 .60; Chi <sup>2</sup> = 468.15, d = 5.91 (P < 0.00001 4.36 2.93 5.31 3.1 3.8 8.3.2 4 4.30; Chi <sup>2</sup> = 32.83, df = 15.40 (P < 0.0000	0.26 0.05 0.34 0.29 0.28 0.46 0.31 f = 8 (F 0.55 0.22 0.53 0.22 0.53 0.22 0.47 0.17 1.42 0.21 = 7 (P 1)	13 30 17 29 18 11 19 39 188 11 19 39 188 2 0 6 6 10 25 113 < 0.000 25 113 1182	13 30 17 29 18 11 19 39 188 0001); I 15 10 21 20 6 6 6 10 25 113 01); I <sup>2</sup> = 1182	2.3% 2.6% 2.2% 2.3% 1.9% 2.3% 20.6% 2.3% 20.6% 2.4% 1.8% 2.4% 1.8% 2.4% 1.9% 2.5% 0.6% 2.4% 15.9% 3.79%	2.91 [2.40, 3.42] 20 4.60 [4.50, 4.70] 20 2.04 [1.37, 2.71] 20 5.50 [4.85, 6.15] 20 2.00 [1.43, 2.57] 20 4.09 [3.54, 4.64] 20 4.20 [3.30, 5.10] 20 2.46 [1.85, 3.07] 20 3.23 [2.16, 4.30] 4.36 [3.28, 5.44] 20 2.93 [2.50, 3.36] 20 5.31 [4.27, 6.35] 20 3.10 [2.67, 3.53] 20 3.80 [2.88, 4.72] 20 3.80 [2.87, 3.53] 20 3.80 [2.87, 3.53] 20 4.00 [1.22, 6.78] 20 4.00 [3.59, 4.41] 20	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	- -
Bechtold et al 2013a Bechtold et al 2013b Mariani et al. 2014 Ali et al 2016 Cozzani et al 2016a Lee et al 2018b Abdelhady et al 2020 Bechtold et al 2020 Song et al 2022 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 2 <b>Zygomatic</b> Nur et al 2012 EI-Dawlaty et al 2014 Kilkis et al 2016 Wu et al 2018 Shahani et al 2019a Shahani et al 2019a Shahani et al 2019a Shahani et al 2021 Rosa et al. 2023 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0 Test for overall effect: Z	2.91 4.6 2.04 5.5 2 4.09 4.2 2.46 .60; Chi <sup>2</sup> = 468.15, d = $5.91 (P < 0.00001$ 4.36 2.93 5.31 3.1 3.1 3.2 4 4 .30; Chi <sup>2</sup> = 32.83, df = $15.40 (P < 0.0000$ .63; Chi <sup>2</sup> = 977.83, d	0.26 0.05 0.34 0.33 0.29 0.28 0.46 0.31 f = 8 (f 0.55 0.22 0.53 0.22 0.47 0.17 1.42 0.21 = 7 (P 1) f = 47	13 30 17 29 18 11 19 39 188 11 19 39 188 2 0 6 6 10 25 113 < 0.000 25 113 1182	13 30 17 29 18 11 19 39 188 0001); I 15 10 21 20 6 6 6 10 25 113 01); I <sup>2</sup> = 1182	2.3% 2.6% 2.2% 2.3% 1.9% 2.3% 20.6% 2.3% 20.6% 2.4% 1.8% 2.4% 1.8% 2.4% 1.9% 2.5% 0.6% 2.4% 15.9% 3.79%	2.91 [2.40, 3.42] 20 4.60 [4.50, 4.70] 20 2.04 [1.37, 2.71] 20 5.50 [4.85, 6.15] 20 2.00 [1.43, 2.57] 20 4.09 [3.54, 4.64] 20 4.20 [3.30, 5.10] 20 2.46 [1.85, 3.07] 20 3.23 [2.16, 4.30] 4.36 [3.28, 5.44] 20 2.93 [2.50, 3.36] 20 5.31 [4.27, 6.35] 20 3.10 [2.67, 3.53] 20 3.20 [2.87, 3.53] 20 4.00 [1.22, 6.78] 20 4.00 [3.59, 4.41] 20 3.68 [3.21, 4.14]	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	

Figure 2. Forest plot of U6 distalization (a), tipping (b), and vertical movement (c) of the palatal, buccal, and zygomatic subgroups.

		~ ~	то	T1		Mean Difference	Mean Difference
Study or Subgroup	Mean Difference	SE	Total	Total	Weight	IV, Random, 95% CI Yea	r IV, Random, 95% Cl
Palatal							
Sar et al. 2013a	1.65	1.94	14	14	1.3%	1.65 [-2.15, 5.45] 2013	
Suzuki et al. 2013		0.89	20	20	2.7%	1.80 [0.06, 3.54] 2013	
Sar et al. 2013b	9	1.8	14	14	1.4%	9.00 [5.47, 12.53] 2013	
Cozzani et al. 2014	2.8	0.52	18	18	3.4%	2.80 [1.78, 3.82] 2014	
Kook et al 2014		1.29	20	20	2.0%	3.42 [0.89, 5.95] 2014	
Caprioglio et al. 2015	3.2	0.69	19	19	3.1%	3.20 [1.85, 4.55] 201	, –
Miresmaelli et al. 2015	0.6	0.84	26	26	2.8%	0.60 [-1.05, 2.25] 201	; +-
Sa'aed et al 2015	1.53	0.2	24	24	3.8%	1.53 [1.14, 1.92] 201	5 7
Cozzani et al. 2016b	3	0.3	24	24	3.7%	3.00 [2.41, 3.59] 2010	
Park et al 2017	3.85	0.66	22	22	3.1%	3.85 [2.56, 5.14] 201	
Jo et al 2018	2.93	0.42	20	20	3.5%	2.93 [2.11, 3.75] 2018	
Lee et al 2018a	2	0.89	22	22	2.7%	2.00 [0.26, 3.74] 2018	
Park et al 2018a	3.68	1.2	17	17	2.2%	3.68 [1.33, 6.03] 2018	
Park et al 2018b	3.07	1.69	16	16	1.5%	3.07 [-0.24, 6.38] 2018	
Cassetta et al. 2019	0.1	3.92	10	10	0.4%	0.10 [-7.58, 7.78] 2019	) —
Lee et al 2019	0.93	1.84	20	20	1.4%	0.93 [-2.68, 4.54] 2019	
Shoaib et al 2019	2.35	1.4	23	23	1.9%	2.35 [-0.39, 5.09] 2019	
Alfaifi et al 2020		0.42	21	21	3.5%	1.86 [1.04, 2.68] 2020	
Chou et al 2021		1.49	20	20	1.8%	1.48 [-1.44, 4.40] 202	
Jung et al 2021a		0.72	20	20	3.0%	0.28 [-1.13, 1.69] 202	
Jung et al 2021b		0.63	20	20	3.2%	2.18 [0.95, 3.41] 202	
Park et al 2021b	0.94	1.7	15	15	1.5%	0.94 [-2.39, 4.27] 202	
Park et al 2021c		2.46	12	12	0.9%	4.36 [-0.46, 9.18] 202	
Lim et al. 2022	0.8	0.2	24	24	3.8%	0.80 [0.41, 1.19] 202	
Alfawaz et al 2022		0.28	25	25	3.7%	3.30 [2.75, 3.85] 202	
Altieri et al. 2022		0.64	22	22	3.2%	0.10 [-1.15, 1.35] 2023	
Kim et al. 2022		0.77	30	30	2.9%	5.09 [3.58, 6.60] 2022	
Subtotal (95% CI)	5.05	0.77	538	538	68.3%	2.37 [1.82, 2.92]	•
Test for overall effect: Z Buccal	2 = 8.40 (P < 0.00001	)					
Bechtold et al 2013a	3.19	1.33	12	12	2.0%	3.19 [0.58, 5.80] 2013	
Bechtold et al 2013b		0.36	13	13	3.6%	1.55 [0.84, 2.26] 2013	
Ali et al 2016		1.93	17	17	1.3%		
Lee et al 2018b						4.59 [0.81, 8.37] 2010	
	7.2	1.23				4.59 [0.81, 8.37] 2010 7.20 [4.79, 9.61] 2010	
		1.23 1.86	18	18	2.1%	7.20 [4.79, 9.61] 2018	
Abdelhady et al 2020	2.48	1.86	18 11		2.1% 1.3%	7.20 [4.79, 9.61] 2018 2.48 [-1.17, 6.13] 2020	
Abdelhady et al 2020 Bechtold et al 2020	2.48 0.6	1.86 0.87	18	18 11	2.1%	7.20 [4.79, 9.61] 2018 2.48 [-1.17, 6.13] 2020 0.60 [-1.11, 2.31] 2020	
Abdelhady et al 2020 Bechtold et al 2020 Song et al 2022	2.48 0.6	1.86	18 11 19	18 11 19	2.1% 1.3% 2.7%	7.20 [4.79, 9.61] 2014 2.48 [-1.17, 6.13] 2024 0.60 [-1.11, 2.31] 2024 2.66 [1.43, 3.89] 2023	
Abdelhady et al 2020 Bechtold et al 2020	2.48 0.6 2.66 .40; Chi² = 25.67, df	1.86 0.87 0.63	18 11 19 39 <b>129</b>	18 11 19 39 <b>129</b>	2.1% 1.3% 2.7% 3.2% 16.3%	7.20 [4.79, 9.61] 2018 2.48 [-1.17, 6.13] 2020 0.60 [-1.11, 2.31] 2020	
Abdelhady et al 2020 Bechtold et al 2020 Song et al 2022 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 2	2.48 0.6 2.66 .40; Chi² = 25.67, df	1.86 0.87 0.63	18 11 19 39 <b>129</b>	18 11 19 39 <b>129</b>	2.1% 1.3% 2.7% 3.2% 16.3%	7.20 [4.79, 9.61] 2014 2.48 [-1.17, 6.13] 2024 0.60 [-1.11, 2.31] 2024 2.66 [1.43, 3.89] 2023	
Abdelhady et al 2020 Bechtold et al 2020 Song et al 2022 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 2 Test for overall effect: Z Zygomatic	2.48 0.6 2.66 .40; Chi <sup>2</sup> = 25.67, df = 4.02 (P < 0.0001)	1.86 0.87 0.63 = 6 (P	18 11 19 39 <b>129</b> = 0.000	18 11 19 39 <b>129</b> 03); I <sup>2</sup> =	2.1% 1.3% 2.7% 3.2% 16.3% 77%	7.20 [4.79, 9.61] 2018 2.48 [-1.17, 6.13] 2020 0.60 [-1.11, 2.31] 2020 2.66 [1.43, 3.89] 2020 2.91 [1.49, 4.33]	• •
Abdelhady et al 2020 Bechtold et al 2020 Song et al 2022 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 2 Test for overall effect: Z Zygomatic Nur et al 2012	2.48 0.6 2.66 .40; Chi <sup>2</sup> = 25.67, df = 4.02 (P < 0.0001) 3.3	1.86 0.87 0.63 = 6 (P 0.59	18 11 19 39 <b>129</b> = 0.000	18 11 19 39 <b>129</b> 03); I <sup>2</sup> =	2.1% 1.3% 2.7% 3.2% 16.3% 77%	7.20 [4.79, 9.61] 2018 2.48 [-1.17, 6.13] 2020 0.60 [-1.11, 2.31] 2020 2.66 [1.43, 3.89] 2022 2.91 [1.49, 4.33] 3.30 [2.14, 4.46] 2012	
Abdelhady et al 2020 Bechtold et al 2020 Song et al 2022 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 2 Test for overall effect: 2 <b>Zygomatic</b> Nur et al 2012 El-Dawlaty et al 2014	2.48 0.6 2.66 2.40; Chi <sup>2</sup> = 25.67, df = 4.02 (P < 0.0001) 3.3 1.21	1.86 0.87 0.63 = 6 (P 0.59 0.28	18 11 19 39 129 = 0.000	18 11 19 39 <b>129</b> 03); I <sup>2</sup> = 15 10	2.1% 1.3% 2.7% 3.2% 16.3% 77% 3.3% 3.7%	7.20 [4.79, 9.61] 2018 2.48 [-1.17, 6.13] 2020 0.60 [-1.11, 2.31] 2020 2.66 [1.43, 3.89] 2022 2.91 [1.49, 4.33] 3.30 [2.14, 4.46] 2011 1.21 [0.66, 1.76] 2014	
Abdelhady et al 2020 Bechtold et al 2020 Song et al 2022 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 2 Test for overall effect: 2 <b>Zygomatic</b> Nur et al 2012 El-Dawlaty et al 2014 Kilkis et al 2016	2.48 0.6 2.66 2.40; Chi <sup>2</sup> = 25.67, df = 4.02 (P < 0.0001) 3.3 1.21 6.39	1.86 0.87 0.63 = 6 (P 0.59 0.28 1.17	18 11 19 39 <b>129</b> = 0.000 15 10 21	18 11 19 39 <b>129</b> 03); I <sup>2</sup> = 15 10 21	2.1% 1.3% 2.7% 3.2% 16.3% 77% 3.3% 3.7% 2.2%	7.20 [4.79, 9.61] 2018 2.48 [-1.17, 6.13] 2020 0.60 [-1.11, 2.31] 2020 2.66 [1.43, 3.89] 2022 2.91 [1.49, 4.33] 3.30 [2.14, 4.46] 2012 1.21 [0.66, 1.76] 2014 6.39 [4.10, 8.68] 2010	• •
Abdelhady et al 2020 Bechtold et al 2020 Song et al 2022 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 2 Test for overall effect: 2 Zygomatic Nur et al 2012 El-Dawlaty et al 2014 Kilkis et al 2016 Shahani et al 2019a	2.48 0.6 2.66 2.40; Chi <sup>2</sup> = 25.67, df = 4.02 (P < 0.0001) 3.3 1.21 6.39 7.41	1.86 0.87 0.63 = 6 (P 0.59 0.28 1.17 0.61	18 11 19 39 129 = 0.000 15 10 21 6	18 11 19 39 <b>129</b> 03); I <sup>2</sup> = 15 10 21 6	2.1% 1.3% 2.7% 3.2% 16.3% 77% 3.3% 3.7% 2.2% 3.2%	7.20 [4.79, 9.61] 2013 2.48 [-1.17, 6.13] 2024 0.60 [-1.11, 2.31] 2024 2.66 [1.43, 3.89] 2022 2.91 [1.49, 4.33] 3.30 [2.14, 4.46] 2013 1.21 [0.66, 1.76] 2014 6.39 [4.10, 8.68] 2011 7.41 [6.21, 8.61] 2019	
Abdelhady et al 2020 Bechtold et al 2020 Song et al 2022 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 2 Test for overall effect: Z Zygomatic Nur et al 2012 El-Dawlaty et al 2014 Kilkis et al 2016 Shahani et al 2019a Shahani et al. 2019b	2.48 0.6 2.66 2.40; Chi <sup>2</sup> = 25.67, df = 4.02 (P < 0.0001) 3.3 1.21 6.39 7.41	1.86 0.87 0.63 = 6 (P 0.59 0.28 1.17	18 11 19 39 <b>129</b> = 0.000 15 10 21	18 11 19 39 <b>129</b> 03); I <sup>2</sup> = 15 10 21 6 6	2.1% 1.3% 2.7% 3.2% 16.3% 77% 3.3% 3.7% 2.2% 3.2% 3.0%	7.20 [4.79, 9.61] 2013 2.48 [-1.17, 6.13] 2024 0.60 [-1.11, 2.31] 2024 2.66 [1.43, 3.89] 2022 2.91 [1.49, 4.33] 3.30 [2.14, 4.46] 2011 1.21 [0.66, 1.76] 2014 6.39 [4.10, 8.68] 2014 7.41 [6.21, 8.61] 2011 3.33 [1.94, 4.72] 2019	
Abdelhady et al 2020 Bechtold et al 2020 Song et al 2022 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 2 Test for overall effect: 2 Zygomatic Nur et al 2012 El-Dawlaty et al 2014 Kilkis et al 2016 Shahani et al 2019a	2.48 0.6 2.66 .40; Chi <sup>2</sup> = 25.67, df = 4.02 (P < 0.0001) 3.3 1.21 6.39 7.41 3.33 .75; Chi <sup>2</sup> = 99.68, df	1.86 0.87 0.63 = 6 (P 0.59 0.28 1.17 0.61 0.71	18 11 19 39 129 = 0.000 15 10 21 6 6 58	18 11 19 39 <b>129</b> 03); l <sup>2</sup> = 15 10 21 6 58	2.1% 1.3% 2.7% 3.2% 16.3% 77% 3.3% 3.7% 2.2% 3.2% 3.0% 15.4%	7.20 [4.79, 9.61] 2013 2.48 [-1.17, 6.13] 2024 0.60 [-1.11, 2.31] 2024 2.66 [1.43, 3.89] 2022 2.91 [1.49, 4.33] 3.30 [2.14, 4.46] 2013 1.21 [0.66, 1.76] 2014 6.39 [4.10, 8.68] 2011 7.41 [6.21, 8.61] 2019	
Abdelhady et al 2020 Bechtold et al 2020 Song et al 2022 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 2 Test for overall effect: 2 <b>Zygomatic</b> Nur et al 2012 El-Dawlaty et al 2014 Kilkis et al 2016 Shahani et al 2019a Shahani et al 2019a Shahani et al. 2019b Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 7 Test for overall effect: 2	2.48 0.6 2.66 .40; Chi <sup>2</sup> = 25.67, df = 4.02 (P < 0.0001) 3.3 1.21 6.39 7.41 3.33 .75; Chi <sup>2</sup> = 99.68, df	1.86 0.87 0.63 = 6 (P 0.59 0.28 1.17 0.61 0.71	18 11 19 39 129 = 0.000 21 6 6 58 < 0.000	18 11 19 39 <b>129</b> 03); I <sup>2</sup> = 15 10 21 6 <b>58</b> 001); I <sup>2</sup>	2.1% 1.3% 2.7% 3.2% 16.3% 77% 3.3% 3.7% 2.2% 3.2% 3.0% 15.4% = 96%	7.20 [4.79, 9.61] 2013 2.48 [-1.17, 6.13] 2024 0.60 [-1.11, 2.31] 2024 2.66 [1.43, 3.89] 2022 2.91 [1.49, 4.33] 3.30 [2.14, 4.46] 2013 1.21 [0.66, 1.76] 2014 6.39 [4.10, 8.68] 2014 7.41 [6.21, 8.61] 2019 3.33 [1.94, 4.72] 2019 4.26 [1.74, 6.78]	
Abdelhady et al 2020 Bechtold et al 2020 Song et al 2022 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 2 Test for overall effect: Z <b>Zygomatic</b> Nur et al 2012 El-Dawlaty et al 2014 Kilkis et al 2016 Shahani et al 2019a Shahani et al 2019b Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 7 Test for overall effect: Z	2.48 0.6 2.66 2.40; Chi <sup>2</sup> = 25.67, df = 4.02 (P < 0.0001) 3.3 1.21 6.39 7.41 3.33 7.75; Chi <sup>2</sup> = 99.68, df = 3.31 (P = 0.0009)	1.86 0.87 0.63 = 6 (P 0.59 0.28 1.17 0.61 0.71 = 4 (P	18 11 19 39 129 = 0.000 15 10 21 6 6 58 < 0.000 725	18 11 19 39 <b>129</b> 03); I <sup>2</sup> = 15 10 21 6 6 58 001); I <sup>2</sup>	2.1% 1.3% 2.7% 3.2% 16.3% 77% 3.3% 3.7% 2.2% 3.2% 3.0% 15.4% = 96%	7.20 [4.79, 9.61] 2013 2.48 [-1.17, 6.13] 2024 0.60 [-1.11, 2.31] 2024 2.66 [1.43, 3.89] 2022 2.91 [1.49, 4.33] 3.30 [2.14, 4.46] 2011 1.21 [0.66, 1.76] 2014 6.39 [4.10, 8.68] 2014 7.41 [6.21, 8.61] 2011 3.33 [1.94, 4.72] 2019	
Abdelhady et al 2020 Bechtold et al 2020 Song et al 2022 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 2 Test for overall effect: 2 <b>Zygomatic</b> Nur et al 2012 El-Dawlaty et al 2014 Kilkis et al 2016 Shahani et al 2019a Shahani et al 2019a Shahani et al. 2019b Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 7 Test for overall effect: 2	2.48 0.6 2.66 2.60 2.40; Chi <sup>2</sup> = 25.67, df = 4.02 (P < 0.0001) 3.3 1.21 6.39 7.41 3.33 2.75; Chi <sup>2</sup> = 99.68, df = 3.31 (P = 0.0009) .85; Chi <sup>2</sup> = 280.08, df	1.86 0.87 0.63 = 6 (P 0.59 0.28 1.17 0.61 0.71 = 4 (P	18 11 19 39 129 = 0.000 15 10 21 6 6 58 < 0.000 725	18 11 19 39 <b>129</b> 03); I <sup>2</sup> = 15 10 21 6 6 58 001); I <sup>2</sup>	2.1% 1.3% 2.7% 3.2% 16.3% 77% 3.3% 3.7% 2.2% 3.2% 3.0% 15.4% = 96%	7.20 [4.79, 9.61] 2013 2.48 [-1.17, 6.13] 2024 0.60 [-1.11, 2.31] 2024 2.66 [1.43, 3.89] 2022 2.91 [1.49, 4.33] 3.30 [2.14, 4.46] 2013 1.21 [0.66, 1.76] 2014 6.39 [4.10, 8.68] 2014 7.41 [6.21, 8.61] 2019 3.33 [1.94, 4.72] 2019 4.26 [1.74, 6.78]	

Figure 2. (Continued)

Distal tipping was higher, although not significantly (P = .30), in the zygomatic group than in the others (4.26 mm; 95% CI, [1.74, 6.78]; P < .0001;  $I^2 = 96\%$ ) despite four studies being excluded because they had mean values strikingly outside the mean of the single subgroup.<sup>10,28,29,59</sup> Intrusion was also higher (-1.16 mm; 95% CI, [-1.84, -0.48]; P < .0001;  $I^2 = 97\%$ ) but not significantly (P = .28) different for zygomatic TADs than the other two groups.

Angle Orthodontist, Vol 00, No 00, 0000

Treatment comparison between 2-TAD-supported and 3-TAD-supported appliances. Figure 3 shows the comparison between 2-TAD-supported and 3-TAD-supported appliances in terms of distalization, tipping, and vertical movement. The comparison showed high heterogeneity between subgroups (I<sup>2</sup> = 87%) and no significant differences (*P* = .86) between the 2-TAD (3.78 mm; 95% Cl, [3.31, 4.24]; *P* < .0001; I<sup>2</sup> = 87%) and 3-TAD (3.73 mm; 95% Cl, [3.43, 4.03]; *P* < .0001; I<sup>2</sup> = 88%) subgroups.




Figure 2. (Continued)

There was heterogeneity ( $l^2 = 82\%$ ) but no significant differences (P = .99) between the 2-TAD (2.37°; 95% Cl, [1.26, 3.49]; P < .0001;  $l^2 = 88\%$ ) and 3-TAD (2.38°; 95% Cl, [1.72, 3.04]; P < .0001;  $l^2 = 83\%$ )

subgroups in terms of distal tipping, even though one study was dropped from the analysis due to a value outside the mean of the subgroup.<sup>35</sup> There was also heterogeneity within subgroups for vertical movement

а			то	T1		Mean Difference		Mean Difference
Study or Subgroup	Mean Difference	SE			Weight	IV, Random, 95% CI	Year	IV, Random, 95% CI
2 TADs								
Sar et al. 2013b	2.93	0.47	14	14	2.8%	2.93 [2.01, 3.85]	2013	
Sar et al. 2013a	2.81	0.7	14	14	1.8%	2.81 [1.44, 4.18]	2013	
Suzuki et al. 2013		0.33	20	20	3.5%	4.50 [3.85, 5.15]		-
Cozzani et al. 2014	4.7	0.38	18	18	3.2%	4.70 [3.96, 5.44]		
Caprioglio et al. 2015		0.32	19	19	3.6%	4.20 [3.57, 4.83]		
Miresmaelli et al. 2015		0.22	26	26	4.1%	2.30 [1.87, 2.73]		
Cozzani et al. 2016b		0.14	24	24	4.5%	3.20 [2.93, 3.47]		
Duran et al. 2016 Cambiano et al. 2017	3.45	0.34	21 18	21 18	3.5% 3.4%	4.10 [3.43, 4.77] 3.45 [2.74, 4.16]		-
Kircali et al. 2018	4.2	0.18	20	20	4.3%	4.20 [3.85, 4.55]		-
Cassetta et al. 2019	5.3	0.66	10	10	1.9%	5.30 [4.01, 6.59]		
Altieri et al. 2022		0.26	22	22	3.9%	3.90 [3.39, 4.41]		-
Subtotal (95% CI)			226	226	40.6%	3.78 [3.31, 4.24]		•
Heterogeneity: Tau <sup>2</sup> = 0.	54; Chi <sup>2</sup> = 87.13, df	= 11 (F	< 0.00	0001); I	² = 87%			
Test for overall effect: Z	= 15.94 (P < 0.0000	1)						
3 TADs								
Kook et al 2014	3.3	0.4	20	20	3.1%	3.30 [2.52, 4.08]		
Sa'aed et al 2015	3.06		24	24	4.6%	3.06 [2.84, 3.28]		· · ·
Park et al 2017 Park et al 2018a	4.22 3.41	0.43	22 17	22 17	3.0% 3.7%	4.22 [3.38, 5.06] 3.41 [2.82, 4.00]		-
Park et al 2018b	3.24		16	16	2.9%	3.24 [2.36, 4.12]		
Jo et al 2018	3.97		20	20	4.5%	3.97 [3.68, 4.26]		-
Lee et al 2018a	4.2		22	22	3.9%	4.20 [3.67, 4.73]		-
Lee et al 2019	1.65	0.84	20	20	1.4%	1.65 [0.00, 3.30]		
Shoaib et al 2019	3.44	0.22	23	23	4.1%	3.44 [3.01, 3.87]	2019	-
Alfaifi et al 2020	3.96		21	21	3.6%	3.96 [3.33, 4.59]	2020	-
Jung et al 2021a	2.69	0.39	20	20	3.2%	2.69 [1.93, 3.45]		-
Jung et al 2021b	4.26	0.37	20	20	3.3%	4.26 [3.53, 4.99]		
Park et al 2021a	3.35	0.03	284	284	4.8%	3.35 [3.29, 3.41]		·
Park et al 2021b Park et al 2021c	4.36	1.1	15	15	0.9%	4.36 [2.20, 6.52]		
Chou et al 2021c	3.18 4.66	0.96	12 20	12 20	1.2% 2.6%	3.18 [1.30, 5.06]		
Kim et al. 2022	3.48	0.5	30	30	3.1%	4.66 [3.68, 5.64] 3.48 [2.70, 4.26]		-
Lim et al. 2022		0.89	24	24	1.3%	4.40 [2.66, 6.14]		
Alfawaz et al 2022		0.22	25	25	4.1%	5.40 [4.97, 5.83]		-
Subtotal (95% CI)			655	655	59.4%	3.73 [3.43, 4.03]	LULL	•
Heterogeneity: Tau <sup>2</sup> = 0.	29; Chi <sup>2</sup> = 146.57, d	f = 18 (	P < 0.0	00001);	l <sup>2</sup> = 88%			
Test for overall effect: Z	= 24.25 (P < 0.0000	1)						
Total (95% CI)			881		100.0%	3.74 [3.51, 3.98]		•
Heterogeneity: Tau <sup>2</sup> = 0.			P < 0.0	)0001);	l <sup>2</sup> = 87%			-4 -2 0 2 4
	= 31.40 (P < 0.0000							mesialization distalization
Test for subgroup differe			9 = 0.86	6), I² = (	0%			mesialization distalization
Test for subgroup differe			9 = 0.86	6), I² = (	)%			mesialization distalization
					)%	Mean Difference		
Test for subaroup differe	nces: Chi <sup>2</sup> = 0.03, d	f = 1 (F	то	T1		Mean Difference IV, Random, 95% CI	Year	Mean Difference
Test for subgroup differe		f = 1 (F	то	T1	)% Weight	Mean Difference IV, Random, 95% CI	Year	
Test for subaroup differe b Study or Subgroup	nces: Chi <sup>2</sup> = 0.03, d	f = 1 (F SE	то	T1				Mean Difference
Test for subaroup differe b Study or Subgroup 2 TADs	nces: Chi² = 0.03, d Mean Difference	f = 1 (F SE	<b>T0</b> Total 14 20	T1 Total 14 20	Weight 1.6% 3.9%	IV, Random, 95% CI 1.65 [-2.15, 5.45] 1.80 [0.06, 3.54]	2013 2013	Mean Difference
Test for subgroup differe b <u>Study or Subgroup</u> <u>2 TADs</u> Sar et al. 2013a Suzuki et al. 2013 Sar et al. 2013b	nces: Chi <sup>2</sup> = 0.03, d <u>Mean Difference</u> 1.65 1.8 9	f = 1 (F SE 1.94 0.89 1.8	T0 Total 14 20 14	T1 Total 14 20 14	Weight 1.6% 3.9% 1.8%	IV, Random, 95% CI 1.65 [-2.15, 5.45] 1.80 [0.06, 3.54] 9.00 [5.47, 12.53]	2013 2013 2013	Mean Difference
Test for subgroup differe b <u>Study or Subgroup</u> 2 TADs Sar et al. 2013a Suzuki et al. 2013 Sar et al. 2013b Cozzani et al. 2014	nces: Chi <sup>2</sup> = 0.03, d <u>Mean Difference</u> 1.65 1.8 9 2.8	f = 1 (F SE 1.94 0.89 1.8 0.52	<b>T0</b> <b>Total</b> 14 20 14 14 18	T1 Total 14 20 14 18	Weight 1.6% 3.9% 1.8% 5.2%	IV, Random, 95% CI 1.65 [-2.15, 5.45] 1.80 [0.06, 3.54] 9.00 [5.47, 12.53] 2.80 [1.78, 3.82]	2013 2013 2013 2014	Mean Difference
Test for subgroup differe b <u>Study or Subgroup</u> <u>2 TADs</u> Sar et al. 2013a Suzuki et al. 2013 Sar et al. 2013b Cozzani et al. 2014 Caprioglio et al. 2015	nces: Chi <sup>2</sup> = 0.03, d <u>Mean Difference</u> 1.65 1.8 9 2.8 3.2	f = 1 (F SE 1.94 0.89 1.8 0.52 0.69	<b>T0</b> <b>Total</b> 14 20 14 18 19	T1 Total 14 20 14 18 19	Weight 1.6% 3.9% 1.8% 5.2% 4.6%	IV, Random, 95% CI 1.65 [-2.15, 5.45] 1.80 [0.06, 3.54] 9.00 [5.47, 12.53] 2.80 [1.78, 3.82] 3.20 [1.85, 4.55]	2013 2013 2013 2014 2015	Mean Difference
Test for subgroup differe b Study or Subgroup 2 TADs Sar et al. 2013a Suzuki et al. 2013 Sar et al. 2013b Cozzani et al. 2014 Caprioglio et al. 2015	nces: Chi <sup>2</sup> = 0.03, d <u>Mean Difference</u> 1.65 1.8 9 2.8 3.2 0.6	f = 1 (F SE 1.94 0.89 1.8 0.52 0.69 0.84	T0 Total 14 20 14 18 19 26	T1 Total 14 20 14 18 19 26	Weight 1.6% 3.9% 1.8% 5.2% 4.6% 4.0%	IV, Random, 95% CI 1.65 [-2.15, 5.45] 1.80 [0.06, 3.54] 9.00 [5.47, 12.53] 2.80 [1.78, 3.82] 3.20 [1.85, 4.55] 0.60 [-1.05, 2.25]	2013 2013 2013 2014 2015 2015	Mean Difference
Test for subgroup differe b Study or Subgroup 2 TADs Sar et al. 2013a Suzuki et al. 2013 Sar et al. 2013b Cozzani et al. 2014 Caprioglio et al. 2015 Miresmaelli et al. 2015	nces: Chi <sup>2</sup> = 0.03, d <u>Mean Difference</u> 1.65 1.8 9 2.8 3.2 0.6 3	f = 1 (F SE 1.94 0.89 1.8 0.52 0.69 0.84 0.3	T0 Total 14 20 14 18 19 26 24	T1 Total 14 20 14 18 19 26 24	Weight 1.6% 3.9% 1.8% 5.2% 4.6% 4.6% 4.0% 5.8%	IV, Random, 95% CI 1.65 [-2.15, 5.45] 1.80 [0.06, 3.54] 9.00 [5.47, 12.53] 2.80 [1.78, 3.82] 3.20 [1.85, 4.55] 0.60 [-1.05, 2.25] 3.00 [2.41, 3.59]	2013 2013 2013 2014 2015 2015 2015	Mean Difference
Test for subgroup differe b Study or Subgroup 2 TADs Sar et al. 2013a Suzuki et al. 2013 Sar et al. 2013 Cozzani et al. 2014 Capriogilo et al. 2015 Miresmaelli et al. 2015 Cozsente et al. 2019	nces: Chi² = 0.03. d <u>Mean Difference</u> 1.65 1.8 9 2.8 3.2 0.6 3 0.1	f = 1 (F SE 1.94 0.89 1.8 0.52 0.69 0.84 0.3 3.92	T0 Total 14 20 14 18 19 26	T1 Total 14 20 14 18 19 26	Weight 1.6% 3.9% 1.8% 5.2% 4.6% 4.0%	IV, Random, 95% Cl 1.65 [-2.15, 5.45] 1.80 [0.06, 3.54] 9.00 [5.47, 12.53] 2.80 [1.78, 3.82] 3.20 [1.85, 4.55] 0.60 [-1.05, 2.25] 3.00 [2.41, 3.59] 0.10 [-7.58, 7.78]	2013 2013 2013 2014 2015 2015 2016 2019	Mean Difference
Test for subgroup differe b Study or Subgroup 2 TADs Sar et al. 2013a Suzuki et al. 2013 Sar et al. 2013b Cozzani et al. 2014 Caprioglio et al. 2015 Miresmaelli et al. 2015	nces: Chi² = 0.03. d <u>Mean Difference</u> 1.65 1.8 9 2.8 3.2 0.6 3 0.1	f = 1 (F SE 1.94 0.89 1.8 0.52 0.69 0.84 0.3	<b>T0</b> <b>Total</b> 14 20 14 18 19 26 24 10	T1 Total 14 20 14 18 19 26 24 10	Weight 1.6% 3.9% 1.8% 5.2% 4.6% 4.0% 5.8% 0.5%	IV, Random, 95% CI 1.65 [-2.15, 5.45] 1.80 [0.06, 3.54] 9.00 [5.47, 12.53] 2.80 [1.78, 3.82] 3.20 [1.85, 4.55] 0.60 [-1.05, 2.25] 3.00 [2.41, 3.59]	2013 2013 2013 2014 2015 2015 2016 2019	Mean Difference
Test for subgroup differe b Study or Subgroup 2 TADs Sar et al. 2013a Suzuki et al. 2013 Cozzani et al. 2013 Cozzani et al. 2014 Caprogilo et al. 2015 Miresmaelli et al. 2015 Cozzani et al. 2016 Cassetta et al. 2019 Altieri et al. 2022 Subtotal (95% Cl) Heterogeneity: Tau <sup>2</sup> = 1.	nces: Chi <sup>2</sup> = 0.03, d <u>Mean Difference</u> 1.65 1.8 9 2.8 3.2 0.6 3 0.1 0.1 85; Chi <sup>2</sup> = 37.54, df	SE 1.94 0.89 1.8 0.52 0.69 0.84 0.3 3.92 0.64	T0 Total 14 20 14 18 19 26 24 10 22 167	T1 Total 14 20 14 18 19 26 24 10 22 167	Weight 1.6% 3.9% 1.8% 5.2% 4.6% 4.6% 5.8% 0.5% 4.7% 32.0%	IV, Random, 95% CI 1.65 [-2.15, 5.45] 1.80 [0.06, 3.54] 9.00 [5.47, 12.53] 2.80 [1.78, 3.82] 3.20 [185, 4.55] 0.60 [-1.05, 2.25] 3.00 [2.41, 3.59] 0.10 [-7.58, 7.78] 0.10 [-1.15, 1.35]	2013 2013 2013 2014 2015 2015 2016 2019	Mean Difference
Test for subgroup differe b Study or Subgroup 2 TADs Sar et al. 2013a Suzuki et al. 2013 Sar et al. 2013b Cozzani et al. 2014 Caprioglio et al. 2015 Miresmaelli et al. 2015 Cozzani et al. 2016 Cassetta et al. 2019 Attieri et al. 2022 Subtotal (95% CI)	nces: Chi <sup>2</sup> = 0.03, d <u>Mean Difference</u> 1.65 1.8 9 2.8 3.2 0.6 3 0.1 0.1 85; Chi <sup>2</sup> = 37.54, df	SE 1.94 0.89 1.8 0.52 0.69 0.84 0.3 3.92 0.64	T0 Total 14 20 14 18 19 26 24 10 22 167	T1 Total 14 20 14 18 19 26 24 10 22 167	Weight 1.6% 3.9% 1.8% 5.2% 4.6% 4.6% 5.8% 0.5% 4.7% 32.0%	IV, Random, 95% CI 1.65 [-2.15, 5.45] 1.80 [0.06, 3.54] 9.00 [5.47, 12.53] 2.80 [1.78, 3.82] 3.20 [185, 4.55] 0.60 [-1.05, 2.25] 3.00 [2.41, 3.59] 0.10 [-7.58, 7.78] 0.10 [-1.15, 1.35]	2013 2013 2013 2014 2015 2015 2016 2019	Mean Difference
Test for subgroup differe b Study or Subgroup 2 TADs Sar et al. 2013a Suzuki et al. 2013 Sar et al. 2013 Cozzani et al. 2014 Caproigilo et al. 2015 Cozzani et al. 2015 Cozzani et al. 2016 Cassetta et al. 2019 Altieri et al. 2022 Subtotal (95% Cl) Heterogeneity: Tau <sup>2</sup> = 1. Test for overall effect: Z	nces: Chi <sup>2</sup> = 0.03, d <u>Mean Difference</u> 1.65 1.8 9 2.8 3.2 0.6 3 0.1 0.1 85; Chi <sup>2</sup> = 37.54, df	SE 1.94 0.89 1.8 0.52 0.69 0.84 0.3 3.92 0.64	T0 Total 14 20 14 18 19 26 24 10 22 167	T1 Total 14 20 14 18 19 26 24 10 22 167	Weight 1.6% 3.9% 1.8% 5.2% 4.6% 4.6% 5.8% 0.5% 4.7% 32.0%	IV, Random, 95% CI 1.65 [-2.15, 5.45] 1.80 [0.06, 3.54] 9.00 [5.47, 12.53] 2.80 [1.78, 3.82] 3.20 [185, 4.55] 0.60 [-1.05, 2.25] 3.00 [2.41, 3.59] 0.10 [-7.58, 7.78] 0.10 [-1.15, 1.35]	2013 2013 2013 2014 2015 2015 2016 2019	Mean Difference
Test for subgroup differe b Study or Subgroup 2 TADs Sar et al. 2013a Suzuki et al. 2013b Cozzani et al. 2013b Cozzani et al. 2014 Caprioglio et al. 2015 Miresmaelli et al. 2015 Cozzani et al. 2016b Cassetta et al. 2019 Attieri et al. 2022 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 1. Test for overall effect: Z	nces: Chi² = 0.03, d <u>Mean Difference</u> 1.65 1.8 9 2.8 3.2 0.6 3 0.1 0.1 85; Chi² = 37.54, df = 4.16 (P < 0.0001)	f = 1 (F SE 1.94 0.89 1.8 0.52 0.69 0.84 0.3 3.92 0.64 = 8 (P	T0 Total 14 20 14 18 19 26 24 10 22 167 < 0.000	T1 Total 14 20 14 18 19 26 24 10 22 167 001); I <sup>2</sup>	Weight 1.6% 3.9% 1.8% 5.2% 4.6% 4.0% 5.8% 0.5% 4.7% 32.0% = 79%	IV, Random, 95% Cl 1.65 [-2.15, 5.45] 1.80 [0.06, 3.54] 9.00 [5.47, 12.53] 2.80 [1.78, 3.82] 3.20 [1.85, 4.55] 3.00 [2.41, 3.59] 0.10 [-7.58, 7.78] 0.10 [-1.15, 1.35] 2.37 [1.26, 3.49]	2013 2013 2013 2014 2015 2015 2016 2019 2022	Mean Difference
Test for subgroup differe b Study or Subgroup 2 TADs Sar et al. 2013a Suzuki et al. 2013 Cozzani et al. 2014 Caprioglio et al. 2015 Miresmaelli et al. 2015 Miresmaelli et al. 2015 Caszetta et al. 2019 Altieri et al. 2020 Subtotal (95% Cl) Heterogeneity: Tau'z = 1. Test for overall effect: Z 3 TADs Kook et al 2014	nces: Chi <sup>2</sup> = 0.03, d <u>Mean Difference</u> 1.65 1.8 9 2.8 3.2 0.6 3 0.1 0.1 85; Chi <sup>2</sup> = 37.54, df = 4.16 (P < 0.0001) 3.42	f = 1 (F SE 1.94 0.89 1.8 0.52 0.69 0.84 0.3 3.92 0.64 = 8 (P 1.29	T0 Total 14 20 14 18 19 26 24 10 22 167 << 0.000	T1 Total 14 20 14 18 19 26 24 10 22 167 001); I <sup>2</sup>	Weight 1.6% 3.9% 1.8% 5.2% 4.6% 4.0% 5.8% 0.5% 32.0% = 79%	IV, Random, 95% Cl 1.65 [-2.15, 5.45] 1.80 [0.06, 324] 9.00 [5.47, 12.53] 2.80 [1.78, 3.82] 3.20 [1.85, 4.55] 3.00 [-1.05, 2.25] 3.00 [2.41, 3.59] 0.10 [-1.15, 1.35] 2.37 [1.26, 3.49] 3.42 [0.89, 5.95]	2013 2013 2014 2015 2015 2016 2019 2022 2014	Mean Difference
Test for subgroup differe b Study or Subgroup 2 TADs Sar et al. 2013a Suzuki et al. 2013 Cozzani et al. 2014 Capriogilo et al. 2015 Miresmaelli et al. 2015 Cozzani et al. 2014 Capsiogilo et al. 2015 Cozzani et al. 2014 Cassetta et al. 2019 Attieri et al. 2022 Subtotal (95% Cl) Heterogeneity: Tau² = 1. Test for overall effect: Z 3 TADs Kook et al 2014 Sa'aed et al.2015	nces: Chi² = 0.03. d <u>Mean Difference</u> 1.65 1.8 9 2.8 3.2 0.6 3 0.1 0.1 85; Chi² = 37.54, df = 4.16 (P < 0.0001) 3.42 1.53	f = 1 (F SE 1.94 0.89 1.8 0.52 0.69 0.84 0.3 3.92 0.64 = 8 (P 1.29 0.2	T0 Total 14 20 14 18 19 26 24 10 22 167 < 0.000 20 24	T1 Total 14 20 14 18 19 26 24 10 22 167 001); I <sup>2</sup>	Weight 1.6% 3.9% 1.8% 5.2% 4.6% 4.0% 5.8% 0.5% 4.7% 32.0% = 79% 2.7% 6.1%	IV, Random, 95% Cl 1.65 [-2.15, 5.45] 1.80 [0.06, 3.54] 9.00 [5.47, 12.53] 2.80 [1.78, 3.82] 3.20 [1.85, 4.55] 0.60 [-1.05, 2.25] 3.00 [2.41, 3.59] 0.10 [-7.58, 7.78] 0.10 [-1.15, 1.35] 2.37 [1.26, 3.49] 3.42 [0.89, 5.95] 1.53 [1.14, 1.92]	2013 2013 2014 2015 2015 2016 2019 2022 2014 2014	Mean Difference
Test for subgroup differe b Study or Subgroup 2 TADs Sar et al. 2013a Suzuki et al. 2013 Cozzani et al. 2013 Cozzani et al. 2014 Caprioglio et al. 2015 Cozzani et al. 2015 Cozzani et al. 2019 Attieri et al. 2022 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 1. Test for overall effect: Z 3 TADs Kook et al 2015 Park et al 2017	nces: Chi² = 0.03, d <u>Mean Difference</u> 1.65 1.8 9 2.8 3.2 0.6 3 0.1 0.1 85; Chi² = 37.54, df = 4.16 (P < 0.0001) 3.42 1.53 3.85	f = 1 (F SE 1.94 0.89 1.8 0.52 0.69 0.84 0.3 3.92 0.64 = 8 (P 1.29 0.2 0.66	T0 Total 14 20 14 18 19 26 24 10 22 167 < 0.000 20 24 22	T1 Total 14 20 14 18 19 26 24 10 001); l <sup>2</sup> 20 20 24 22	Weight 1.6% 3.9% 5.2% 4.6% 4.0% 5.8% 0.5% 4.7% 32.0% = 79%	IV, Random, 95% Cl 1.65 [-2.15, 5.45] 1.80 [0.06, 334] 9.00 [5.47, 12.53] 2.80 [1.78, 3.82] 3.20 [1.85, 4.55] 0.60 [-1.05, 2.25] 3.00 [2.41, 3.59] 0.10 [-1.15, 1.35] 2.37 [1.26, 3.49] 3.42 [0.89, 5.95] 1.53 [1.14, 1.92] 3.88 [2.56, 5.14]	2013 2013 2014 2015 2015 2016 2019 2022 2014 2022	Mean Difference
Test for subgroup differe b Study or Subgroup 2 TADs Sar et al. 2013a Suzuki et al. 2013 Cozzani et al. 2014 Capriogilo et al. 2015 Miresmaelli et al. 2015 Cozzani et al. 2014 Capsiogilo et al. 2015 Cozzani et al. 2014 Cassetta et al. 2019 Attieri et al. 2022 Subtotal (95% Cl) Heterogeneity: Tau² = 1. Test for overall effect: Z 3 TADs Kook et al 2014 Sa'aed et al.2015	nces: Chi² = 0.03. d <u>Mean Difference</u> 1.65 1.8 9 2.8 3.2 0.6 3 0.1 0.1 85; Chi² = 37.54, df = 4.16 (P < 0.0001) 3.42 1.53	f = 1 (F SE 1.94 0.89 1.8 0.52 0.69 0.84 0.3 3.92 0.64 = 8 (P 1.29 0.2	T0 Total 14 20 14 18 19 26 24 10 22 167 < 0.000 20 24	T1 Total 14 20 14 18 19 26 24 10 22 167 001);   <sup>2</sup> 20 24	Weight 1.6% 3.9% 1.8% 5.2% 4.6% 4.0% 5.8% 0.5% 4.7% 32.0% = 79% 2.7% 6.1%	IV, Random, 95% Cl 1.65 [-2.15, 5.45] 1.80 [0.06, 3.54] 9.00 [5.47, 12.53] 2.80 [1.78, 3.82] 3.20 [1.85, 4.55] 0.60 [-1.05, 2.25] 3.00 [2.41, 3.59] 0.10 [-7.58, 7.78] 0.10 [-1.15, 1.35] 2.37 [1.26, 3.49] 3.42 [0.89, 5.95] 1.53 [1.14, 1.92]	2013 2013 2014 2015 2015 2016 2019 2022 2014 2015 2017 2018	Mean Difference
Test for subgroup differe b Study or Subgroup 2 TADs Sar et al. 2013a Suzuki et al. 2013 Cozzani et al. 2013 Cozzani et al. 2014 Caprioglio et al. 2015 Miresmaelli et al. 2015 Cozzani et al. 2019 Attieri et al. 2029 Subtotal (95% CI) Heterogeneity: Tau² = 1. Test for overall effect: Z 3 TADs Kook et al 2014 Sa'aed et al 2015 Park et al 2018	nces: Chi² = 0.03, d <u>Mean Difference</u> 1.65 1.8 9 2.8 3.2 0.6 3 0.1 85; Chi² = 37.54, df = 4.16 (P < 0.0001) 3.42 1.53 3.85 2.93	se f = 1 (P SE 1.94 0.89 1.8 0.52 0.69 0.84 0.3 3.92 0.64 = 8 (P 1.29 0.2 0.2 0.2 0.2 0.2 0.2	T0 Total 14 20 14 18 19 26 24 10 22 26 24 167 <0.000 20 24 22 20	T1 Total 14 20 14 18 19 26 24 10 22 26 20 20 24 22 20	Weight 1.6% 3.9% 5.2% 4.6% 4.6% 0.5% 4.7% 32.0% 5.8% 2.7% 6.1% 4.7% 5.5%	IV, Random, 95% Cl 1.65 [-2.15, 5.45] 1.80 [0.06, 3.54] 9.00 [5.47, 12.53] 2.80 [1.78, 3.82] 3.20 [1.85, 4.55] 0.60 [-1.05, 2.25] 3.00 [2.41, 3.59] 0.10 [-7.58, 7.78] 0.10 [-7.58, 7.78] 0.10 [-7.53, 7] 1.53 [1.14, 1.92] 3.42 [0.89, 5.95] 1.53 [1.14, 1.92] 3.85 [2.56, 5.14] 2.93 [2.11, 3.75]	2013 2013 2014 2015 2015 2016 2019 2022 2014 2015 2017 2018 2018	Mean Difference
Test for subgroup differe b Study or Subgroup 2 TADs Sar et al. 2013a Suzuki et al. 2013 Cozzani et al. 2013 Cozzani et al. 2013 Cozzani et al. 2015 Cozzani et al. 2015 Miresmaelli et al. 2015 Cozzani et al. 2019 Altieri et al. 2029 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 1. Test for overall effect: Z 3 TADs Kokk et al 2014 Sa'aed et al 2015 Park et al 2015 Park et al 2017 Jo et al 2018 Lee et al 2018	nces: Chi² = 0.03, d Mean Difference 1.65 1.8 9 2.8 3.2 0.6 3 0.1 0.1 85; Chi² = 37.54, df = 4.16 (P < 0.0001) 3.42 1.53 3.85 2.93 2	<b>SE</b> 1.94 0.89 1.8 0.52 0.69 0.69 0.69 0.64 = 8 (P 1.29 0.64 = 8 (P 1.29 0.62 0.64 1.29 0.62 0.64 1.29	T0 Total 14 20 14 18 19 26 24 10 22 167 <0.000 24 22 20 22	T1 Total 14 20 14 18 19 26 24 10 22 167 001);   <sup>2</sup> 20 24 22 20 22	Weight 1.6% 3.9% 1.8% 5.2% 4.6% 5.8% 0.5% 4.7% 32.0% = 79% 2.7% 6.1% 4.7% 5.5% 3.9%	IV, Random, 95% Cl 1.65 [-2.15, 5.45] 1.80 [0.06, 3.54] 9.00 [5.47, 12.53] 2.80 [1.78, 3.82] 3.20 [1.85, 4.55] 0.60 [-1.05, 2.25] 3.00 [2.41, 3.59] 0.10 [-7.58, 7.78] 0.10 [-7.58, 7.78] 0.10 [-1.15, 1.35] 2.37 [1.26, 3.49] 3.42 [0.89, 5.95] 1.53 [1.14, 1.92] 3.85 [2.56, 5.14] 2.30 [2.11, 3.75] 2.00 [0.26, 3.74]	2013 2013 2014 2014 2015 2015 2016 2019 2022 2014 2015 2017 2018 2018	Mean Difference
Test for subgroup differe b Study or Subgroup 2 TADs Sar et al. 2013a Suzuki et al. 2013 Cozzani et al. 2013 Cozzani et al. 2014 Caprioglio et al. 2015 Cozzani et al. 2019 Attieri et al. 2019 Attieri et al. 2022 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 1. Test for overall effect: Z 3 TADs Kook et al 2015 Park et al 2018 Park et al 2018a Park et al 2018a Park et al 2018b Shoaib et al 2019	nces: Chi² = 0.03, d <u>Mean Difference</u> 1.65 1.8 9 2.8 3.2 0.6 3 0.1 0.1 85; Chi² = 37.54, df = 4.16 (P < 0.0001) 3.42 1.53 3.85 2.93 2.8 3.85 2.93 2.83 3.68	<b>SE</b> 1.94 0.89 1.8 0.52 0.69 0.69 0.69 0.64 = 8 (P 1.29 0.64 = 8 (P 1.29 0.62 0.64 1.29 0.62 0.64 1.29	T0 Total 14 20 14 18 19 26 24 10 22 167 <0.000 24 22 20 24 22 20 22 17	T1 Total 14 20 14 18 19 26 24 10 22 167 20 20 24 20 22 20 22 20 22 21 7 7 6 23	Weight 1.6% 3.9% 1.8% 5.2% 4.6% 4.0% 5.8% 0.5% 4.7% 32.0% 2.7% 6.1% 4.7% 5.5% 3.9%	IV, Random, 95% Cl 1.65 [-2.15, 5.45] 1.80 [0.66, 32] 9.00 [5.47, 12.53] 2.80 [1.78, 3.82] 3.20 [1.85, 4.55] 0.60 [-1.05, 2.25] 3.00 [2.41, 3.59] 0.10 [-7.15, 1.35] 2.37 [1.26, 3.49] 3.42 [0.89, 5.95] 1.53 [1.14, 1.92] 3.82 [2.65, 5.14] 2.93 [2.11, 3.76] 2.00 [0.26, 3.74] 3.68 [1.33, 6.03]	2013 2013 2014 2015 2015 2016 2019 2022 2014 2015 2017 2018 2018 2018 2018	Mean Difference
Test for subgroup differe b Study or Subgroup 2 TADs Sar et al. 2013a Suzuki et al. 2013 Cozzani et al. 2013 Cozzani et al. 2014 Caprioglio et al. 2015 Miresmeelli et al. 2015 Miresmeelli et al. 2015 Altieri et al. 2022 Subtotal (95% CI) Heterogeneity: Tau² = 1. Test for overall effect: Z 3 TADs Kook et al 2014 Sa'aed et al 2015 Park et al 2017 Jo et al 2018 Lee et al 2019 Lee et al 2019 Lee et al 2019	nces: Chi² = 0.03, d <u>Mean Difference</u> 1.65 1.8 9 2.8 3.2 0.6 3 0.1 85; Chi² = 37.54, df = 4.16 (P < 0.0001) 3.42 1.53 3.85 2.93 2 3.68 3.07 2.35 0.93	se 1.94 1.94 0.89 0.89 0.84 0.3 3.92 0.64 1.29 0.2 0.66 0.42 0.42 0.42 0.42 0.42 0.42 1.69 1.4 1.44	T0 Total 14 20 14 19 26 24 10 22 167 <0.000 24 22 20 22 17 16 23 20 22 20 20	T1 Total 14 200 14 18 19 26 24 10 22 107 20 24 20 001); l <sup>2</sup> 20 24 22 20 001; l <sup>2</sup> 21 7 16 22 20 22 20 20 24 22 20 20 24 22 20 20 24 22 20 20 24 22 20 20 24 22 20 20 24 20 20 24 20 26 20 26 20 26 26 20 26 26 26 26 26 26 26 26 26 26 26 26 26	Weight 1.6% 3.9% 1.8% 5.2% 4.6% 4.0% 5.8% 0.5% 32.0% = 79% 2.7% 6.1% 4.7% 5.5% 3.9% 2.9% 1.9% 2.9% 1.9% 2.7%	IV, Random, 95% Cl           1.65 [-2.15, 5.45]           1.80 (0.66, 324)           9.00 [5.47, 12.53]           2.80 [1.78, 3.82]           3.20 [1.85, 4.55]           0.61 [-105, 2.25]           3.00 [2.41, 3.59]           0.10 [-7.15, 1.35]           0.10 [-7.15, 1.35]           2.37 [1.26, 3.49]           3.42 [0.89, 5.95]           1.53 [1.14, 1.92]           3.85 [2.56, 5.14]           2.93 [2.11, 3.75]           2.00 [0.26, 3.74]           3.68 [1.33, 6.03]           3.07 [-0.24, 6.38]           2.35 [-0.39, 5.95]           0.3 [-2.68, 4.54]	2013 2013 2014 2015 2015 2019 2022 2019 2022 2014 2015 2017 2018 2018 2018 2018 2018 2019 2019	Mean Difference
Test for subgroup differe b Study or Subgroup 2 TADs Sar et al. 2013a Suzuki et al. 2013 Cozzani et al. 2013 Cozzani et al. 2014 Capriogilo et al. 2015 Cozzani et al. 2019 Altieri et al. 2019 Altieri et al. 2029 Subtotal (95% Cl) Heterogeneity: Tau² = 1. Test for overall effect: Z 3 TADs Kook et al 2014 Sa'aed et al 2015 Park et al 2017 Jo et al 2018 Lee et al 2018 Park et al 2018 Park et al 2018 Shoaib et al 2019 Lee et al 2019	nces: Chi² = 0.03. d <u>Mean Difference</u> 1.65 1.8 9 2.8 3.2 0.6 3 0.1 0.1 85; Chi² = 37.54, df = 4.16 (P < 0.0001) 3.42 1.53 3.85 2.93 2 3.68 3.07 2.35 0.93 1.86	f = 1 (F SE 1.94 0.89 0.89 0.84 0.3 3.92 0.64 = 8 (P 1.29 0.2 0.66 0.42 0.89 1.2 1.29 0.89 1.4 1.84 0.42	T0 Total 14 20 14 18 19 26 24 10 22 167 < 0.000 24 22 20 24 22 20 22 21 7 16 23 20 22 21	T1 Total 14 20 14 18 19 26 24 10 22 167 001); l <sup>2</sup> 20 24 22 20 001; l <sup>2</sup> 21 7 16 23 20 22 21 7	Weight 1.6% 3.9% 1.8% 4.6% 4.6% 4.6% 4.7% 32.0% 6.1% 4.7% 3.2% 6.1% 1.7% 5.5%	IV, Random, 95% Cl 1.65 [-2.15, 5.45] 1.80 [0.06, 3.54] 9.00 [5.47, 12.53] 2.80 [1.78, 3.82] 3.20 [1.85, 4.55] 0.00 [-1.05, 2.25] 3.00 [2.41, 3.59] 0.10 [-7.58, 7.78] 2.37 [1.26, 3.49] 3.42 [0.89, 5.95] 1.53 [1.14, 1.92] 3.85 [2.56, 5.14] 2.93 [2.11, 3.75] 2.00 [0.26, 3.74] 3.68 [1.33, 6.03] 3.07 [-0.24, 6.38] 2.35 [-0.39, 5.09] 0.33 [-2.68, 4.54] 1.86 [1.04, 2.68]	2013 2013 2014 2015 2015 2016 2019 2022 2014 2019 2022 2014 2015 2017 2018 2018 2018 2018 2019 2020	Mean Difference
Test for subgroup differe b Study or Subgroup 2 TADs Sar et al. 2013a Suzuki et al. 2013 Cozzani et al. 2013 Cozzani et al. 2013 Cozzani et al. 2015 Cozzani et al. 2015 Cozzani et al. 2016 Cassetta et al. 2019 Attieri et al. 2025 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 1. Test for overall effect: Z 3 TADs Kook et al 2015 Park et al 2018 Park et al 2018a Park et al 2019a Park et al 2	nces: Chi² = 0.03, d <u>Mean Difference</u> 1.65 1.8 9 2.8 3.2 0.6 3 0.1 0.1 85; Chi² = 37.54, df = 4.16 (P < 0.0001) 3.42 1.53 3.85 2.93 2.35 0.93 1.86 3.07 2.35 0.93 1.86 1.48	f = 1 (F SE 1.94 0.89 1.8 0.52 0.69 0.84 0.3 3.92 0.64 = 8 (P 1.29 0.2 0.66 0.42 0.89 1.2 1.69 1.2 1.69 1.4 1.89	T0 Total 14 20 14 18 19 266 24 10 22 167 <0.000 24 22 20 22 20 22 21 77 16 23 20 22 21 17 16 23 20 22 21 20 22 21 20 22 20 20	T1 Total 14 20 26 24 167 20 24 22 20 22 20 22 20 22 21 67 167 20 22 21 17 16 23 20 22 21 21 20 22 21 21 20 22 21 20 22 21 20 22 20 20	Weight 1.6% 3.9% 1.8% 5.2% 4.6% 5.8% 0.5% 5.8% 0.5% 32.0% 2.7% 6.1% 4.7% 5.5% 3.9% 2.7% 1.9% 2.9% 1.9% 2.9% 1.9% 2.9% 1.9% 2.9% 1.9% 2.9% 1.9% 2.9% 1.9% 2.9% 1.9% 2.9% 1.9% 2.9% 1.9% 2.9% 1.9% 2.9% 1.9% 2.9% 1.9% 2.9% 1.9% 2.9% 1.9% 2.7% 2.9% 2.7% 2.9% 2.3% 2.9% 2.9% 2.3% 2.9% 2.3% 2.9% 2.3% 2.9% 2.3% 2.3% 2.9% 2.3% 2.3% 2.3% 2.9% 2.3% 2.3% 2.3% 2.9% 2.3% 2.3% 2.3% 2.9% 2.3% 2.3% 2.3% 2.3% 2.3% 2.9% 2.3% 2.3% 2.3% 2.3% 2.3% 2.9% 2.3	$\begin{array}{c} \textbf{IV, Random, 95\% Cl} \\ \textbf{I,65} [-2.15, 5.45] \\ 1.80 [0.06, 3.74] \\ 9.00 [5.47, 12.53] \\ 2.80 [1.78, 3.82] \\ 3.20 [1.85, 4.55] \\ 0.60 [-1.05, 2.25] \\ 3.00 [2.41, 3.59] \\ 0.10 [-7.15, 1.35] \\ 2.37 [1.26, 3.49] \\ \textbf{3.42} [0.89, 5.95] \\ 1.53 [1.14, 1.92] \\ 3.82 [2.56, 5.14] \\ 2.93 [2.11, 3.76] \\ 2.00 [0.26, 3.74] \\ 3.68 [1.33, 6.03] \\ 3.07 [-0.24, 6.38] \\ 1.36 [1.34, 2.86] \\ 1.48 [-1.44, 2.68] \\ 1.48 [-1.44, 4.40] \\ \end{array}$	2013 2013 2014 2015 2016 2019 2022 2014 2019 2022 2014 2018 2018 2018 2018 2018 2018 2018 2019 2019	Mean Difference
Test for subaroup differe b Study or Subgroup 2 TADs Sar et al. 2013a Suzuki et al. 2013 Sar et al. 2013b Cozzani et al. 2014 Caproigilo et al. 2015 Miresmaelli et al. 2015 Cozzani et al. 2016 Cassetta et al. 2019 Altieri et al. 2022 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 1. Test for overall effect: 2 3 TADs Kook et al 2014 Sa'aed et al 2015 Park et al 2018 Lee et al 2018a Park et al 2019 Lee et al 2019 Altiefi et al 2020 Chou et al 2021 Jung et al 2021a	nces: Chi² = 0.03. d <u>Mean Difference</u> 1.65 1.8 9 2.8 3.2 0.6 3.3 0.1 0.1 85; Chi² = 37.54, df = 4.16 (P < 0.0001) 3.42 1.53 3.85 2.93 2.93 2.93 3.68 3.07 2.35 0.93 1.86 1.48 0.93 1.87 0.93 0.93 1.86 1.48 0.93 0.9	SE 1.94 0.89 1.8 0.69 0.84 0.39 0.69 0.84 0.39 0.64 0.69 0.84 0.69 0.84 0.69 0.84 0.69 0.64 0.69 0.64 0.64 0.64 0.69 0.64 0.42 0.68 1.2 1.44 0.42	T0 Total 14 20 14 18 19 26 24 22 10,000 20 22 17 16 23 20 22 17 16 23 20 22 20 22 20 22 20 22 20 22 20 22 20 22 20 22 20 22 20 22 20 22 20 22 20 22 20 22 20 22 20 22 22	T1 Total 14 20 24 167 7001);  2 20 24 22 20 24 22 20 22 167 16 23 20 22 21 20 22 21 20 22 20 22 20 22 20 22 20 22 20 22 20 22 20 22 20 22 20 20	Weight 1.6% 3.9% 1.8% 4.6% 4.6% 4.7% 32.0% 2.7% 6.1% 4.7% 5.5% 3.9% 2.5% 1.9% 5.5% 3.2%	IV, Random, 95% Cl           1.65 [-2.15, 5.45]           1.80 [0.06, 3.54]           9.00 [5.47, 12.53]           2.80 [1.78, 3.82]           3.20 [1.85, 4.55]           0.61 [-1.05, 2.25]           3.00 [2.41, 3.59]           0.10 [-7.15, 1.35]           0.10 [-7.15, 1.35]           2.37 [1.26, 3.49]           3.42 [0.89, 5.95]           1.53 [1.14, 1.92]           3.85 [2.56, 5.14]           2.93 [2.11, 3.75]           2.00 [0.26, 3.74]           3.68 [1.3, 6.03]           3.07 [-0.24, 6.38]           2.35 [-0.39, 5.95]           1.86 [1.04, 2.68]           1.86 [1.04, 2.68]           1.86 [1.04, 2.68]           1.86 [1.44, 4.40]           0.28 [-1.13, 1.68]	2013 2013 2014 2015 2016 2019 2022 2014 2015 2017 2018 2018 2018 2018 2018 2018 2019 2020 2021	Mean Difference
Test for subgroup differe b Study or Subgroup 2 TADs Sar et al. 2013a Suzuki et al. 2013 Cozzani et al. 2013 Cozzani et al. 2013 Cozzani et al. 2015 Cozzani et al. 2015 Cozzani et al. 2015 Cozzani et al. 2015 Cozzani et al. 2016 Cassetta et al. 2019 Attieri et al. 2022 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 1. Test for overall effect: Z 3 TADs Kokk et al 2014 Sa'aed et al 2015 Park et al 2018 Park et al 2019 Lee et al 2019 Lee et al 2020 Chou et al 2021 Jung et al 2021b	nces: Chi² = 0.03, d Mean Difference 1.65 1.8 9 2.8 3.2 0.6 3 0.1 0.1 85; Chi² = 37.54, df = 4.16 (P < 0.0001) 3.42 1.53 3.85 2.93 2 3.68 3.07 2.35 0.93 1.86 1.48 0.28 2.48	SE 1.94 0.89 1.8 0.52 0.69 0.84 0.33 3.92 0.64 0.32 0.64 0.42 1.29 0.2 0.66 0.42 1.84 0.42 1.84 0.42 1.84 0.72 0.63	T0 Total 14 200 14 18 19 26 24 167 <0.000 22 20 20	T1 Total 14 200 14 18 19 26 24 107 20 22 20 20	Weight 1.6% 3.9% 1.8% 5.2% 5.5%	IV, Random, 95% Cl 1.65 [-2.15, 5.45] 1.80 [0.06, 3.54] 9.00 [5.47, 12.53] 2.80 [1.78, 3.82] 3.20 [1.85, 4.55] 0.00 [-1.05, 2.25] 3.00 [2.41, 3.59] 0.10 [-7.58, 7.78] 0.10 [-1.15, 1.35] 2.37 [1.26, 3.49] 3.42 [0.89, 5.95] 1.53 [1.14, 1.92] 3.85 [2.56, 5.14] 2.93 [2.11, 3.75] 2.00 [0.26, 3.74] 3.68 [1.33, 6.03] 2.35 [-0.39, 5.09] 0.93 [-2.68, 4.54] 1.86 [-1.04, 2.68] 1.48 [-1.44, 4.40] 0.28 [-1.13, 1.69] 2.18 [0.95, 3.41]	2013 2013 2014 2015 2016 2019 2022 2014 2015 2017 2018 2018 2018 2018 2018 2019 2020 2021	Mean Difference
Test for subgroup differe b Study or Subgroup 2 TADs Sar et al. 2013a Suzuki et al. 2013 Cozzani et al. 2013 Cozzani et al. 2014 Caprioglio et al. 2015 Cozzani et al. 2015 Cozzani et al. 2019 Altieri et al. 2029 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 1. Test for overall effect: Z 3 TADs Kook et al 2014 Sa'aed et al 2015 Park et al 2018 Park et al 2018 Park et al 2019 Alfafii et al 2020 Chou et al 2021 Jung et al 2021b Park et al 2021 Jung et al 2021b	nces: Chi² = 0.03, d <u>Mean Difference</u> 1.65 1.8 9 2.8 3.2 0.6 3 0.1 0.1 85; Chi² = 37.54, df = 4.16 (P < 0.0001) 3.42 1.53 3.85 2.93 2.35 0.93 1.86 3.07 2.35 0.93 1.86 1.48 0.28 2.18 0.94	5 = 1 (F 5 = 1 (F 5 = 1 (F 1.94 0.89 1.8 0.52 0.69 0.89 0.84 0.52 0.69 0.84 0.52 0.69 0.84 0.52 0.69 0.89 0.89 0.89 0.52 0.69 0.89 0.52 0.69 0.89 0.52 0.69 0.89 0.52 0.69 0.89 0.52 0.69 0.89 0.52 0.69 0.89 0.52 0.69 0.84 0.52 0.69 0.84 0.52 0.64 1.29 0.64 1.29 0.64 1.29 0.64 1.29 0.64 1.29 0.64 1.29 0.62 0.64 1.29 0.64 1.29 0.42 0.62 0.64 1.29 0.42 0.62 0.64 1.29 0.42 0.62 0.62 0.64 1.29 0.42 0.62 0.64 1.29 0.42 0.62 0.62 0.64 1.29 0.42 0.62 0.42 0.62 0.42 0.62 0.42 0.42 0.42 0.42 0.42 0.42 1.4 1.49 0.42 1.49 1.72 1.74 1.74 1.74 1.75 1.75 1.75 1.75 1.	T0 Total 14 200 14 18 19 22 167 <0.000 24 22 200 22 200 22 200 22 200 22 200 22 200 22 200 22 17 16 20 20 22 200 22 17 16 20 20 20 20 20 20 20 20 20 20 20 20 20	<b>T1</b> <b>Total</b> 14 20 14 18 9 26 24 40 10 22 <b>167</b> 0001);   <sup>2</sup> 20 24 22 20 22 21 77 16 23 20 22 21 77 16 23 20 22 21 17 20 22 20 22 21 17 20 20 22 21 17 20 20 22 21 20 22 20 22 21 20 22 20 22 21 20 22 20 22 20 22 21 20 22 20 20	Weight 1.6% 3.9% 1.8% 5.2% 4.6% 4.6% 5.8% 0.5% 32.0% 2.7% 6.1% 5.5% 3.9% 1.9% 2.5% 3.9% 1.9% 2.9% 1.9%	IV, Random, 95% Cl           1.65 [-2.15, 5.45]           1.80 [0.06, 3.54]           9.00 [5.47, 12.53]           2.80 [1.78, 3.82]           3.20 [1.85, 4.55]           0.60 [-105, 2.25]           3.00 [2.41, 3.59]           0.10 [-7.15, 1.35]           2.37 [1.26, 3.49]           3.42 [0.89, 5.95]           1.53 [1.14, 1.92]           3.82 [2.65, 5.14]           2.93 [2.11, 3.76]           2.05 [0.26, 5.45]           3.64 [1.33, 6.03]           3.07 [-0.24, 6.38]           2.35 [2.68, 5.14]           2.93 [2.11, 3.76]           2.03 [0.24, 6.39, 5.99]           0.33 [-2.68, 4.54]           1.86 [1.04, 2.68]           1.86 [1.04, 2.68]           2.35 [-3.93, 5.09]           0.93 [-2.68, 4.54]           1.86 [1.04, 2.68]           1.86 [1.04, 2.68]           2.85 [2.65, 3.41]           0.28 [-1.13, 1.69]           2.18 [0.95, 3.41]           0.94 [-2.39, 4.27]	2013 2013 2014 2015 2016 2019 2022 2014 2015 2017 2022 2014 2018 2018 2018 2018 2018 2018 2018 2019 2021 2021	Mean Difference
Test for subgroup differe b Study or Subgroup 2 TADs Sar et al. 2013a Suzuki et al. 2013 Cozzani et al. 2013 Cozzani et al. 2014 Caproigilo et al. 2015 Cozzani et al. 2016 Cassetta et al. 2019 Altieri et al. 2020 Subtotal (95% Cl) Heterogeneity: Tau <sup>2</sup> = 1. Test for overall effect: Z 3 TADs Kook et al 2014 Sa'aed et al 2015 Park et al 2018 Lee et al 2018 Lee et al 2018 Lee et al 2018 Lee et al 2019 Let al 2019 Lee et al 2019 Lee et al 2019 Lee et al 2019 Lee et al 2020 Chou et al 2021 Jung et al 2021b Park et al 2021b	nces: Chi² = 0.03. d Mean Difference 1.65 1.8 9 2.8 3.2 0.6 3 0.1 0.1 85; Chi² = 37.54, df = 4.16 (P < 0.0001) 3.422 1.53 3.85 2.93 2.368 1.48 0.93 1.86 1.48 0.94 4.36	SE           1.94         0.89           0.82         0.62           0.84         0.33           0.64         3.3.92           0.64         9.0.2           0.66         0.42           0.42         0.42           1.4         1.84           0.42         1.49           0.42         1.49           1.43         1.77           2.46         1.47	T0 Total 14 20 14 18 19 26 24 167 22 167 20 24 22 20 24 22 20 22 217 16 23 20 22 17 16 23 20 22 17 16 23 20 22 17 16 23 20 22 17 16 22 17 17 16 26 16 26 16 22 16 22 16 22 16 22 16 22 16 22 16 22 16 22 16 22 16 16 16 22 16 22 16 7 22 16 7 22 16 7 22 16 7 22 16 7 7 20 22 22 20 22 22 20 22 22 16 7 7 7 16 7 7 17 16 7 7 17 16 7 20 22 22 20 22 22 20 22 22 20 22 22 20 22 22	T1 Total 14 19 26 24 10 22 167 7001);   <sup>2</sup> 20 24 22 20 001);   <sup>2</sup> 20 24 22 20 0024 22 20 20 24 22 20 0024 22 20 20 20 20 21 20 20 21 17 16 23 20 20 21 21 22 20 20 21 22 20 20 21 22 20 22 22	Weight 1.6% 3.9% 1.8% 4.6% 4.6% 4.6% 4.7% 32.0% 6.1% 4.7% 5.5% 3.9% 2.7% 6.1% 1.9% 5.5% 5.5% 5.5% 5.5% 4.8% 1.9% 5.5% 1.9% 5.5% 1.9% 1.9% 1.9% 1.9% 1.1% 1.9% 1.1% 1.0	IV, Random, 95% Cl           1.65 [-2.15, 5.45]           1.80 [0.06, 3.54]           9.00 [5.47, 12.53]           2.80 [1.78, 3.82]           3.20 [1.85, 4.55]           0.10 [-7.58, 7.78]           0.10 [-7.58, 7.78]           0.10 [-7.58, 7.78]           0.10 [-7.58, 7.78]           0.10 [-7.15, 1.35]           0.342 [0.89, 5.95]           1.53 [1.14, 1.92]           3.85 [2.56, 5.14]           2.93 [2.11, 3.75]           2.00 [0.26, 3.74]           3.68 [1.33, 6.03]           3.07 [-0.24, 6.38]           2.35 [-0.39, 5.99]           1.86 [1.04, 2.68]           1.48 [-1.44, 4.40]           0.28 [-1.13, 1.69]           2.18 [0.95, 3.41]           0.42 [-1.31, 1.69]           2.18 [0.45, 3.42]	2013 2013 2014 2015 2016 2019 2022 2014 2015 2017 2018 2018 2018 2018 2018 2019 2020 2021 2021	Mean Difference
Test for subgroup differe b Study or Subgroup 2 TADs Sar et al. 2013a Suzuki et al. 2013 Cozzani et al. 2013 Cozzani et al. 2014 Caprioglio et al. 2015 Cozzani et al. 2015 Cozzani et al. 2019 Altieri et al. 2029 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 1. Test for overall effect: Z 3 TADs Kook et al 2014 Sa'aed et al 2015 Park et al 2018 Park et al 2018 Park et al 2019 Alfafii et al 2020 Chou et al 2021 Jung et al 2021b Park et al 2021 Jung et al 2021b	nces: Chi² = 0.03. d Mean Difference 1.65 1.8 9 2.8 3.2 0.6 3 0.1 0.1 85; Chi² = 37.54, df = 4.16 (P < 0.0001) 3.422 1.53 3.85 2.93 2.368 1.48 0.93 1.86 1.48 0.94 4.36	5 = 1 (F 5 = 1 (F 5 = 1 (F 1.94 0.89 1.8 0.52 0.69 0.89 0.84 0.52 0.69 0.84 0.52 0.69 0.84 0.52 0.69 0.89 0.89 0.89 0.52 0.69 0.89 0.52 0.69 0.89 0.52 0.69 0.89 0.52 0.69 0.89 0.52 0.69 0.89 0.52 0.69 0.89 0.52 0.69 0.84 0.52 0.69 0.84 0.52 0.64 1.29 0.64 1.29 0.64 1.29 0.64 1.29 0.64 1.29 0.64 1.29 0.42 0.64 1.29 0.64 1.29 0.42 0.64 1.29 0.42 0.62 0.64 1.29 0.42 0.62 0.64 1.29 0.42 0.62 0.42 0.62 0.64 1.29 0.42 0.62 0.42 0.62 0.42 0.42 0.42 0.42 0.42 0.42 0.42 0.42 0.42 0.42 0.42 0.42 0.42 1.4 1.49 0.42 1.49 1.	T0 Total 14 200 14 18 19 22 167 <0.000 24 22 200 22 200 22 200 22 200 22 200 22 200 22 200 22 17 16 20 20 22 200 22 17 16 20 20 20 20 20 20 20 20 20 20 20 20 20	<b>T1</b> <b>Total</b> 14 20 14 18 9 26 24 40 10 22 <b>167</b> 0001);   <sup>2</sup> 20 24 22 20 22 21 77 16 23 20 22 21 77 16 23 20 22 21 17 20 22 20 22 21 17 20 20 22 21 17 20 20 22 21 20 22 20 22 21 20 22 20 22 21 20 22 20 22 20 22 21 20 22 20 20	Weight 1.6% 3.9% 1.8% 5.2% 4.6% 4.6% 5.8% 0.5% 32.0% 2.7% 6.1% 5.5% 3.9% 2.7% 6.1% 5.5% 3.9% 1.9% 2.9% 1.9% 2.9% 1.9% 1.7% 1.7% 1.9% 1.9% 1.8% 1.7% 1.9	$\begin{array}{c} \textbf{IV, Random, 95\% Cl} \\ \textbf{I,65} [-2.15, 5.45] \\ 1.80 [0.06, 3.54] \\ 9.00 [5.47, 12.53] \\ 2.80 [1.78, 3.82] \\ 3.20 [1.85, 4.55] \\ 0.60 [-1.05, 2.25] \\ 3.00 [2.41, 3.59] \\ 0.10 [-1.51, 3.15] \\ \textbf{2.37} [1.26, 3.49] \\ \textbf{3.42} [0.89, 5.95] \\ 1.53 [1.14, 1.92] \\ 3.82 [2.56, 5.14] \\ 2.93 [2.11, 3.75] \\ 2.00 [2.68, 3.74] \\ 3.68 [1.33, 6.03] \\ 3.07 [-0.24, 6.38] \\ 2.35 [-0.39, 5.09] \\ 0.39 [-2.68, 4.54] \\ 1.86 [1.44, 2.68] \\ 1.48 [1.44, 2.68] \\ 1.48 [-1.44, 4.40] \\ 0.28 [-1.13, 1.69] \\ 2.18 [0.95, 3.41] \\ 0.94 [-2.39, 4.27] \\ 4.36 [-0.46, 9.18] \\ 3.30 [2.75, 3.85] \end{array}$	2013 2013 2014 2015 2015 2019 2022 2019 2022 2019 2022 2017 2018 2018 2018 2018 2018 2018 2019 2020 2021 2021 2021 2021	Mean Difference
Test for subgroup differe b Study or Subgroup 2 TADs Sar et al. 2013a Suzuki et al. 2013 Cozzani et al. 2013 Cozzani et al. 2013 Cozzani et al. 2015 Cozzani et al. 2015 Cozzani et al. 2015 Cozzani et al. 2016 Cassetta et al. 2019 Attieri et al. 2022 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 1. Test for overall effect: Z 3 TADs Kokk et al 2014 Sa'aed et al 2015 Park et al 2018 Lee et al 2018 Park et al 2018 Park et al 2018 Park et al 2018 Park et al 2019 Atfaifi et al 2020 Chou et al 2021 Jung et al 2021b Park et al 2021c Alfawaz et al 2022 Lim et al. 2022	nces: Chi² = 0.03, d Mean Difference 1.65 1.8 9 2.8 3.2 0.6 3 0.1 0.1 85; Chi² = 37.54, df = 4.16 (P < 0.0001) 3.42 1.53 3.85 2.93 3.68 3.07 2.35 0.93 1.86 1.48 0.28 2.42 3.68 3.07 2.35 0.93 1.86 1.48 0.24 3.67 1.86 3.7 1.53 3.85 2.93 3.68 3.07 2.35 0.93 1.86 1.86 3.7 2.95 0.93 1.86 1.86 1.85 1.85 1.85 1.95 1.53 1.65 1.86 1.75 1.53 1.65 1.86 1.65 1.86 1	5 SE 1.94 0.89 1.8 0.52 0.69 0.84 0.3 3.92 0.64 1.29 0.2 0.66 0.42 0.69 0.42 0.69 0.42 0.69 0.42 1.69 1.84 0.42 0.42 0.44 0.42 0.42 0.44 0.42 0.44 0.42 0.44 0.44 0.44 0.4	T0 Total 14 20 14 19 26 24 10 216 7 7 < 0.000 22 20 24 22 20 22 20 22 20 22 20 22 17 16 23 20 22 17 16 20 20 21 21 20 20 22 20 22 20 20 22 20 20 24 21 20 20 20 20 20 20 20 20 20 20 20 20 20	T1 Total 14 20 14 19 26 24 10 22 167 7001):   <sup>2</sup> 20 24 22 20 22 20 22 20 22 20 22 20 22 20 22 17 16 23 20 22 12 20 20	Weight 1.6% 3.9% 1.8% 5.2% 4.6% 5.8% 0.5% 2.7% 6.1% 4.7% 2.7% 6.1% 1.9% 2.7% 2.7% 2.7% 1.9% 2.3% 4.4% 4.4% 4.4% 4.4% 1.9% 5.5%	IV, Random, 95% Cl 1.65 [-2.15, 5.45] 1.80 [0.06, 3.54] 9.00 [5.47, 12.53] 2.80 [1.78, 3.82] 3.20 [1.85, 4.55] 0.00 [-1.05, 2.25] 3.00 [2.41, 3.59] 0.10 [-7.58, 7.78] 2.37 [1.26, 3.49] 3.42 [0.89, 5.95] 1.53 [1.14, 1.92] 3.85 [2.56, 5.14] 2.93 [2.11, 3.75] 2.00 [0.26, 3.74] 3.68 [1.33, 6.03] 3.07 [-0.24, 6.38] 2.35 [-0.39, 5.09] 1.86 [1.34, 1.63] 2.37 [2.64, 9.18] 3.30 [2.75, 3.85] 5.09 [3.58, 6.60] 0.80 [0.41, 1.19]	2013 2013 2014 2015 2015 2019 2022 2019 2022 2014 2019 2022 2018 2018 2018 2018 2018 2018 2019 2020 2021 2021 2021 2021	Mean Difference
Test for subgroup differe b Study or Subgroup 2 TADs Sar et al. 2013a Suzuki et al. 2013b Cozzani et al. 2014 Caprioglio et al. 2015 Cozzani et al. 2015 Cozzani et al. 2019b Cassetta et al. 2019 Attieri et al. 2026 Subtotal (95% Ct) Heterogeneity: Tau <sup>2</sup> = 1. Test for overall effect: Z 3 TADs Kook et al 2014 Sa'aed et al 2015 Park et al 2018a Park et al 2018a Park et al 2018a Park et al 2018b Shoaib et al 2019 Lee et al 2018a Park et al 2018b Shoaib et al 2019 Lee et al 2019a Lee et al 2019a Atfaifi et al 2021b Park et al 2021c Lim et al. 2022c Subtotal (95% Ct)	nces: Chi <sup>2</sup> = 0.03, d <u>Mean Difference</u> 1.65 1.8 9 2.8 3.2 0.6 3 0.1 0.1 85; Chi <sup>2</sup> = 37.54, df = 4.16 (P < 0.0001) 3.42 1.53 3.85 2.93 1.53 3.85 2.93 1.68 3.07 2.35 0.93 1.86 1.88 0.94 4.36 0.94 4.36 0.94 4.36 0.94 0.95 0.94 0.94 0.94 0.94 0.94 0.94 0.94 0.94 0.94 0.94 0.94 0.94 0.94 0.94 0.94 0.94 0.95 0	f = 1 (F SE 1.94 0.89 1.8 0.62 0.69 0.69 0.69 0.64 = 8 (P 1.29 0.2 0.64 = 8 (P 1.29 0.2 0.66 0.42 0.68 1.2 1.69 0.2 0.68 1.4 1.49 0.72 0.63 1.4 9 0.77 0.2	T0 Total 14 20 14 19 266 24 22 167 <0.000 20 24 22 20 0 22 20 20 22 217 7 12 20 20 22 20 20 22 217 7 12 20 20 20 20 20 21 20 20 20 20 20 20 20 20 20 20 20 20 20	T1 Total 14 20 14 18 19 26 24 20 20 22 167 7001); l <sup>2</sup> 20 20 22 20 20 22 21 77 12 20 20 22 20 20 22 17 71 20 20 20 20 20 20 20 20 20 20 20 20 20	Weight 1.6% 3.9% 1.8% 5.2% 4.6% 4.6% 4.7% 5.8% 0.5% 4.7% 5.5% 4.7% 5.5% 4.7% 5.5% 4.7% 5.5% 4.7% 5.5% 1.9% 1.9% 1.9% 1.9% 1.9% 4.8% 4.8% 4.8% 4.7% 5.9% 5.9% 1.8% 5.9% 5.2% 5.5% 6.5% 5.5% 5.5% 5.5% 6.5% 5.5% 5.5% 6.5% 5.5% 6.5% 5.5% 6.5% 5.5% 6.5% 5.5% 6.5% 5.5% 6.5% 5.5% 6.5% 5.5% 5.5% 6.5% 5.5%	$\begin{array}{c} \textbf{IV, Random, 95\% Cl} \\ \textbf{I,65} [-2.15, 5.45] \\ 1.80 [0.06, 35.45] \\ 9.00 [5.47, 12.53] \\ 2.80 [1.78, 3.82] \\ 3.20 [1.85, 4.55] \\ 0.50 [-105, 2.25] \\ 3.00 [2.41, 3.59] \\ 0.10 [-1.15, 1.35] \\ 2.37 [1.26, 3.49] \\ \textbf{S}_{2} [3.66, 5.14] \\ 2.33 [1.14, 1.92] \\ 3.85 [2.66, 5.14] \\ 2.93 [2.11, 3.75] \\ 2.00 [0.26, 3.74] \\ 3.68 [1.33, 6.03] \\ 3.07 [-0.24, 6.38] \\ 2.35 [-0.39, 5.09] \\ 0.33 [-2.68, 4.54] \\ 1.86 [1.04, 2.68] \\ 1.48 [1.44, 4.40] \\ 0.28 [-1.13, 1.69] \\ 2.18 [0.95, 3.42] \\ 1.68 [-2.39, 4.27] \\ 4.36 [-0.46, 9.18] \\ 3.00 [2.58, 8.66] \\ \end{array}$	2013 2013 2014 2015 2015 2019 2022 2019 2022 2014 2019 2022 2018 2018 2018 2018 2018 2018 2019 2020 2021 2021 2021 2021	Mean Difference
Test for subgroup differe <b>Study or Subgroup</b> <b>2 TADs</b> Sar et al. 2013a Suzuki et al. 2013 Sar et al. 2013b Cozzani et al. 2013 Cozzani et al. 2015 Cozzani et al. 2015 Cozzani et al. 2016 Cassetta et al. 2019 Altieri et al. 2020 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 1. Test for overall effect: Z <b>3 TADs</b> Kook et al 2015 Park et al 2017 Jo et al 2018 Lee et al 2018 Lee et al 2018 Dark et al 2019 Alfaifi et al 2020 Chou et al 2021 Jung et al 2021b Park et al 2021c Alfami et al 2022c Lim et al. 2022c Kim et al. 2022 Kim et al. 2022 Kim et al. 2022 Kim et al. 2022	nces: Chi <sup>2</sup> = 0.03. d Mean Difference 1.65 1.8 9 2.8 3.2 0.6 3.1 0.1 0.1 85; Chi <sup>2</sup> = 37.54, df = 4.16 (P < 0.0001) 3.422 1.53 3.85 2.93 2.93 2.93 3.68 1.48 0.94 1.48 0.94 4.36 0.94 4.36 0.94 4.36 0.94 4.36 0.94 1.86 1.86 1.87 1.86 1.48 1.87 1.87 1.87 1.87 1.86 1.48 1.86 1.48 1.87 1.87 1.87 1.87 1.87 1.87 1.87 1.87 1.87 1.87 1.87 1.87 1.87 1.87 1.87 1.86 1.48 1.87 1.87 1.87 1.87 1.86 1.48 1.87 1.86 1.48 1.87 1.86 1.48 1.86 1.86 1.48 1.86 1.48 1.86 1.48 1.86 1.48 1.86 1.8	f = 1 (F SE 1.94 0.89 0.69 0.84 0.3 3.92 0.64 = 8 (P 1.29 0.64 0.84 0.42 0.66 0.42 0.66 0.42 0.66 0.42 0.66 0.42 1.29 0.64 1.29 0.64 0.33 1.2 1.29 0.64 0.64 0.64 0.84 0.59 0.64 0.84 0.59 0.64 0.84 0.59 0.64 0.84 0.59 0.64 0.84 0.59 0.64 0.84 0.59 0.64 0.64 0.64 0.64 0.64 0.64 0.64 0.64	T0 Total 14 20 14 19 266 24 22 167 <0.000 20 24 22 20 0 22 20 20 22 217 7 12 20 20 22 20 20 22 217 7 12 20 20 20 20 20 21 20 20 20 20 20 20 20 20 20 20 20 20 20	T1 Total 14 20 14 18 19 26 24 20 20 22 167 7001); l <sup>2</sup> 20 20 22 20 20 22 21 77 12 20 20 22 20 20 22 17 71 20 20 20 20 20 20 20 20 20 20 20 20 20	Weight 1.6% 3.9% 1.8% 5.2% 4.6% 4.6% 4.7% 5.8% 0.5% 4.7% 5.5% 4.7% 5.5% 4.7% 5.5% 4.7% 5.5% 4.7% 5.5% 1.9% 1.9% 1.9% 1.9% 1.9% 4.8% 4.8% 4.8% 4.7% 5.9% 5.9% 1.8% 5.9% 5.2% 5.5% 6.5% 5.5% 5.5% 5.5% 6.5% 5.5% 5.5% 6.5% 5.5% 6.5% 5.5% 6.5% 5.5% 6.5% 5.5% 6.5% 5.5% 6.5% 5.5% 6.5% 5.5% 5.5% 6.5% 5.5%	IV, Random, 95% Cl 1.65 [-2.15, 5.45] 1.80 [0.06, 3.54] 9.00 [5.47, 12.53] 2.80 [1.78, 3.82] 3.20 [1.85, 4.55] 0.00 [-1.05, 2.25] 3.00 [2.41, 3.59] 0.10 [-7.58, 7.78] 2.37 [1.26, 3.49] 3.42 [0.89, 5.95] 1.53 [1.14, 1.92] 3.85 [2.56, 5.14] 2.93 [2.11, 3.75] 2.00 [0.26, 3.74] 3.68 [1.33, 6.03] 3.07 [-0.24, 6.38] 2.35 [-0.39, 5.09] 1.86 [1.34, 1.63] 2.37 [2.64, 9.18] 3.30 [2.75, 3.85] 5.09 [3.58, 6.60] 0.80 [0.41, 1.19]	2013 2013 2014 2015 2015 2019 2022 2019 2022 2014 2019 2022 2018 2018 2018 2018 2018 2018 2019 2020 2021 2021 2021 2021	Mean Difference
Test for subgroup differe b Study or Subgroup 2 TADs Sar et al. 2013a Suzuki et al. 2013b Cozzani et al. 2014 Caprioglio et al. 2015 Cozzani et al. 2015 Cozzani et al. 2019b Cassetta et al. 2019 Attieri et al. 2026 Subtotal (95% Ct) Heterogeneity: Tau <sup>2</sup> = 1. Test for overall effect: Z 3 TADs Kook et al 2014 Sa'aed et al 2015 Park et al 2018a Park et al 2018a Park et al 2018a Park et al 2018b Shoaib et al 2019 Lee et al 2018a Park et al 2018b Shoaib et al 2019 Lee et al 2019a Lee et al 2019a Atfaifi et al 2021b Park et al 2021c Lim et al. 2022c Subtotal (95% Ct)	nces: Chi <sup>2</sup> = 0.03. d Mean Difference 1.65 1.8 9 2.8 3.2 0.6 3.1 0.1 0.1 85; Chi <sup>2</sup> = 37.54, df = 4.16 (P < 0.0001) 3.422 1.53 3.85 2.93 2.93 2.93 3.68 1.48 0.94 1.48 0.94 4.36 0.94 4.36 0.94 4.36 0.94 4.36 0.94 1.86 1.86 1.87 1.86 1.48 1.87 1.87 1.87 1.87 1.86 1.48 1.86 1.48 1.87 1.87 1.87 1.87 1.87 1.87 1.87 1.87 1.87 1.87 1.87 1.87 1.87 1.87 1.87 1.86 1.48 1.87 1.87 1.87 1.87 1.86 1.48 1.87 1.86 1.48 1.87 1.86 1.48 1.86 1.86 1.48 1.86 1.48 1.86 1.48 1.86 1.48 1.86 1.8	f = 1 (F SE 1.94 0.89 0.69 0.84 0.3 3.92 0.64 = 8 (P 1.29 0.64 0.84 0.42 0.66 0.42 0.66 0.42 0.66 0.42 0.66 0.42 1.29 0.64 1.29 0.64 0.33 1.2 1.29 0.64 0.64 0.64 0.84 0.59 0.64 0.84 0.59 0.64 0.84 0.59 0.64 0.84 0.59 0.64 0.84 0.59 0.64 0.84 0.59 0.64 0.64 0.64 0.64 0.64 0.64 0.64 0.64	T0 Total 14 20 14 19 266 24 22 167 <0.000 20 24 22 20 0 22 20 20 22 217 7 12 20 20 22 20 20 22 217 7 12 20 20 20 20 20 21 20 20 20 20 20 20 20 20 20 20 20 20 20	T1 Total 14 20 14 18 19 26 24 20 20 22 167 7001); l <sup>2</sup> 20 20 22 20 20 22 21 77 12 20 20 22 20 20 22 17 71 20 20 20 20 20 20 20 20 20 20 20 20 20	Weight 1.6% 3.9% 1.8% 5.2% 4.6% 4.6% 4.7% 5.8% 0.5% 4.7% 5.5% 4.7% 5.5% 4.7% 5.5% 4.7% 5.5% 4.7% 5.5% 1.9% 1.9% 1.9% 1.9% 1.9% 4.8% 4.8% 4.8% 4.7% 5.9% 5.9% 1.8% 5.9% 5.2% 5.5% 6.5% 5.5% 5.5% 5.5% 6.5% 5.5% 5.5% 6.5% 5.5% 6.5% 5.5% 6.5% 5.5% 6.5% 5.5% 6.5% 5.5% 6.5% 5.5% 6.5% 5.5% 5.5% 6.5% 5.5%	IV, Random, 95% Cl 1.65 [-2.15, 5.45] 1.80 [0.06, 3.54] 9.00 [5.47, 12.53] 2.80 [1.78, 3.82] 3.20 [1.85, 4.55] 0.00 [-1.05, 2.25] 3.00 [2.41, 3.59] 0.10 [-7.58, 7.78] 2.37 [1.26, 3.49] 3.42 [0.89, 5.95] 1.53 [1.14, 1.92] 3.85 [2.56, 5.14] 2.93 [2.11, 3.75] 2.00 [0.26, 3.74] 3.68 [1.33, 6.03] 3.07 [-0.24, 6.38] 2.35 [-0.39, 5.09] 1.86 [1.34, 1.63] 2.37 [2.64, 9.18] 3.30 [2.75, 3.85] 5.09 [3.58, 6.60] 0.80 [0.41, 1.19]	2013 2013 2014 2015 2015 2019 2022 2019 2022 2014 2019 2022 2018 2018 2018 2018 2018 2018 2019 2020 2021 2021 2021 2021	Mean Difference
Test for subaroup differe b Study of Subgroup 2 TAD2 Sar et al. 2013a Suzuki et al. 2013 Sar et al. 2013b Cozzani et al. 2014 Caproigio et al. 2015 Cozzani et al. 2016 Cozsarit et al. 2019 Altieri et al. 2022 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 1. Test for overall effect. 2 3 TAD2 Kook et al 2014 Sa'aed et al 2015 Park et al 2018 Lee et al 2019 Alfaifi et al 2020 Chou et al 2021 Jung et al 2021b Park et al 2021b Park et al 2021b Park et al 2021c Alfaifi et al 2022c Lim et al. 2022 Lim et al. 2022 Lim et al. 2022 Lim et al. 2022 Kim	nces: Chi <sup>2</sup> = 0.03. d Mean Difference 1.65 1.8 9 2.8 3.2 0.6 3.1 0.1 0.1 85; Chi <sup>2</sup> = 37.54, df = 4.16 (P < 0.0001) 3.422 1.53 3.85 2.93 2.93 2.93 3.68 1.48 0.94 1.48 0.94 4.36 0.94 4.36 0.94 4.36 0.94 4.36 0.94 1.86 1.86 1.87 1.86 1.48 1.87 1.87 1.87 1.87 1.86 1.48 1.86 1.48 1.87 1.87 1.87 1.87 1.87 1.87 1.87 1.87 1.87 1.87 1.87 1.87 1.87 1.87 1.87 1.86 1.48 1.87 1.87 1.87 1.87 1.86 1.48 1.87 1.86 1.48 1.87 1.86 1.48 1.86 1.86 1.48 1.86 1.48 1.86 1.48 1.86 1.48 1.86 1.8	f = 1 (F SE 1.94 0.89 0.69 0.84 0.3 3.92 0.64 = 8 (P 1.29 0.64 0.84 0.42 0.66 0.42 0.66 0.42 0.66 0.42 0.66 0.42 1.29 0.64 1.29 0.64 1.2 9 0.2 1.4 1.8 0.52 0.69 0.54 0.59 0.54 0.59 0.54 0.59 0.54 0.59 0.54 0.59 0.54 0.59 0.54 0.59 0.54 0.59 0.54 0.59 0.54 0.59 0.54 0.59 0.54 0.54 0.54 0.54 0.55 0.54 0.54 0.54	<b>T0</b> <b>Total</b> 14 20 14 19 22 24 167 22 20 24 422 200 22 200 22 17 16 23 20 22 17 16 20 22 17 16 20 20 22 17 16 20 22 20 20 22 20 22 20 22 20 22 20 22 20 22 20 22 20 22 20 22 20 22 20 22 20 22 20 22 20 22 20 22 20 22 20 22 20 22 20 20	T1 Total 14 20 14 18 19 22 24 10 22 24 00 22 20 02 24 22 20 02 22 10 7 16 23 20 22 20 22 17 16 22 20 22 20 20 22 20 20 22 17 16 20 22 20 20 22 20 20 20 20 20 20 20 20	Weight 1.6% 3.9% 1.8% 4.6% 4.6% 4.7% 5.2% 32.0% 2.7% 6.1% 4.7% 5.5% 3.9% 2.7% 6.1% 4.7% 5.5% 3.9% 1.9% 2.7% 6.1% 4.7% 5.2% 4.7% 5.2% 6.1% 4.7% 5.2% 6.1% 4.7% 5.2% 6.1% 4.7% 5.2% 6.1% 6.1% 5.2% 6.1% 6.1% 5.2% 6.1% 6.2% 6.1	IV, Random, 95% Cl           1.65 [-2.15, 5.45]           1.80 [0.06, 3.54]           9.00 [5.47, 12.53]           2.80 [1.78, 3.82]           3.20 [1.85, 4.55]           0.60 [-105, 2.25]           3.00 [2.41, 3.59]           0.10 [-7.15, 1.35]           2.37 [1.26, 3.49]           3.42 [0.89, 5.95]           1.53 [1.14, 1.92]           3.85 [2.66, 5.14]           2.93 [2.11, 3.76]           2.04 [0.24, 6.38]           2.35 [2.66, 5.14]           2.93 [2.11, 3.76]           2.05 [2.66, 5.44]           2.93 [2.11, 3.76]           2.05 [2.68, 5.44]           2.93 [2.11, 3.76]           2.93 [2.11, 3.76]           2.93 [2.44, 4.40]           0.28 [-1.33, 1.60]           2.36 [2.68, 4.54]           1.86 [1.04, 2.68]           1.86 [1.04, 2.68]           2.46 [-2.39, 4.27]           4.36 [-2.39, 4.27]           4.36 [-2.39, 4.27]           4.36 [-2.39, 4.27]           4.36 [-2.39, 5.60]           0.80 [0.41, 1.19]           2.38 [1.72, 3.04]	2013 2013 2014 2015 2015 2019 2022 2019 2022 2014 2019 2022 2018 2018 2018 2018 2018 2018 2019 2020 2021 2021 2021 2021	Mean Difference
Test for subgroup differe b Study or Subgroup 2 TADs Sar et al. 2013a Suzuki et al. 2013b Cozzani et al. 2013b Cozzani et al. 2015 Cozzani et al. 2015 Cozzani et al. 2016 Cassetta et al. 2019 Attieri et al. 2022 Subtotal (95% CI) Heterogeneity: Tau² = 1. Test for overall effect: Z 3 TADs Kook et al 2014 Sa'aed et al 2015 Park et al 2017 Jo et al 2018 Lee et al 2019 Atfailf et al 2020 Chou et al 2021 Jung et al 2021b Park et al 2021c Atfailf et al 2022 Lim et al. 2022 Kim et al. 2022 Subtotal (95% CI)	nces: Chi <sup>2</sup> = 0.03, d Mean Difference 1.65 1.8 9 2.8 3.2 0.6 3 0.1 0.1 85; Chi <sup>2</sup> = 37.54, df = 4.16 (P < 0.0001) 3.422 1.53 3.85 2.93 2 3.68 1.48 0.93 1.86 1.48 0.93 0.93 1.86 1.48 0.94 1.86 1.97 1.97 0.97 0.98 1.97	f = 1 (F SE 1.94 0.89 1.8 0.69 0.84 0.3 3.92 0.64 1.29 0.2 0.64 1.29 0.2 0.64 1.29 0.42 0.89 1.4 1.69 0.42 0.57 0.2 1.7 0.2 1.7 1.7 0.2 1.7 1.7 1.7 1.7 1.7 1.7 1.7 1.7	T0 Total 14 20 14 19 26 24 167 22 20 24 22 20 22 21 20 22 21 20 22 21 20 22 21 20 22 21 20 22 21 167 7 16 7 16 21 20 22 20 22 21 22 20 22 21 22 20 22 21 22 20 22 21 22 20 22 21 22 20 22 21 22 20 22 21 22 20 20 22 21 20 20 22 21 20 20 22 21 20 20 22 21 20 20 22 21 20 20 20 22 21 20 20 20 20 20 20 20 20 20 20	T1 Total 14 20 14 18 19 26 24 22 167 7001);   <sup>2</sup> 20 24 22 20 22 20 22 20 22 20 22 20 22 21 16 23 30 20 20 20 21 20 20 21 12 20 20 20 21 14 20 20 21 20 20 21 20 20 21 20 20 21 20 20 21 20 20 20 21 20 20 20 20 20 21 20 20 20 20 20 20 20 20 20 20 20 20 20	Weight 1.6% 3.9% 1.8% 4.6% 4.6% 4.7% 5.2% 4.7% 32.0% 2.7% 6.1% 4.7% 5.5% 3.9% 2.5% 5.5% 3.9% 2.5% 1.9% 5.5% 5.5% 4.4% 4.7% 5.5% 6.1% 4.7% 6.1% 6.1% 6.1% 6.2% 6.1% 6.1% 6.2% 6.1% 6.1% 6.2% 6.1% 6.1% 6.1% 6.1% 6.2% 6.2	IV, Random, 95% Cl 1.65 [-2.15, 5.45] 1.80 [0.06, 3.54] 9.00 [5.47, 12.53] 2.80 [1.78, 3.82] 3.20 [1.85, 4.55] 0.00 [-1.05, 2.25] 3.00 [2.41, 3.59] 0.10 [-7.58, 7.78] 2.37 [1.26, 3.49] 3.42 [0.89, 5.95] 1.53 [1.14, 1.92] 3.85 [2.56, 5.14] 2.93 [2.11, 3.75] 2.00 [0.26, 3.74] 3.68 [1.33, 6.03] 3.07 [-0.24, 6.38] 2.35 [-0.39, 5.09] 1.86 [1.34, 1.63] 2.37 [2.64, 9.18] 3.30 [2.75, 3.85] 5.09 [3.58, 6.60] 0.80 [0.41, 1.19]	2013 2013 2014 2015 2015 2019 2022 2019 2022 2014 2019 2022 2018 2018 2018 2018 2018 2018 2019 2020 2021 2021 2021 2021	Mean Difference IV, Random, 95% CI
Test for subgroup differe b Study or Subgroup 2 TADs Sar et al. 2013a Suzuki et al. 2013 Cozzani et al. 2013 Cozzani et al. 2013 Cozzani et al. 2013 Cozzani et al. 2015 Cozzani et al. 2015 Cozzani et al. 2016 Cassetta et al. 2019 Attieri et al. 2022 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 1. Test for overall effect: Z 3 TADs Kok et al 2014 Sa'aed et al 2015 Park et al 2018 Park et al 2019 Lee et al 2019 Lee et al 2019 Atfailf et al 2021 Jung et al 2021a Jung et al 2021a Park et al 2021b Park et al 2021c Lim et al. 2022 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 1. Total (95% CI)	nces: Chi <sup>2</sup> = 0.03, d Mean Difference 1.65 1.8 9 2.8 3.2 0.6 3 0.1 0.1 85; Chi <sup>2</sup> = 37.54, df = 4.16 (P < 0.0001) 3.42 1.53 3.85 2.93 3.68 3.07 2.35 0.93 1.86 1.48 0.28 2.18 0.94 4.36 1.86 1.48 0.28 2.18 0.94 4.36 1.86 1.86 1.85 1.53 3.85 2.93 3.68 3.07 2.35 0.93 1.86 1.86 1.86 1.86 1.85 3.97 2.35 0.93 1.86 1.86 1.86 1.86 1.85 3.97 2.35 0.93 1.86 1.86 1.86 1.86 1.86 1.87 1.86 1.85 1.86 1.87 1.86 1.86 1.86 1.86 1.86 1.86 1.86 1.86 1.86 1.86 1.86 1.86 1.86 1.86 1.86 1.87 1.86 1.86 1.87 1.86 1.86 1.86 1.86 1.86 1.87 1.86 1.86 1.87 1.86 1.86 1.87 1.87 1.87 1.87 1.86 1.87 1.87 1.86 1.87 1.8	f = 1 (F SE 1.94 0.89 1.8 0.52 0.69 0.69 0.69 0.69 0.69 0.69 0.69 0.69	T0 Total 14 20 14 19 26 24 167 22 20 24 22 20 22 21 20 22 21 20 22 21 20 22 21 20 22 21 20 22 21 167 7 16 7 16 21 20 22 20 22 21 22 20 22 21 22 20 22 21 22 20 22 21 22 20 22 21 22 20 22 21 22 20 22 21 22 20 20 22 21 20 20 22 21 20 20 22 21 20 20 22 21 20 20 22 21 20 20 20 22 21 20 20 20 20 20 20 20 20 20 20	T1 Total 14 20 14 18 19 26 24 22 167 7001);   <sup>2</sup> 20 24 22 20 22 20 22 20 22 20 22 20 22 21 16 23 30 20 20 20 21 20 20 21 12 20 20 20 21 14 20 20 21 20 20 21 20 20 21 20 20 21 20 20 21 20 20 20 21 20 20 20 20 20 21 20 20 20 20 20 20 20 20 20 20 20 20 20	Weight 1.6% 3.9% 1.8% 4.6% 4.6% 4.7% 5.2% 4.7% 32.0% 2.7% 6.1% 4.7% 5.5% 3.9% 2.5% 5.5% 3.9% 2.5% 1.9% 5.5% 5.5% 4.4% 4.7% 5.5% 6.1% 4.7% 6.1% 6.1% 6.1% 6.2% 6.1% 6.1% 6.2% 6.1% 6.1% 6.2% 6.1% 6.1% 6.1% 6.1% 6.2% 6.2	IV, Random, 95% Cl           1.65 [-2.15, 5.45]           1.80 [0.06, 3.54]           9.00 [5.47, 12.53]           2.80 [1.78, 3.82]           3.20 [1.85, 4.55]           0.60 [-105, 2.25]           3.00 [2.41, 3.59]           0.10 [-7.15, 1.35]           2.37 [1.26, 3.49]           3.42 [0.89, 5.95]           1.53 [1.14, 1.92]           3.85 [2.66, 5.14]           2.93 [2.11, 3.76]           2.04 [0.24, 6.38]           2.35 [2.66, 5.14]           2.93 [2.11, 3.76]           2.05 [2.66, 5.44]           2.93 [2.11, 3.76]           2.05 [2.68, 5.44]           2.93 [2.11, 3.76]           2.93 [2.11, 3.76]           2.93 [2.44, 4.40]           0.28 [-1.33, 1.60]           2.36 [2.68, 4.54]           1.86 [1.04, 2.68]           1.86 [1.04, 2.68]           2.46 [-2.39, 4.27]           4.36 [-2.39, 4.27]           4.36 [-2.39, 4.27]           4.36 [-2.39, 4.27]           4.36 [-2.39, 5.60]           0.80 [0.41, 1.19]           2.38 [1.72, 3.04]	2013 2013 2014 2015 2015 2019 2022 2019 2022 2014 2019 2022 2018 2018 2018 2018 2018 2018 2019 2020 2021 2021 2021 2021	Mean Difference IV, Random, 95% Cl
Test for subgroup differe b Study or Subgroup 2 TADs Sar et al. 2013a Suzuki et al. 2013b Cozzani et al. 2013b Cozzani et al. 2015 Cozzani et al. 2015 Cozzani et al. 2016 Cassetta et al. 2019 Attieri et al. 2022 Subtotal (95% CI) Heterogeneity: Tau² = 1. Test for overall effect: Z 3 TADs Kook et al 2014 Sa'aed et al 2015 Park et al 2017 Jo et al 2018 Lee et al 2019 Atfailf et al 2020 Chou et al 2021 Jung et al 2021b Park et al 2021c Atfailf et al 2022 Lim et al. 2022 Kim et al. 2022 Subtotal (95% CI)	nces: Chi <sup>2</sup> = 0.03. d Mean Difference 1.65 1.8 9 2.8 3.2 0.6 3.3 0.1 0.1 85; Chi <sup>2</sup> = 37.54, df = 4.16 (P < 0.0001) 3.42 1.53 3.85 2.93 2.93 2.93 3.68 3.07 2.35 0.93 1.86 1.48 0.94 4.36 1.48 0.94 4.36 1.48 0.94 4.36 1.48 0.94 4.36 1.48 0.94 4.36 1.48 0.94 4.36 1.48 0.94 4.36 1.48 0.94 4.36 1.48 0.94 4.36 1.48 0.94 4.36 1.48 0.94 4.36 1.48 0.94 4.36 1.48 0.94 4.36 1.48 0.94 4.36 1.48 0.94 4.36 1.69	SE           1.94           0.89           1.8           0.69           0.84           0.63           0.64           = 8 (P           1.29           0.64           1.29           0.64           1.29           0.64           1.29           0.64           1.29           0.64           0.42           0.89           1.4           0.42           1.69           1.7           2.46           0.27           0.63           1.7           2.46           0.77           0.2           f = 17 (           )	T0 Total 14 20 14 19 24 16 24 22 20 22 20 22 20 22 20 21 17 16 23 30 20 20 24 22 20 22 20 20 21 17 16 20 21 21 21 20 22 20 20 22 20 22 20 22 20 22 20 22 20 22 20 22 20 22 20 22 20 22 20 22 20 20	T1 Total 14 20 14 18 19 26 24 10 22 20 22 20 22 20 22 20 22 20 22 20 22 20 22 20 22 20 22 20 22 20 22 20 22 20 22 20 20	Weight 1.6% 3.9% 1.8% 4.6% 4.6% 4.7% 32.0% 2.7% 6.1% 5.5% 3.9% 2.5% 3.9% 1.9% 2.5% 4.7% 4.7% 5.5% 3.9% 1.9% 1.7% 5.5% 4.4% 1.7% 6.1% 1.7% 5.2% 1.7% 6.1% 1.7% 5.2% 1.7% 6.1% 1.7% 5.2% 1.7% 6.1% 1.7% 5.2% 1.7% 6.1% 1.7% 5.2% 1.7% 6.1% 1.7% 5.2% 1.7% 6.1% 1.7% 1.7% 5.2% 1.7% 6.1% 1.7% 1.9% 1.7% 1.7% 1.9% 1.7% 1.9	IV, Random, 95% Cl           1.65 [-2.15, 5.45]           1.80 [0.06, 3.54]           9.00 [5.47, 12.53]           2.80 [1.78, 3.82]           3.20 [1.85, 4.55]           0.60 [-105, 2.25]           3.00 [2.41, 3.59]           0.10 [-7.15, 1.35]           2.37 [1.26, 3.49]           3.42 [0.89, 5.95]           1.53 [1.14, 1.92]           3.85 [2.66, 5.14]           2.93 [2.11, 3.76]           2.04 [0.24, 6.38]           2.35 [2.66, 5.14]           2.93 [2.11, 3.76]           2.05 [2.66, 5.44]           2.93 [2.11, 3.76]           2.05 [2.68, 5.44]           2.93 [2.11, 3.76]           2.93 [2.11, 3.76]           2.93 [2.44, 4.40]           0.28 [-1.33, 1.60]           2.36 [2.68, 4.54]           1.86 [1.04, 2.68]           1.86 [1.04, 2.68]           2.46 [-2.39, 4.27]           4.36 [-2.39, 4.27]           4.36 [-2.39, 4.27]           4.36 [-2.39, 4.27]           4.36 [-2.39, 5.60]           0.80 [0.41, 1.19]           2.38 [1.72, 3.04]	2013 2013 2014 2015 2015 2019 2022 2019 2022 2014 2019 2022 2018 2018 2018 2018 2018 2018 2019 2020 2021 2021 2021 2021	Mean Difference IV, Random, 95% CI

Figure 3. Forest plot of U6 distalization (a), tipping (b), and vertical movement (c) of the 2-TAD and 3-TAD subgroups.

			то	T1		Mean Difference		Mean Difference
Study or Subgroup	Mean Difference	SE	Total	Total	Weight	IV, Random, 95% CI	Year	IV, Random, 95% CI
2 TADs								
Suzuki et al. 2013	-1	0.18	20	20	4.1%	-1.00 [-1.35, -0.65]	2013	-
Cozzani et al. 2014	0.7	0.45	18	18	3.3%	0.70 [-0.18, 1.58]	2014	+
Miresmaelli et al. 2015	-0.53	0.11	26	26	4.2%	-0.53 [-0.75, -0.31]	2015	-
Caprioglio et al. 2015	0.3	0.18	19	19	4.1%	0.30 [-0.05, 0.65]	2015	-
Cozzani et al. 2016b	0.2	0.06	24	24	4.3%	0.20 [0.08, 0.32]	2016	-
Duran et al. 2016	-0.59	0.11	21	21	4.2%	-0.59 [-0.81, -0.37]	2016	-
Cambiano et al. 2017	-0.74	0.16	18	18	4.1%	-0.74 [-1.05, -0.43]	2017	-
Kircali et al. 2018	-0.6	0.22	20	20	4.0%	-0.60 [-1.03, -0.17]	2018	
Cassetta et al. 2019	-0.9	0.06	10	10	4.3%	-0.90 [-1.02, -0.78]	2019	-
Altieri et al. 2022	0.6	0.13	22	22	4.2%	0.60 [0.35, 0.85]	2022	
Subtotal (95% CI)			198	198	40.6%	-0.29 [-0.68, 0.10]		•
Heterogeneity: Tau <sup>2</sup> = 0.	36; Chi <sup>2</sup> = 267.61, d	f = 9 (F	> < 0.00	0001); I	² = 97%			
Test for overall effect: Z	= 1.44 (P = 0.15)							
3 TADs								
Kook et al 2014	-1.75	0.3	20	20	3.8%	-1.75 [-2.34, -1.16]	2014	
Sa'aed et al 2015	-1.66	0.11	24	24	4.2%	-1.66 [-1.88, -1.44]		-
Park et al 2017	-2.53	0.3	22	22	3.8%	-2.53 [-3.12, -1.94]	2017	
Jo et al 2018	-1.31	0.3	20	20	3.8%	-1.31 [-1.90, -0.72]	2018	
Lee et al 2018a	-1.64	0.44	22	22	3.3%	-1.64 [-2.50, -0.78]		
Park et al 2018a	-1.02	0.4	17	17	3.4%	-1.02 [-1.80, -0.24]	2018	
Park et al 2018b	-1.41	0.51	16	16	3.1%	-1.41 [-2.41, -0.41]	2018	· · · · ·
Lee et al 2019	-0.35	0.47	20	20	3.2%	-0.35 [-1.27, 0.57]	2019	
Shoaib et al 2019	1.42	0.23	23	23	4.0%	1.42 [0.97, 1.87]	2019	
Alfaifi et al 2020	1.6	0.31	21	21	3.7%	1.60 [0.99, 2.21]	2020	
Chou et al 2021	-0.25	0.78	20	20	2.2%	-0.25 [-1.78, 1.28]	2021	
Jung et al 2021a	-0.57	0.42	20	20	3.4%	-0.57 [-1.39, 0.25]	2021	
Jung et al 2021b	-0.15	0.39	20	20	3.5%	-0.15 [-0.91, 0.61]	2021	
Park et al 2021b	-0.04	0.65	15	15	2.6%	-0.04 [-1.31, 1.23]	2021	
Park et al 2021c	-0.95	0.74	12	12	2.3%	-0.95 [-2.40, 0.50]	2021	· · · · ·
Lim et al. 2022	-2.6	0.73	24	24	2.4%	-2.60 [-4.03, -1.17]	2022	
Kim et al. 2022	-2.53	0.44	30	30	3.3%	-2.53 [-3.39, -1.67]	2022	
Alfawaz et al 2022	-1.3	0.36	25	25	3.6%	-1.30 [-2.01, -0.59]	2022	
Subtotal (95% CI)			371	371	59.4%	-0.94 [-1.57, -0.31]		◆
Heterogeneity: Tau <sup>2</sup> = 1.	67; Chi <sup>2</sup> = 280.54, d	f = 17	(P < 0.0	00001);	l <sup>2</sup> = 94%			
Test for overall effect: Z	= 2.91 (P = 0.004)							
Total (95% CI)			569	569	100.0%	-0.66 [-0.99, -0.34]		•
Heterogeneity: Tau <sup>2</sup> = 0.	65; Chi <sup>2</sup> = 634.38, d	f = 27	(P < 0.0	00001):	l <sup>2</sup> = 96%			
Test for overall effect: Z				,,				-4 -2 0 2
Test for subgroup differe		f = 1 (F	P = 0.09	a) $ ^2 = 6$	6.3%			intrusion extrusion

Figure 3. (Continued)

 $(l^2 = 96\%)$ ; no significant difference in intrusion (*P* = .09) was found between devices with 2 TADs (-0.29 mm; 95% CI, [-0.68, 0.10]; *P* < .0001;  $l^2 = 97\%$ ) and those with 3 TADs (-0.94 mm; 95% CI, [-1.57, -0.31]; *P* < .0001;  $l^2 = 94\%$ ).

Treatment comparison between rigid and nonrigid TAD-supported appliances. Figure 4 shows the comparison between rigid and nonrigid appliances in terms of distalization, tipping, and vertical movement. High heterogeneity ( $I^2 = 87\%$ ) and no significant differences (P = .63) between the nonrigid (3.61 mm; 95% Cl, [2.85, 4.38]; P < .0001;  $I^2 = 77\%$ ) and rigid (3.85 mm; 95% Cl, [3.27, 4.44]; P < .0001;  $I^2 = 89\%$ ) appliances were found regarding distalization amount.

Distal tipping was significantly higher (P < .0001) in nonrigid (9.84°; 95% CI, [8.08, 11.60]; P < .0001;  $I^2 = 60\%$ ) than in rigid (1.97°; 95% CI, [1.01, 2.92]; P < .0001;  $I^2 = 71\%$ ) appliances, with high heterogeneity within subgroups ( $I^2 = 95\%$ ); one study with mean values outside the mean of the group was excluded.<sup>29</sup>

Finally, for vertical movements, there was considerable heterogeneity ( $I^2 = 97\%$ ) and no significant difference (P = .06) within the nonrigid (-0.69 mm; 95% CI, [-0.95, -0.44]; P < .61;  $I^2 = 0\%$ ) and rigid (-0.19 mm; 95% CI, [-0.64, 0.26]; P < .0001;  $I^2 = 97\%$ ) subgroups.

#### DISCUSSION

TADs may reduce the need for tooth extraction for orthodontic purposes and orthognathic surgery. Maxillary molar distalization may be able to correct Class II malocclusion using different TAD-supported appliances. This review assessed the effectiveness of molar distalization based on TAD number, TAD position, and device design.

#### **Distalization Movement**

Data analysis revealed nonsignificant differences in the magnitude of distalization for the subgroup using palatal TADs (3.74 mm) compared to buccal (3.23 mm) and zygomatic (3.68 mm) TADs. Therefore, no significant clinical differences were observed among the different device positions. These results were similar to those of a 2021 review that found distalization values of 2.75 mm for buccal TADs, 4.07 mm for palatal TADs, and 4.17 mm for zygomatic anchorage.<sup>17</sup> A 2022 systematic review also reported similar values for the distalization of molars by buccal TADs (2.44 mm) and palatal appliances (modified C-palatal plates [MCPPs]) in adults (4.00 mm) and adolescents (3.54 mm).<sup>18</sup>

One possible explanation for any differences would be that buccal TAD root proximity may be a factor limiting distalization, in contrast to extra-alveolar anchorage, which could allow greater movement. Also, palatal appliances allow force application closer to the center

а								
Study or Subgroup	Mean Difference	SE	T0 Total	T1 Total	Weight	Mean Difference IV, Random, 95% C	Year	Mean Difference IV, Random, 95% Cl
Nonrigid		0.47			7 40/	0.00 10.01 0.051	0040	
Sar et al. 2013b Cambiano et al. 2017		0.47 0.36	14 18	14 18	7.4% 8.4%	2.93 [2.01, 3.85] 3.45 [2.74, 4.16]		
Kircali et al. 2018		0.30	20	20	9.8%	4.20 [3.85, 4.55]		-
Subtotal (95% CI)		0110	52	52	25.6%	3.61 [2.85, 4.38]	2010	•
Heterogeneity: Tau <sup>2</sup> = 0. Test for overall effect: Z			: 0.01);	² = 77º	%			
Rigid								
Suzuki et al. 2013	4.5	0.33	20	20	8.7%	4.50 [3.85, 5.15]	2013	-
Sar et al. 2013a	2.81	0.7	14	14	5.5%	2.81 [1.44, 4.18]		
Cozzani et al. 2014 Miresmaelli et al. 2015		0.38 0.22	18 26	18 26	8.2% 9.6%	4.70 [3.96, 5.44] 2.30 [1.87, 2.73]		
Caprioglio et al. 2015		0.32	19	19	8.8%	4.20 [3.57, 4.83]		
Cozzani et al. 2016b	3.2	0.14	24	24	10.1%	3.20 [2.93, 3.47]		-
Duran et al. 2016	4.1	0.34	21	21	8.6%	4.10 [3.43, 4.77]		-
Cassetta et al. 2019		0.66	10	10	5.8%	5.30 [4.01, 6.59]		
Altieri et al. 2022 Subtotal (95% CI)	3.9	0.26	22 174	22 174	9.3% 74.4%	3.90 [3.39, 4.41] 3.85 [3.27, 4.44]	2022	•
Heterogeneity: Tau <sup>2</sup> = 0. Test for overall effect: Z			< 0.000					-
Total (95% CI)	- 12.07 (1 < 0.0000	"	226	226	100.0%	3.78 [3.31, 4.24]		•
Heterogeneity: Tau <sup>2</sup> = 0.	54; Chi² = 87.13. df	= 11 (F				0.10 [0.01, 4.24]		
Test for subgroup differe	= 15.94 (P < 0.0000	1)						-4 -2 0 2 4 mesialization distalization
b			то	T1		Mean Difference		Mean Difference
Study or Subgroup	Mean Difference	SE			Weight		Year	IV, Random, 95% Cl
Nonrigid		1200.000			1000000			
Sar et al. 2013b	9	1.8	14	14	7.9%	9.00 [5.47, 12.53]		
Cambiano et al. 2017 Kircali et al. 2018	11.24	0.81	18 20	18 20	9.9% 10.0%	11.24 [9.65, 12.83] 8.90 [7.55, 10.25]		
Subtotal (95% CI)	0.9	0.09	52	52	27.8%	9.84 [8.08, 11.60]	2010	•
Heterogeneity: Tau <sup>2</sup> = 1. Test for overall effect: Z			• 0.08);	l <sup>2</sup> = 60 <sup>6</sup>	%			
Rigid								
Sar et al. 2013a	1.65	1.94	14	14	7.6%	1.65 [-2.15, 5.45]	2013	
Suzuki et al. 2013		0.89	20	20	9.7%	1.80 [0.06, 3.54]		
Cozzani et al. 2014		0.52	18	18	10.2%	2.80 [1.78, 3.82]		
Miresmaelli et al. 2015 Caprioglio et al. 2015		0.84 0.69	26 19	26 19	9.8% 10.0%	0.60 [-1.05, 2.25] 3.20 [1.85, 4.55]		
Cozzani et al. 2016b	3	0.3	24	24	10.4%	3.00 [2.41, 3.59]		-
Cassetta et al. 2019	0.1	3.92	10	10	4.1%	0.10 [-7.58, 7.78]		
Altieri et al. 2022	0.1	0.64	22	22	10.1%	0.10 [-1.15, 1.35]	2022	+
Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 1.	11: Chi <sup>2</sup> = 24 38 df	= 7 (P	153	153 10): l <sup>2</sup> =	72.2%	1.97 [1.01, 2.92]		•
Test for overall effect: Z		- 7 (1						
Total (95% CI)	06: Chi2 - 212 10 d	6 - 10	205		100.0%	4.01 [2.01, 6.02]		<b>◆</b>
Heterogeneity: Tau <sup>2</sup> = 9. Test for overall effect: Z Test for subgroup differe	= 3.92 (P < 0.0001)		2			%		-10 -5 0 5 10 mesial tipping distal tipping
С			то	T1		Mean Difference		Mean Difference
Study or Subgroup	Mean Difference	SE			Weight	IV, Random, 95% C	Year	IV, Random, 95% Cl
Nonrigid								
Cambiano et al. 2017	-0.74		18	18	10.2%	-0.74 [-1.05, -0.43]		+
Kircali et al. 2018 Subtotal (95% CI)	-0.6	0.22	20 38	20 38	9.6% 19.8%	-0.60 [-1.03, -0.17] -0.69 [-0.95, -0.44]	2018	▲
Heterogeneity: $Tau^2 = 0$ . Test for overall effect: Z						-0.00 [-0.00, -0.44]		· ·
Rigid		0.40	00	00	10.00/	1001405 0.05	2012	-
Suzuki et al. 2013 Cozzani et al. 2014		0.18 0.45	20 18	20 18	10.0% 7.0%	-1.00 [-1.35, -0.65] 0.70 [-0.18, 1.58]		- <u>-</u>
Miresmaelli et al. 2015	-0.53		26	26	10.6%	-0.53 [-0.75, -0.31]		-
Caprioglio et al. 2015	0.3	0.18	19	19	10.0%	0.30 [-0.05, 0.65]	2015	+-
Cozzani et al. 2016b		0.06	24	24	10.8%	0.20 [0.08, 0.32]		<b>T</b>
Duran et al. 2016	-0.59		21	21	10.6%	-0.59 [-0.81, -0.37]		Ţ
Cassetta et al. 2019 Altieri et al. 2022		0.06 0.13	10 22	10 22	10.8% 10.4%	-0.90 [-1.02, -0.78] 0.60 [0.35, 0.85]		·   -
Subtotal (95% CI)	0.0	0.10	160	160	80.2%	-0.19 [-0.64, 0.26]	2022	•
Heterogeneity: $Tau^2 = 0$ . Test for overall effect: Z		f = 7 (F	⊃ < 0.00	0001); I	² = 97%			
Total (95% CI)			198	198	100.0%	-0.29 [-0.68, 0.10]		•
Heterogeneity: Tau <sup>2</sup> = 0.	36; Chi² = 267.61. d	f = 9 (F				0.20 [ 0.00, 0.10]		
Test for overall effect: Z	= 1.44 (P = 0.15)							-4 -2 0 2 4 intrusion extrusion
Test for subgroup differe	nces: Chi <sup>2</sup> = 3.62, d	f = 1 (F	P = 0.06	5), l² = 7	72.4%			

Figure 4. Forest plot of U6 distalization (a), tipping (b), and vertical movement (c) of the rigid and nonrigid subgroups.

of resistance, leading to more distalization. No differences were found between 2-TAD-supported and 3-TAD-supported appliances as well as when comparing nonrigid and rigid devices.

## **Tipping Movement**

Distal tipping is a common effect of molar distalization. There were no significant differences in distal tipping when comparing by position and number of TADs, but the difference was statistically and clinically significant when rigid (1.97°) and nonrigid (9.84°) appliances were compared. These results were consistent with the specific biomechanical properties involved. Palatal devices with pendulum arms result in distal tipping because the force is applied to the clinical crown, far from the center of resistance.<sup>60</sup>

Among all rigid palatal devices, the tipping values were generally low, as expected. The least tipping was shown by 3-TAD-supported devices (MCPPs) that used a controlled force vector that passed through the center of resistance of the U6, increasing distal movement while reducing distal tipping simultaneously.<sup>61</sup> Therefore, the direction of the force vector applied to the distalization system can certainly alter the tipping of teeth during distalization.

### **Vertical Movement**

In this meta-analysis, no significant differences were found for vertical movements among the buccal, palatal, and zygomatic TADs, but zygomatic TADs showed the greatest degree of intrusion (-1.16 mm). These findings contradicted those reported in two previous reviews.<sup>17,18</sup> It was expected that rigid appliances would provide better vertical control of maxillary molars due to their nonelastic nature, ensuring complete control over vertical movements. However, in a few cases, there was slight extrusive movement (ranging from 0.2 mm<sup>28</sup> to 0.70 mm<sup>23</sup>), observed exclusively with rigid palatal appliances. As discussed above, the direction of the resultant force vector plays a role in the effectiveness of the intrusion of teeth connected to the appliance.

Zygomatic anchorage should allow better vertical control and intrusion since the resulting vector force is above the center of resistance of the U6 and maxilla, therefore enabling intrusion of the upper arch simultaneously with a clockwise rotation of the occlusal plane.

#### Limitations

Only 4 RCTs were eligible to be reviewed. To enhance our understanding of distalization effects, prospective and retrospective cohort studies were included. Bias and study design differences may The methods used to assess U6 movement varied among the studies reviewed. Most commonly, measurements were made on lateral cephalograms, cone beam computed tomography (CBCT) images, and three-dimensional (3D) dental models using different landmarks. Although each method was validated and accurate, variations among studies may limit generalizations and comparisons.

Additionally, the limited information provided on the severity of the Class II molar relationships within the studies could confound the meta-analysis.

# CONCLUSIONS

- There were no significant differences in the magnitude of molar distalization, molar distal tipping, or molar intrusion among distalization appliances using palatal, zygomatic, or buccal TAD anchorages.
- The use of 3-TAD-supported appliances compared to 2-TAD-supported appliances for appliance anchorage did not improve the molar distalization magnitude or modify the extent of tipping and intrusion observed.
- Nonrigid palatal appliances resulted in significantly greater distal tipping than rigid appliances, although rigid and nonrigid appliances showed similar magnitudes of molar distalization and molar intrusion.
- Further well-designed, high-quality RCTs or prospective cohort studies are needed to provide clinical evidence of the efficacy of molar distalization with TADs.

# REFERENCES

- 1. Fontana M, Cozzani M, Caprioglio A. Non-compliance maxillary molar distalizing appliances: an overview of the last decade. *Prog Orthod*. 2012;13(2):173–184.
- 2. Yin Y, Wang Z, Huang L, et al. Orthodontic maximum anchorages in malocclusion treatment: a systematic review and network meta-analysis. *J Evid Based Med.* 2021;14(4): 295–302.
- Feldmann I, Bondemark L. Orthodontic anchorage: a systematic review. Angle Orthod. 2006;76(3):493–501.
- Jambi S, Thiruvenkatachari B, O'Brien KD, Walsh T. Orthodontic treatment for distalising upper first molars in children and adolescents. *Cochrane Database Syst Rev.* 2013; 2013(10):CD008375.
- Odman J, Lekholm U, Jemt T, Brånemark PI, Thilander B. Osseointegrated titanium implants—a new approach in orthodontic treatment. *Eur J Orthod.* 1988;10(2):98–105.
- Huang LH, Shotwell JL, Wang HL. Dental implants for orthodontic anchorage. *Am J Orthod Dentofacial Orthop.* 2005; 127(6):713–722.
- Wehrbein H, Feifel H, Diedrich P. Palatal implant anchorage reinforcement of posterior teeth: a prospective study. *Am J Orthod Dentofacial Orthop.* 1999;116(6):678–686.

- Costa A, Raffainl M, Melsen B. Miniscrews as orthodontic anchorage: a preliminary report. *Int J Adult Orthodon Orthognath Surg.* 1998;13(3):201–209.
- 9. Serafin M, Maspero C, Bocchieri S, Fastuca R, Caprioglio A. Subperiosteal anchorage in orthodontics: a narrative review. *Appl Sci.* 2021;11:8376.
- Mariani L, Maino G, Caprioglio A. Skeletal versus conventional intraoral anchorage for the treatment of class II malocclusion: dentoalveolar and skeletal effects. *Prog Orthod.* 2014;15(1):43.
- 11. Lee JS, Kim DH, Park YC, Kyung SH, Kim TK. The efficient use of midpalatal miniscrew implants. *Angle Orthod.* 2004;74(5):711–714.
- Ye C, Zhihe Z, Zhao Q, Ye J. Treatment effects of distal movement of lower arch with miniscrews in the retromolar area compared with miniscrews in the posterior area of the maxillary. *J Craniofac Surg.* 2013;24(6):1974–1979.
- Seres L, Kocsis A. Closure of severe skeletal anterior open bite with zygomatic anchorage. *J Craniofac Surg.* 2009;20(2): 478–482.
- 14. Afrashtehfar KI. Patient and miniscrew implant factors influence the success of orthodontic miniscrew implants. *Evid Based Dent.* 2016;17(4):109–110.
- Mohamed RN, Basha S, Al-Thomali Y. Maxillary molar distalization with miniscrew-supported appliances in Class II malocclusion: a systematic review. *Angle Orthod.* 2018;88(4): 494–502.
- Soheilifar S, Mohebi S, Ameli N. Maxillary molar distalization using conventional versus skeletal anchorage devices: a systematic review and meta-analysis. *Int Orthod.* 2019;17(3): 415–424.
- 17. Bayome M, Park JH, Bay C, Kook YA. Distalization of maxillary molars using temporary skeletal anchorage devices: a systematic review and meta-analysis. *Orthod Craniofac Res.* 2021;24(suppl 1):103–112.
- Raghis TR, Alsulaiman TMA, Mahmoud G, Youssef M. Efficiency of maxillary total arch distalization using temporary anchorage devices (TADs) for treatment of Class II-malocclusions: a systematic review and meta-analysis. *Int Orthod.* 2022;20(3):100666.
- Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264–269, w264.
- 20. Lockwood C, Oh EG. Systematic reviews: guidelines, tools and checklists for authors. *Nurs Health Sci.* 2017;19(3):273–277.
- Sar C, Kaya B, Ozsoy O, Özcirpici AA. Comparison of two implant-supported molar distalization systems. *Angle Orthod.* 2013;83(3):460–467.
- Suzuki EY, Suzuki B. Maxillary molar distalization with the indirect palatal miniscrew for anchorage and distalization appliance (iPANDA). Orthodontics (Chic). 2013;14(1):e228–e241.
- 23. Cozzani M, Pasini M, Zallio F, et al. Comparison of maxillary molar distalization with an implant-supported distal jet and a traditional tooth-supported distal jet appliance. *Int J Dent.* 2014;2014:937059.
- 24. Kook YA, Bayome M, Trang VT, et al. Treatment effects of a modified palatal anchorage plate for distalization evaluated with cone-beam computed tomography. *Am J Orthod Dentofacial Orthop.* 2014;146(1):47–54.
- 25. Caprioglio A, Cafagna A, Fontana M, Cozzani M. Comparative evaluation of molar distalization therapy using pendulum

and distal screw appliances. *Korean J Orthod.* 2015;45(4): 171–179.

- 26. Miresmaeili A, Sajedi A, Moghimbeigi A, Farhadian N. Threedimensional analysis of the distal movement of maxillary 1st molars in patients fitted with mini-implant-aided trans-palatal arches. *Korean J Orthod.* 2015;45(5):236–244.
- Sa'aed NL, Park CO, Bayome M, Park JH, Kim Y, Kook YA. Skeletal and dental effects of molar distalization using a modified palatal anchorage plate in adolescents. *Angle Orthod.* 2015;85(4):657–664.
- Cozzani M, Fontana M, Maino G, Maino G, Palpacelli L, Caprioglio A. Comparison between direct vs indirect anchorage in two miniscrew-supported distalizing devices. *Angle Orthod.* 2016;86(3):399–406.
- 29. Duran GS, Görgülü S, Dindaroğlu F. Three-dimensional analysis of tooth movements after palatal miniscrew-supported molar distalization. *Am J Orthod Dentofacial Orthop.* 2016;150(1):188–197.
- Cambiano AO, Janson G, Fuziy A, Garib DG, Lorenzoni DC. Changes consequent to maxillary molar distalization with the bone-anchored pendulum appliance. *J Orthod Sci.* 2017;6(4):141–146.
- 31. Park CO, Sa'aed NL, Bayome M, et al. Comparison of treatment effects between the modified C-palatal plate and cervical pull headgear for total arch distalization in adults. *Korean J Orthod.* 2017;47(6):375–383.
- Lee SK, Abbas NH, Bayome M, et al. A comparison of treatment effects of total arch distalization using modified C-palatal plate vs buccal miniscrews. *Angle Orthod.* 2018;88(1):45–51.
- Jo SY, Bayome M, Park J, Lim HJ, Kook YA, Han SH. Comparison of treatment effects between four premolar extraction and total arch distalization using the modified C-palatal plate. *Korean J Orthod.* 2018;48(4):224–235.
- Park JH, Kim S, Lee YJ, et al. Three-dimensional evaluation of maxillary dentoalveolar changes and airway space after distalization in adults. *Angle Orthod.* 2018;88(2):187–194.
- Kırcalı M, Yüksel AS. Evaluation of dentoalveolar and dentofacial effects of a mini-screw-anchored pendulum appliance in maxillary molar distalization. *Turk J Orthod.* 2018;31(4): 103–109.
- Lee YJ, Kook YA, Park JH, et al. Short-term cone-beam computed tomography evaluation of maxillary third molar changes after total arch distalization in adolescents. *Am J Orthod Dentofacial Orthop.* 2019;155(2):191–197.
- Shoaib AM, Park JH, Bayome M, Abbas NH, Alfaifi M, Kook YA. Treatment stability after total maxillary arch distalization with modified C-palatal plates in adults. *Am J Orthod Dentofacial Orthop.* 2019;156(6):832–839.
- Cassetta M, Brandetti G, Altieri F. Miniscrew-supported distal jet versus conventional distal jet appliance: a pilot study. *J Clin Exp Dent.* 2019;11(7):e650–e658.
- Alfaifi M, Park JH, Tai K, et al. Comparison of treatment effects with modified C-palatal plates vs Greenfield molar distalizer appliances in adolescents. *J Clin Pediatr Dent.* 2020;44(3): 202–208.
- Chou AHK, Park JH, Shoaib AM, et al. Total maxillary arch distalization with modified C-palatal plates in adolescents: a long-term study using cone-beam computed tomography. *Am J Orthod Dentofacial Orthop.* 2021;159(4):470–479.
- Jung CY, Park JH, Ku JH, Lee NK, Kim Y, Kook YA. Dental and skeletal effects after total arch distalization using modified C-palatal plate on hypo- and hyperdivergent Class II

malocclusions in adolescents. Angle Orthod. 2021;91(1): 22-29.

- Park JH, Kim Y-J, Kim J, et al. Use of artificial intelligence to predict outcomes of nonextraction treatment of Class II malocclusions. Semin Orthod. 2021;27(2):87–95.
- Park JH, Kim Y, Park JH, Lee NK, Kim SH, Kook YA. Longterm evaluation of maxillary molar position after distalization using modified C-palatal plates in patients with and without second molar eruption. *Am J Orthod Dentofacial Orthop.* 2021;160(6):853–861.
- 44. Alfawaz F, Park JH, Lee NK, et al. Comparison of treatment effects from total arch distalization using modified C-palatal plates versus maxillary premolar extraction in Class II patients with severe overjet. Orthod Craniofac Res. 2022;25(1):119–127.
- 45. Kim S, Lee NK, Park JH, et al. Treatment effects after maxillary total arch distalization using a modified C-palatal plate in patients with Class II malocclusion with sinus pneumatization. Am J Orthod Dentofacial Orthop. 2022;162(4):469–476.
- Lim HJ, Kim Y, Park JH, Lee NK, Kim KB, Kook YA. Cephalometric and model evaluations after molar distalization using modified C-palatal plates in patients with severe arch length discrepancy. *Am J Orthod Dentofacial Orthop.* 2022; 162(6):870–880.
- Altieri F, Mezio M, Guarnieri R, Cassetta M. Comparing distal-jet with dental anchorage to distal-jet with skeletal anchorage: a prospective parallel cohort study. *Dent J (Basel).* 2022; 10(10):179.
- Bechtold TE, Kim JW, Choi TH, Park YC, Lee KJ. Distalization pattern of the maxillary arch depending on the number of orthodontic miniscrews. *Angle Orthod.* 2013;83(2):266–273.
- Ali D, Mohammed H, Koo SH, Kang KH, Kim SC. Three-dimensional evaluation of tooth movement in Class II malocclusions treated without extraction by orthodontic mini-implant anchorage. *Korean J Orthod.* 2016;46(5):280–289.
- Abdelhady NA, Tawfik MA, Hammad SM. Maxillary molar distalization in treatment of angle class II malocclusion growing patients: uncontrolled clinical trial. *Int Orthod.* 2020; 18(1):96–104.
- 51. Bechtold TE, Park YC, Kim KH, Jung H, Kang JY, Choi YJ. Long-term stability of miniscrew anchored maxillary molar

distalization in Class II treatment. *Angle Orthod.* 2020;90(3): 362–368.

- Song B-J, Lee K-J, Cha J-Y, Lee J-S, Mo S-S, Yu H-S. Stability of the maxillary and mandibular total arch distalization using temporary anchorage devices (TADs) in adults. *Appl Sci.* 2022;12:2898.
- 53. Nur M, Bayram M, Celikoglu M, Kilkis D, Pampu AA. Effects of maxillary molar distalization with zygoma-gear appliance. *Angle Orthod.* 2012;82(4):596–602.
- EI-Dawlatly MM, Abou-EI-Ezz AM, EI-Sharaby FA, Mostafa YA. Zygomatic mini-implant for Class II correction in growing patients. *J Orofac Orthop.* 2014;75(3):213–225.
- 55. Kilkis D, Celikoglu M, Nur M, Bayram M, Candirli C. Effects of zygoma-gear appliance for unilateral maxillary molar distalization: a prospective clinical study. *Am J Orthod Dentofacial Orthop.* 2016;150(6):989–996.
- Wu X, Liu H, Luo C, Li Y, Ding Y. Three-dimensional evaluation on the effect of maxillary dentition distalization with miniscrews implanted in the infrazygomatic crest. *Implant Dent.* 2018;27(1):22–27.
- Shahani M, Singh G, Gupta N, et al. En masse distalisation of maxillary arch using TADs (IZC); passive self-ligating appliance v/s clear aligner—a comparative cephalometric study. *J Contemp Orthod.* 2019;3(3):11–17.
- Shaikh A, Jamdar AF, Galgali SA, Patil S, Patel I, Hemagiriyappa MS. Efficacy of infrazygomatic crest implants for full-arch distalization of maxilla and reduction of gummy smile in Class II malocclusion. *J Contemp Dent Pract.* 2021; 22(10):1135–1143.
- 59. Rosa WGN, de Almeida-Pedrin RR, Oltramari PVP, et al. Total arch maxillary distalization using infrazygomatic crest miniscrews in the treatment of Class II malocclusion: a prospective study. *Angle Orthod*. 2023;93(1):41–48.
- Kinzinger GS, Diedrich PR. Biomechanics of a modified pendulum appliance—theoretical considerations and in vitro analysis of the force systems. *Eur J Orthod.* 2007; 29(1):1–7.
- Bayome M, Park JH, Kook Y-A. Clinical applications and treatment outcomes with modified C-palatal plates. *Semin Orthod.* 2018;24(1):45–51.